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Abstract 
 
Influenza viruses cause significant morbidity and mortality worldwide, especially for 
susceptible populations such as the very young and the elderly. The most effective 
strategy for the prevention of influenza is vaccination. Current seasonal influenza 
vaccines offer protection to the majority of the worldwide population, however vaccine 
efficacy in the elderly is variable. In addition, dose sparing strategies are required for 
pandemic preparedness. Evidence clearly suggests that adjuvants included in current 
influenza vaccines enhances immunity in the elderly and may be of benefit.  
 
MicroRNAs (miRNAs) are small, non-coding RNAs which play an important role in 
regulating anti-viral immunity and have been shown to be involved in immune cell 
development and function. In this thesis, we investigated a reverse genetics strategy 
to generate self-adjuvanting recombinant influenza virus vaccines that express 
immunomodulatory miRNAs. This was achieved by generating a linearised 
recombinant NS gene segment that allowed the insertion of an artificial intron encoding 
a miRNA of choice. Ten recombinant influenza viruses were rescued encoding 
multiple miRNAs/shRNA constructs. These rescues were confirmed through 
haemagglutination assays and sequencing. Replication kinetics of the recombinant 
viruses were assessed using plaque assays and showed that all the recombinant 
viruses were attenuated when compared to the wild type control.  
 
miR-150 is an important immunomodulatory miRNA that has been shown to influence 
B cell, T cell and NK cell development and differentiation. Importantly, miR-150 is 
required for CD8+ T cell function following virus infection. In this project, we were able 
to generate a pair of recombinant influenza viruses (PR8-150 (H1N1) and X31-150 
(H3N2)) that expressed miR-150. We confirmed mature miR-150 expression using 
real-time PCR and function was validated through in vitro analysis of target gene 
knockdown (c-Myb) using a dual luciferase assay. We also observed enhanced 
cytokine and chemokine production (IL-6, IFN-β, CCL5, CXCL10). Mice were infected 
with X31-150 virus and accelerated innate immune cell kinetics were observed 
(neutrophils, DCs and macrophages). Higher numbers of influenza-specific CD8+ T 
  
VIII 
 
cells specific for the DbNP366 and DbPA224 epitopes were detected in X31-150 infected 
mice when compared to X31-WT controls at 10dpi through tetramer staining and 
intracellular cytokine staining. This was also noted following secondary infection. 
 
These results demonstrate that recombinant influenza viruses expressing 
immunomodulatory miRNAs can serve as self-adjuvanting live attenuated vaccines 
capable of enhancing immunity. 
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Chapter 1  Introduction 
 
1.1  MicroRNAs  
 
MicroRNAs (miRNAs) are small non-coding RNA molecules which are viewed 
as fundamental regulators of post-transcriptional gene expression. miRNAs are 
involved in a wide range of physiological and pathological processes including 
embryonic development (Gangaraju & Lin 2009), organogenesis (Asli, 
Pitulescu & Kessel 2008), tumourogenesis (Ambros 2004), and human 
diseases such as arrhythmia (Yang et al. 2007), ischaemic heart disease 
(Caroli et al. 2013), cardiac hypertrophy (Care et al. 2007), viral hepatitis 
(Pedersen et al. 2007), diabetes (Poy et al. 2004) and cancer (Calin & Croce 
2006). miRNAs were first discovered in 1993 during a study of the gene lin-14 
in C. elegans (Lee, Feinbaum & Ambros 1993). Since their discovery in C. 
elegans, miRNAs have been found across many different animal and plant 
species. miRNAs are approximately 22 nucleotides long and bind to 
complementary sequences in the 3’ untranslated region (UTR) of target 
messenger RNA (mRNA) that lead to repression of protein translation or 
degradation of the target mRNA transcript. In animals, miRNAs typically exhibit 
only partial complementarity to their mRNA targets with nucleotides 2–8 of the 
miRNA vital for pairing with target mRNA. This region is referred to as the 
miRNA ‘seed sequence’ (Lewis, Burge & Bartel 2005). In contrast, plant 
miRNAs usually have perfect or near-perfect pairing with their mRNA targets 
(Brodersen et al. 2008). This complementary sequence then associates with 
the RNA-induced silencing complex (RISC) to initiate RNA interference (Figure 
1.1). Other studies have reported the presence of miRNA targeting sites in 5’ 
UTRs and open reading frames (Orom, Nielsen & Lund 2008; Tay et al. 2008). 
 
 2 
 
 
 
 
Figure 1.1. Sliencing mechanisms of animal and plant miRNAs. After incorporation into the 
RNA-induced silencing complex (RISC), mature miRNAs guide the RISC complex to the target 
mRNA. Most animal miRNAs exhibit partial complementarity to mRNA targets with nucleotides 
2–8 of the miRNA vital for pairing with the target. In contrast, plant miRNAs and siRNAs show 
perfect homology with target mRNA (Ekiert et al. 2012).  
 
1.1.1 Biogenesis of miRNAs  
 
The majority of defined primary miRNAs are located in introns while others are 
found in non-coding RNA transcription units (Rodriguez et al. 2004). Some 
miRNAs are clustered in the genome and can sometimes be considered as 
members of a miRNA family. Commonly, miRNAs that share the same ‘seed 
sequence’ are classified as part of a family.  
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Figure 1.2. miRNA genomic organisation, biogenesis and function. The sequence of 
mature miRNA is shown in red. TF is transcription factor. (A) One primary miRNA transcript 
contains multiple pre-miRNAs; (B) miRNA is produced through independent transcriptional 
units; (C) miRNA is produced in intronic sequences (in grey), black cylinders represent exonic 
sequences. (Fazi & Nervi 2008). 
 
The four steps involved in miRNA production can be seen in Figure 1.2. The 
first step in miRNA biogenesis involves transcription of miRNAs in the nucleus 
(Figure 1.2). RNA polymerase II produces the majority of miRNAs through host 
gene transcripts or independent transcription units. The primary miRNA 
transcripts are capped with 7-methylguanosine (7mGpppG) at the 5’-end and 
have 3’-polyadenylated tails (Bracht et al. 2004; Lee et al. 2004). In rare cases, 
miRNAs with upstream Arthrobacter luteus (Alu) elements are transcribed by 
RNA polymerase III (Borchert, Lanier & Davidson 2006). The second step in 
miRNA biogenesis involves processing of primary miRNA transcripts (also 
known as pri-miRNAs) into precursor miRNAs (pre-miRNAs) in the nucleus 
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(Han et al. 2004; Lee et al. 2003). Usually, one pri-miRNA contains one to six 
miRNA precursors (Figure 1.2A). Following this, pri-miRNAs are cleaved to 
form stem-loop pre-miRNAs. Cleavage is performed by the microprocessor 
complex, which is composed of the RNase III enzyme Drosha (also referred to 
as ribonuclease 3) and DGCR8 (DiGeorge syndrome critical region gene 8), 
also termed Pasha (Denli et al. 2004; Gregory et al. 2004; Landthaler, Yalcin & 
Tuschl 2004). The enzyme Drosha, with its cofactor DGCR8, cuts RNA to 
liberate hairpins from pri-miRNA to produce a 60–70 nucleotide pre-miRNA. 
The third step in miRNA biogenesis is nuclear export which is facilitated by the 
nucleocytoplasmic shuttle Exportin-5, a high-affinity protein that binds pre-
miRNAs with the help of cofactor Ran-GTP(Lee et al. 2002). The miRNA is 
released into the cytoplasm by the hydrolysis of GTP to GDP. The final step in 
the miRNA biogenesis pathway is miRNA maturation following processing by 
the enzyme Dicer in the cytoplasm. Pre-miRNAs are cleaved by Dicer (RNase 
III enzyme) to form a mature 21-24 nucleotide miRNA. Many factors influence 
the efficiency of Dicer processing, including: hairpin length, loop size and the 
imperfect nature of the miRNA pairing. The guide strand (mature miRNAs) is 
then incorporated into the RNA-induced silencing complex (RISC), which is 
comprised of Argonaute (Ago) and other proteins. Mature miRNAs can direct 
the RISC complex to the target mRNAs and directly degrade mRNAs or 
suppress mRNA translation (Figure 1.2) (Huntzinger & Izaurralde 2011; 
Pasquinelli 2012).   
 
1.1.2 miRNA degradation/repression 
 
There are two defined mechanisms by which miRNAs function in the regulation 
of gene expression that are associated with the RISC complex. The first is 
known as mRNA degradation and involves the degradation of target mRNA by 
the RISC complex. The second refers to prevention of mRNA translation, also 
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known as translational repression (Figure 1.2). The activation of either pathway 
is determined by the degree of miRNA-mRNA complementarity. Ago-catalysed 
cleavage of the miRNA requires perfect complementarity whereas repression 
of mRNA translation requires only partial complementarity. There is however 
an ongoing discussion of the process itself as Brodersen and colleagues 
demonstrated that two mutants of the Arabidopsis species are characterised by 
normal miRNA-induced mRNA cleavage, but have defective miRNA-induced 
translation repression (Brodersen et al. 2008). Therefore, the exact mechanism 
by which the RISC complex regulates translation is under investigation. 
 
1.1.2.1 Degradation of mRNAs by miRNA 
 
The observation of mRNA can be degraded by miRNAs came from a study in 
which the quantity of target mRNAs decreased significantly after miRNAs were 
transfected into cells (Lim et al. 2005). mRNA degradation is initiated by the 
removal of the mRNA poly(A) tail and followed by progressive 3’ -5’ decay or 
by 5’-3’ degradation after the de-capping process (Figure 1.2). The final step in 
the degradation process is thought to happen in processing bodies (P-bodies), 
also termed GW bodies (glycine (G)/tryptophan (W); as the original paper found 
these proteins contain glycine/tryptophan repeats) (Eystathioy et al. 2002) that 
are distinct foci within the cytoplasm of the eukaryotic cell consisting of many 
enzymes involved in mRNA turnover (Parker & Sheth 2007).  
 
The mechanism of miRNA-mediated mRNA degradation can be summarised in 
a number of steps. Once a miRNA is combined with Ago in the RISC complex 
(Figure 1.3), it allows the RISC complex to the target mRNA through base 
pairing. The Ago then interacts with GW182 in P-bodies to attract the RISC-
mRNA complex to P-bodies. The mRNAs are then deadenylated, de-capped or 
degraded (Figure 1.3) (Nilsen 2007). Even though multiple lines of evidence 
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support the P-body hypothesis, there are many incompatible observations for 
this process such as a low concentration of Ago protein in P-bodies (Leung, 
Calabrese & Sharp 2006).  
 
Figure 1.3. miRNA-mediated mRNA translation repression in P-bodies (GW bodies). The 
assembly of mature miRNA (in red) into RISC initiates early stage of P-bodies (GW body). The 
complex interacts with GW182 in P-bodies to form a specific structure that causes miRNA-
mediated translational repression (Jakymiw et al. 2007). 
 
1.1.2.2 Translational repression of mRNA by miRNAs 
 
Another mechanism by which miRNAs regulate gene expression is translational 
repression. In early C. elegans studies, Wightman and colleagues observed 
that LIN-14 protein expression decreased rapidly following LIN-4 RNA 
repression even though LIN-14 mRNA levels were not substantially altered 
(Wightman, Ha & Ruvkun 1993). Multiple lines of evidence suggest that 
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translation is repressed by miRNAs after initiation of protein synthesis (Olsen & 
Ambros 1999; Seggerson, Tang & Moss 2002). However, some reports 
demonstrate that repression occurs at the completion of protein synthesis 
(Maroney et al. 2006; Nottrott, Simard & Richter 2006). Collectively, there are 
five proposed mechanisms for translational repression: cap-40S initiation 
inhibition; 60S ribosomal unit joining inhibition; elongation inhibition; ribosome 
drop-off (premature termination); and co-translational nascent protein 
degradation (Morozova et al. 2012). It apperas that miRNAs demonstrate 
different mechanisms of repression. Further studies of these mechanisms may 
elucidate individual mRNA or mRNA-miRNA complex characteristics. 
 
1.1.3 miRNAs and virus infection  
 
miRNAs play an important role in virus replication and clearance by not only 
influencing the host immune response against pathogens but also through 
targeting of viral genes. For instance, cellular miRNAs can regulate infection of 
many viruses including; prototype foamy virus (PFV-1), vaccinia virus (VV), 
human immunodeficiency virus subtype 1 (HIV-1) and hepatitis C virus (HCV) 
by directly targeting viral genes (Huang et al. 2007; Jopling et al. 2005; Lecellier 
et al. 2005; Otsuka et al. 2007). It is also imprtant to note that the immune 
system itself can modulate miRNA expression as part of its antiviral strategy. 
Interferon-beta (IFN-β), a key cytokine in innate immunity can induce several 
miRNAs including miR-196 and miR-448 to inhibit HCV replication through 
targeting of HCV genomic RNA (Pedersen et al. 2007).  
 
Viruses encode miRNAs to assist in replication, a phenomenom well studied in 
DNA viruses (Figure 1.4). The discovery of viral encoded miRNAs was first 
reported by Pfeffer, whose team identified 5 Epstein-Barr virus (EBV)-encoded 
pre-miRNAs in B95-8 cells (Pfeffer et al. 2004). Further studies confirmed 44 
 8 
 
 
additional pre-miRNAs encoded by EBV (Cai et al. 2006; Grundhoff, Sullivan & 
Ganem 2006; Zhu et al. 2009), that were involved in the repression of cell-
mediated immunity or modulation of apoptosis (Barth, Meister & Grasser 2011). 
Kaposi sarcoma-associated herpesvirus (KSHV) has also been reported to 
generate 12 pre-miRNAs (Cai et al. 2005; Grundhoff, Sullivan & Ganem 2006; 
Pfeffer et al. 2005; Samols et al. 2005) for immune evasion. Additionally, 
members of the polyomavirus family such as simian vacuolating virus 40 
(SV40), as well as adenoviruses and baculoviruses have been shown to 
encode miRNAs or miRNA-like molecules (Aparicio et al. 2006; Cantalupo et 
al. 2005; Seo, Chen & Sullivan 2009; Seo et al. 2008; Singh et al. 2010; Sullivan 
et al. 2005; Sullivan et al. 2009).  
 
Figure 1.4. miRNAs encoded by DNA viruses regulate the host-immune response. After 
entering the nucleus of the host cell, viral DNA expresses miRNAs for export into the cytoplasm 
and incorporation into RISC. Viral miRNAs then modulate multiple cellular activities, including 
apoptosis, cell-mediated immunity, viral latency and and cell cycle (Boss & Renne 2010). 
 
Until recently, the capacity of RNA viruses to encode miRNAs has been a 
subject of great debate. Several recent studies revealed that at least five 
retroviruses can express their own miRNAs (Harwig et al. 2016; Kincaid, Burke 
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& Sullivan 2012; Kincaid et al. 2014; Whisnant et al. 2014; Yao et al. 2014). It 
is thought that these viral miRNAs contribute to viral replication and 
oncogenesis. Bovine leukaemia virus (BLV) expresses viral miRNAs that 
contribute to the maintenance of higher viral loads in the infected animals (Gillet 
et al. 2016). In vitro reporter assay shows that BLV viral miRNAs target genes 
involved in immunity and oncogenesis. Apart from encoding viral miRNAs, RNA 
viruses also hijack host miRNAs or change cellular miRNA profiles to modulate 
various cellular pathways (ie. immunity, apoptosis, cell cycle). As apoptosis can 
be a self-defence mechanism for the host, alterations in activity can significantly 
change the outcome of infection. Like DNA viruses, RNA viruses also utilise 
miRNA for immune evasion. Eastern equine encephalitis virus (EEEV) infection 
results in miR-142-3p upregulation that targets its own genome to repress viral 
protein translation. By using this process, EEEV silences the induction of the 
Type I IFN response and exacerbates severity of disease to benefit the infection 
microenvironment (Trobaugh et al. 2014). 
 
1.1.4 miRNAs and infleunza virus infection 
 
Changes in host miRNA expression have been observed during influenza 
infection. With the development of high-throughput deep sequencing and 
microarray technology, our understanding of host miRNA profiles during 
influenza infection has significantly expanded in recent years. miRNA patterns 
exhibit strain specific and species dependent variation following infection. Dicer, 
a miRNA processing enzyme, shows variable expression following influenza 
virus infection. Knockdown of Dicer expression has been shown to moderately 
increase influenza virus replication in African green monkey epithelial (Vero) 
cells (Matskevich & Moelling 2007). In addition, significant modulation of the 
host miRNA expression in multiple cell lines (avian, murine and primate) have 
been observed during influenza infection following analysis using microarray or 
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deep sequencing technologies (Li et al. 2010; Li et al. 2011a; Peng et al. 2011; 
Wang et al. 2009).  
 
Lung epithelial cells are the main target for influenza virus replication. These 
cells act as the first line of antiviral defence by releasing cytokines and 
chemokines to initiate innate and adaptive immune responses. As such, lung 
epithelial cell lines serve as ideal in vitro model to evaluate host-pathogen 
interactions. A549 cells are a widely used in vitro model for influenza virus 
infection. Several studies show diverse miRNA expression patterns in these 
cells that are transient, strain-specific and time-dependent (Buggele, Johnson 
& Horvath 2012; Loveday et al. 2012; Tambyah et al. 2013; Terrier et al. 2013). 
However, some miRNAs are commonly dysregulated in A549 cells following 
infection including; let-7b, miR-10a, miR-155, miR-34b (upregulated) and let-
7g, miR-29b (downregulated).  
 
Cellular miRNAs (miR-323, miR-491 and miR-654) have been shown to be  
involved in inhibition of influenza virus replication by directly targeting the 
influenza PB1 gene leading to viral mRNA degradation (Song et al. 2010). let-
7c can bind to the 3’ UTR of the influenza virus M gene to greatly reduce viral 
titres in vitro (Figure 1.5) (Ma et al. 2012). miR-144 is upregulated in lung 
epithelial cells of mice infected with A/PR8 virus at 72 hours post-infection and 
targets TRF6 and IRF7 mRNA and protein levels (Figure 1.5). As TRF6 is a key 
negative regulator of the innate immune signalling pathway, the upregulation of 
miR-144 by influenza virus infection impairs the antiviral response in the 
epithelial cells. This was further confirmed in miR-144 knockout (miR-144-/-) 
mice, where influenza virus replication was well controlled (Rosenberger et al. 
2017). 
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Influenza viruses can also modulate host miRNA expression to assist 
replication by disrupting the cell cycle or cellular pathways (Figure 1.5) (Buggele, 
Johnson & Horvath 2012; Fan & Wang 2016; Guan et al. 2012; Hussain, Taft 
& Asgari 2008; Loveday et al. 2015; Rosenberger et al. 2017). At different 
stages of infection, influenza viruses can hijack cellular miRNAs that bind to 
pre- or anti-apoptotic genes leading to the activation or inhibition of the cellular 
apoptosis. Increased miR-4276 expression, for example, has been shown to 
effectively block apoptosis of the infected A549 cells (Hussain, Taft & Asgari 
2008). miR-29c is also upregulated early following influenza virus infection of 
A549 cells and has been shown to inhibit the expression of an anti-apoptosis 
protein BCL2L2 through translational repression (Figure 1.5) (Guan et al. 2012). 
 
 
Figure 1.5. Influenza viruses, miRNAs and host interactions. After entering host cells, 
influenza viruses start mRNA and vRNA synthesis and protein translation. Although the 
mechanism has not been fully understood, current evidence suggests influenza viruses can 
manipulate cellular miRNA expression to modulate multiple cellular activities, including 
apoptosis.  
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The function of many miRNAs in host-virus interactions during influenza 
infection has been understudied, and so a detailed understanding of the role of 
miRNAs in viral infection may provide novel strategies for antiviral therapies 
and vaccine development. 
 
1.1.5 Immunomodulatory role of miRNAs 
 
miRNAs play an important role in the immune response through the regulation 
of development and differentiation of immune cell populations (Figure 1.6), 
antibody class switching and the release of inflammatory mediators. Indeed, 
recent evidence suggests that some miRNAs (such as miR-150, miR-146a and 
the let-7 family) are involved in influencing immune responses through 
regulation of immune cell development and differentiation or through 
manipulation of function (Ma et al. 2012; Moran et al. 2015; Shen et al. 2015; 
Terrier et al. 2013). 
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Figure 1.6. The role of miRNAs in haematopoietic cell development and maturation. 
miRNAs are involved in immune cell development and maturation; including B cell, T cell, NK 
cell, macrophage and DC differentiation. miRNAs such as miR-17-92, miR-146a, miR-150, 
miR-155 and miR-181a play significant roles in multiple immune cell differentiation pathways 
(Detailed in 1.1.5)(Baltimore et al. 2008). 
 
1.1.5.1 miRNA regulation of innate immune responses 
 
The innate immune response is the first line of defence against pathogens and 
is initiated by recognition of viral components by pattern recognition receptors 
(PPRs), such as retinoic acid-inducible gene 1 (RIG-1)-like helicases, 
nucleotide-binding oligomerization domain-like receptors (NLRs) and Toll-like 
receptors (TLRs) (Mogensen 2009). This stimulates release of pro-
inflammatory factors, allowing recruitment of neutrophils, monocytes, dendritic 
cells (DCs), macrophages (Mϕ) and natural killer cells (NK) to the site of 
infection (Figure 1.7) (Abbas AK 2012). Neutrophils and monocytes are 
recruited early after influenza virus infection and accumulate in the lung to clear 
the virus. NK cells can directly kill infected cells and produce cytokines. Alveolar 
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macrophage and DCs act through phagocytic mechanisms and present 
antigens to T cells to initiate adaptive immune responses (Iwasaki & Pillai 2014). 
 
Figure 1.7. Immune cells involved in innate and adaptive immune responses. Innate and 
adaptive immune cells involved in clearance of influenza virus infection. Revised from (Abbas 
AK 2012). 
 
1.1.5.1.1 miRNA-mediated DC regulation  
 
DCs are professional antigen-presenting cells that form the bridge between 
innate and adaptive immunity and are regulated by miRNAs. In DC 
development, miR-21 and miR-34a are thought to take part in the regulation of 
the genes WNT1 (coding for Wnt-1) and JAG1 (coding for Notch ligand Jagged-
1) leading to the translational suppression of these two proteins. WNT1 and 
JAG1 are involved in haematopoietic development and have been shown to 
modulate DC differentiation in vitro (Hashimi et al. 2009). miRNAs are also 
thought to influence DC subset differentiation and specialisation. For example, 
some members in the miR-17~92 cluster (detailed in Table A.6) are highly 
expressed in plasmacytoid DCs (pDCs, produce IFN-α/β) compared with 
conventional DCs (cDCs, that activate CD4+ and CD8+ T cells), while the miR-
23a/24/27a clusters are highly expressed in cDCs compared with pDCs 
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(Kuipers, Schnorfeil & Brocker 2010). Murine miR-22 is differentially expressed 
in cDCs (high) and pDCs (low). Luciferase report assays have confirmed that 
miR-22 can directly target the 3’ UTR region of interferon regulatory factor 8 
(IRF8) transcription factor, a protein responsible for DC development and 
cytokine production (Tamura et al. 2005; Tsujimura, Tamura & Ozato 2003), (Li 
et al. 2012). During DC maturation, several miRNAs (including let-7i, miR155, 
miR-142, miR-148 and miR-221) influence the expression of several cell 
surface makers, such as MHC II, CD80, CD86 and CD40, that are found on 
mature DCs (Figure 1.8) (Turner, Schnorfeil & Brocker 2011). Current studies 
have not clearly defined a role for miRNA function in DCs and further 
understanding of their role may identify new approaches to manipulate DC 
function. 
 
Figure 1.8. Changes in miRNA expression involved in regulating DC maturation and 
function. Upregulation or downregulation of miRNAs controls the expression of surface 
markers resulting in pro- or anti-inflammatory responses in mature DCs (Smyth et al. 2015). 
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1.1.5.1.2 miRNA-mediated NK cell regulation 
 
NK cells are innate immune cells essential for host defence from pathogens 
and tumours. miRNAs have been implicated in their differentiation and function. 
NK cell development has been shown to be influenced by two miRNAs; miR-
150 that targets c-Myb (Bezman et al. 2011) and miR-181a/b that targets a 
NEMO-like kinase (NLK) (Cichocki et al. 2011). miR-150-/- mice have a 
deficiency in NK cell maturation and proliferation, while miR-150 
overexpression induces NK accumulation. These findings were also replicated 
in c-Myb+/- mice, a confirmed target of miR-150 (Bezman et al. 2011). NLK is a 
negative regulator of the Notch signalling pathway, involved in NK cell 
differentiation (Bachanova et al. 2009). miR-181 is thought to target NLK to 
enhance the Notch signalling pathway. Overexpression of miR-181 through 
lentivirus constructs results in differentiation of CD56+ NK progenitor cells in 
vitro (Cichocki et al. 2011). Several studies have also investigated the role of 
miRNAs in regulating NK cytotoxicity. The work has focused on two major 
enzymes, granzyme B (GzmB) and perforin-1 (Prf1) (Sullivan, Leong & 
Fehniger 2013). Both GzmB and Prf1 are targeted by miR-27a-5p and 
overexpression of miR-27a-5p results in reduction of both proteins in human 
NK cells in vitro (Kim et al. 2011). miR-378 and miR-30e have also been found 
to target the murine 3’UTR of GzmB and Prf1 respectively. Downregulation of 
both miRNAs inversely correlates with increased production of GzmB and Prf1 
and greater NK cytotoxic function (Wang et al. 2012b). Investigations of miRNA-
mediated control of NK cell development and function have thus far primarily 
focused on global or specific miRNA deficiency and over-expression. With 
increasing knowledge of miRNA regulation of NK cells, novel pathways will be 
manipulated to enhance or attenuate NK cell function. 
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1.1.5.2 miRNA function in the adaptive immune response 
 
The adaptive immune response is comprised of two arms; cellular immunity and 
humoral immunity. CD8+ T cells (also known as cytotoxic T lymphocytes) are  
activated via antigen-presenting cells (DCs) and directly kill the infected cells 
(Abbas AK 2012). Activated B cells produce antigen-specific antibodies that 
neutralise excellular viral particles or initiate antibody-dependent cell-mediated 
cytotoxicity (ADCC) (Abbas AK 2012).  
 
1.1.5.2.1 miRNAs and T cell development and function 
 
miRNAs can alter the differentiation of T cells. Wu and colleagues 
demonstrated that antigen-induced T cell differentiation is regulated by miRNAs. 
Seven miRNAs (let-7f, miR-142-3p, miR-142-5p, miR-15b, miR-150, miR-16 
and miR-21) have been found to be dominantly expressed in naïve, effector 
and memory CD8+ T cells when compared with all the other miRNAs. Further 
comparison between these three stages showed that six of the above miRNAs 
(except miR-21) were downregulated in effector T cells compared to naïve cells, 
and were expressed again in the memory T cells. These findings suggest that 
altered miRNA profiles can be correlated with different stages of T cell function 
(Wu et al. 2007). Other studies have focused on global changes in miRNA 
expression following activation of CD4+ T cells. Cobb and colleagues showed 
CD4+ T regulatory (Treg) cells have a miRNA profile distinct from that observed 
in conventional CD4+ T cells (Cobb et al. 2006). Neilson and colleagues have 
reported that T cell development was regulated by the miR-181 family, a miRNA 
highly expressed at the CD4+ CD8+ double positive (DP) stage that is then  
dramatically decreased at the CD4+ or CD8+ single positive (SP) stage (Neilson 
et al. 2007). The predicted target of the miR-181 family is B-cell lymphoma 2 
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(Bcl2) (Gratiot-Deans et al. 1993). Bcl2 is a proapoptotic gene involved in T cell 
differentiation in the thymus (Gratiot-Deans et al. 1994). 
 
1.1.5.2.2 miRNAs and B cell development and function 
 
B cells are important contributors to adaptive immunity by generating antibodies 
to neutralise pathogens and induce ADCC to assist NK cell, macrophages and 
neutrophils killing of infected cells. Studies have demonstrated that B cell 
development from the pro- to pre- B cell stage is blocked in mice with a 
conditional deletion of the Dicer enzyme at the earliest stage of B cell 
development. Moreover, miRNA profiling of early B cell development 
demonstrated that the miR-17~92 cluster could control B cell development 
through modulating Bim (Bcl-2 interacting mediator of cell death), a member of 
the pro-apoptotic Bcl2 family, and Pten which positively regulates Bim 
expression (Koralov et al. 2008). B cells from miR-155 deficient mice are unable 
to antibody class switch or differentiate into plasma cells when immunised with 
T-dependent antigen 4-hydroxy-3-nitrophenlacetyl conjugated to keyhole 
limpet hemocyanin (NP-KLH), a well-characterised model for studying B cell 
responses (Vigorito et al. 2007). Thus, it is clear that miRNAs play a vital role 
in normal B cell development. 
 
1.1.6 miRNA delivery 
 
The application of miRNAs into novel therapies has attracted significant interest. 
However, the delivery of miRNAs continues to be an impediment for translation 
in vivo. Major limitations include the stability of the miRNA following delivery, 
off-target effects, interruption of endogenous RNA processes and toxicity 
caused by over-expression of miRNA (Zhang, Wang & Gemeinhart 2013). 
Multiple strategies have been developed to deliver miRNAs in vivo, including 
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viral and non-viral delivery systems. In the present study, we will focus on viral 
miRNA delivery systems. 
 
Most viruses can be modified to express miRNAs, including adeno-associated 
viruses, retroviruses and lentiviruses. The main advantages of a viral delivery 
system is the efficient and consistent high level of miRNA expression. To allay 
safety concerns, the viruses are usually attenuated by deleting key regulatory 
genes to stop replication. Other issues include production of viruses that cause 
pathology in the targeted cells and integration of the viral genome into the host 
chromosomes with the potential to stimulate oncogenes (Larocca & Schlom 
2011). Although these types of viral delivery systems are a promising and 
effective tool to induce the expression of miRNAs, further refinements of this 
technology is required to minimise potential side effects. 
 
1.1.6.1 Adeno-associated virus vectors 
 
Adeno-associated viruses, which belong to the Parvoviridae family, are popular 
viral vectors due to their high infection efficacy and large DNA capacity (Ginn 
et al. 2013). Adeno-associated virus vectors (AAVs) can infect both dividing and 
non-dividing cells and grow to high titres in vitro without integrating into the 
genome of host cells, which makes the vector particularly attractive for miRNA 
delivery. Common challenges for AAV clinical therapy include immune evasion, 
modification of AAV tissue tropism and efficiency of transgenic expression.  
 
1.1.6.2 Retroviral vectors  
     
Retroviral vectors (RVs) are another common viral vector. Most RVs have been 
developed from the Molony murine leukaemia virus (MoMLV). RVs integrate 
into genome of dividing cells. RVs were first used to deliver miRNAs in 2004, 
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where Bartel’s lab ectopically expressed miR-181 in progenitor B cells to 
investigate its role in B cell development (Chen et al. 2004). The main safety 
issue with RVs is the random insertion of genetic material into the host genome, 
resulting in interuption of host gene expression or uncontrolled cell division and 
oncogenesis (Hacein-Bey-Abina et al. 2003). Recent developments using zinc 
finger nucleases (Lombardo et al. 2007) or introduction of phage ϕC31 
integrase may resolve this issue (Olivares et al. 2002).  
 
1.1.6.3 Lentiviral vectors 
 
Lentiviral vectors (LVs) are derived from single-stranded RNA lentiviruses, that 
belong to a subgroup of the retroviruses. LVs can transduce both dividing and 
non-dividing cells (Frimpong & Spector 2000; Naldini et al. 1996), a unique 
feature among retroviral vectors. LVs have the ability to integrate into the host 
genome promoting long-term expression of transgenes and can accommodate 
the introduction of large segments of foreign DNA. This feature is attractive for 
gene therapy applications, where repetitive injection of the vector is impractical 
(Cartier et al. 2012; Palfi et al. 2014). LVs have been used for systemic delivery 
of miR-24, the expression of which is lower in gastric cancer tissue when 
compared to normal tissue. Overexpression of miR-24 inhibits in vitro 
proliferation, migration and invasion of the prostate cancer cell line SGC-7901 
by targeting the RegIV gene that is highly expressed in gastric cancer patients. 
Moreover, injection of lentiviral constructs overexpressing miR-24 into nude 
mice suppresses tumorigenicity (Duan et al. 2014). With the ability to transfer 
gene sequences as big as 8 kb into host cells (Thomas, Ehrhardt & Kay 2003), 
LVs have been used to co-express more than one miRNA. miR-142 and miR-
223 have been expressed in tandem within a single cassette to efficiently knock 
down the GFP-expressing cell line with the target at the 3’UTR of the GFP 
(Amendola et al. 2009).  
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1.1.6.4 Influenza virus vectors 
 
Unlike the vectors mentioned above, influenza viruses do not integrate into the 
host genome and so delivery of miRNAs by recombinant influenza viruses is 
transient given the self-limiting nature of this acute infection. 
 
Recent studies have show that influenza A viruses can be used for delivery of 
miRNAs (Izzard et al. 2014; Perez et al. 2009; Shen et al. 2015; Varble et al. 
2010). Influenza virus genes including NP (Perez et al. 2009), PB1 (Shen et al. 
2015) and NS (Izzard et al. 2014; Varble et al. 2010) have been manipulated to 
allow insertion of miRNAs or miRNA response elements (Perez et al. 2009; 
Shen et al. 2015; Varble et al. 2010). One strategy involved mutagenesis of the 
NS gene segment to interupt normal expression of its two gene products (NS1 
and NEP). miR-124 was expressed from an the artificial intron between linear 
NS1 and NEP genes to generate a recombinant NS gene segment (Varble et 
al. 2010). Using an eight-plasmid reverse genetics system, a recombinant 
influenza virus was rescued that expressed functional miR-124 (Varble et al. 
2010). In summary, miRNA delivery from influenza viruses is effective, transient 
and isolated to the respiratory system. This addresses some of the delivery and 
overexpression issues noted for other viral delivery systems.  
 
1.1.7 miRNA application and use 
     
The application and use of miRNA technology is attracting increased attention 
due to its vital role in the regulation of protein expression. With the discovery of 
miRNA function in human diseases, it is of great significance to utilise miRNAs 
as biomarkers for disease or as a novel molecules for treatment (Mendell & 
Olson 2012). A successful example of miRNA application and translation is the 
use of anti-miR-122 antagomirs (Miravirsen). miR-122 is expressed in the liver, 
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and its expression is essential to support the hepatitis C virus (HCV) replication. 
Miravirsen, an antisense RNA that binds miR-122 has been shown to effectively 
inhibit production of viral RNA and is currently in phase II clinical trials (Janssen 
et al. 2013; Ottosen et al. 2015).  
 
The application of miRNA technology in influenza virus research is still in its 
infancy. Recent studies using high-throughput RNA interference screening 
technology have focused on the relationship between miRNAs and influenza 
virus infection and uncovered potential novel disease intervention strategies, 
which require further investigation (Meliopoulos et al. 2012). Additionally, there 
has been increasing interest in generating live attenuated influenza vaccines 
expressing miRNA recognition elements within influenza gene segments 
including NP ,NS or PB1. The miRNA recognition elements can be recognised 
by mammalian-specific miRNAs leading to restricted replication of live vaccine 
in the lungs of mice but not in chicken eggs (production of virus) (Li et al. 2015; 
Perez et al. 2009; Shen et al. 2015). Other startegies include delivery of artificial 
miRNAs by adenovirus vectors that target conserved regions of influenza genes 
(NP, M1 or M2 ) resulting in inhibition of virus replication and protection of mice 
from lethal influenza virus challenge (Zhang et al. 2015a).  
 
The impressive role of miRNAs in the immune system highlights their potential 
application in vaccine development through enhancement of host immune 
responses. Currently, researchers are trying to generate genetically modified 
disease resistant animals using RNA interference technology. There have been 
only a handful of studies discussing modulation of host immune responses 
through the expression of miRNA using recombinant influenza viruses except 
for those carried out by our lab (Izzard et al. 2014). We demostrated that 
insertion of immunomodulatory miR-155, into the A/PR8 H1N1 influenza virus 
enhanced the type 1 interferon antiviral response, by increasing expression of 
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IL-6 and INF-β in vitro as a result of inhibition of the suppressor of cytokine 
signalling 1 (SOCS1) protein expression (Izzard et al. 2014). In this PhD project, 
we will investigate other miRNAs that may be used to modulate host immune 
response, which will be discussed in greater detail bellow.  
 
1.2  miR-150 
 
miR-150 has been found in diverse species, from zebrafish to mammals. 
Precursor miR-150 is located on chromosome 19 in humans and chromosome 
7 in mice, and mature miR-150 is conserved between humans and mice. miR-
150 is considered to be an important regulator of haematopoiesis, and is 
expressed in mature lymphocytes (Monticelli et al. 2005).  
 
1.2.1 The role of miR-150 in immune cell development 
 
miR-150 is highly expressed in mature, resting B cells in mice spleen as well 
as in naïve T cells, but not in pro-B cells isolated from bone marrow, double-
negative thymocytes, or further differentiated T helper 1 (Th1) or T-helper 2 
(Th2) cell clones (Monticelli et al. 2005). Ectopically expressed miR-150 in 
haematopoietic stem and progenitor cells results in the blockage of B cell 
differentiation from progenitor B cell to precursor B cell stage, leading to a 
significant decrease in numbers of mature B cells in the spleen, lymph nodes 
and circulation, with little impact on T cells, granulocytes and macrophages 
(Zhou et al. 2007). This has been associated with the role of miR-150 regulation 
on c-Myb, a transcription factor controlling multiple steps of lymphocyte 
development (Xiao et al. 2007). Further investigation has confirmed that c-Myb 
is directly targeted by miR-150 in vitro. In vivo gain- and loss-of-function 
experiments in miR-150 knockout transgenic mice (miR-150-/-) have correlated 
with prior in vivo studies characterising conditional c-Myb expression.  
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miR-150 also plays an important role in NK cell maturation and NKT cell 
differentiation (Ginn et al. 2013; Larocca & Schlom 2011). miR-150-/- mice 
exhibit decreased numbers of mature invariant NKT (iNKT) cells in both the 
thymus and peripheral lymphoid organs when compared to WT mice. miR-150 
has also been implicated in the development of T cells but through modulation 
of Notch 3 expression (Ghisi et al. 2011). Notch 3 belongs to the Notch receptor 
family and plays an important role in T cell development and leukemogenesis 
(Bellavia et al. 2003). Both mRNA and protein levels of Notch 3 decrease during 
differentiation of T cells at the double positive to single positive stage. 
Overexpression of miR-150 and luciferase report assays of T-cell acute 
lymphoblast leukaemia (T-ALL) cell lines confirmed that miR-150 targets a 
binding site in the 3’UTR of Notch 3. Downregulation of Notch 3 through 
overexpression of miR-150 in T-ALL cells resulted in apoptosis and reduced 
proliferation (Ghisi et al. 2011).  
 
miR-150 has also been shown to co-operate with other miRNAs to regulate of 
CD4+ T cells. miR-150 was consistently highly expressed during differentiation 
of CD4+ T cells into regulatory T cells and a recent study showed that miR-150 
in conjuction with miR-99 repressed Mtor, a known negative regulator of Treg 
cell differentiation. Downregulation of miR-150 using antagomirs inhibited Treg 
cell differentiation in vitro and in vivo. The role of miR-150 during this process 
was miR-99 dependent. Indeed, this was confirmed using Dicer-deficient cells 
in association with miR-99a and/or miR-150 expression (Warth et al. 2015). As 
the target site of miR-150 in the 3’UTR of Mtor is in close proximity to the miR-
99a target site (only 24 nt upstream), co-regulation of protein expression is 
thought to occur (Broderick et al. 2011; Grimson et al. 2007; Saetrom et al. 
2007).  
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1.2.2 The role of miR150 in immune responses 
 
miR-150 has been shown to target c-Myb and Notch 3. Recently, other target 
genes (validated) have been reported and are shown in Table 1.1. 
Table 1.1. miR-150 target genes 
Target gene Cell Type Biological Consequences 
c-Myb B cells (Xiao et al. 2007) Cell development, maturation 
c-Myb Endothelial cell (Zhang et al. 2010) Cell migration 
c-Myb NK cells (Bezman et al. 2011) Cell maturation 
Notch 3 T cells (Ghisi et al. 2011) Cell proliferation and survival 
P2X7 Cancer epithelial cells (Huang et al. 2013) Apoptosis 
IL2-R(CD25) Cytotoxic CD8+ T cells (Trifari et al. 2013) Adaptive immunity  
CCR6 Advanced cutaneous 
T-cell lymphomas (Ito et al. 2014) 
Tumor invasion/metastasis 
CXCR4 Bone marrow-derived mononuclear cell 
(Tano, Kim & Ashraf 2011) 
Cell mobilization and 
migration 
Perforin-1 NK cells (Kim et al. 2014) Innate immunity 
STAT1 Adult T leukaemia/lymphoma (ATL) cells 
(Moles, Bellon & Nicot 2015) 
Tumour cell proliferation 
Mtor CD4+ regulatory T cells (Warth et al. 2015) Cell development, 
differentiation 
KLF2 Macrophages (Manoharan et al. 2014) Proinflammatory 
p53 Non-small cell lung cancer tissue, and 
A549 cell (Wang et al. 2013; Zhang, Wei & 
Xu 2013) 
Tumor cell cycle/proliferation/ 
apoptosis 
EGR2 Human gastric adenocarcinoma cell lines, 
human gastric epithelial cell lines (Wu et al. 
2010)  
Tumor cell  
proliferation/ apoptosis 
SOCS1 Leukocytes from denge haemorrhagic 
fever patients(Chen et al. 2014), human 
kidney cells (Zhou et al. 2013) 
Innate and adaptive immunity; 
Renal fibrosis 
 
1.2.2.1 miR-150 in innate immunity 
 
miR-150 has been implicated in multiple innate immune system components, 
such as NK cells, DCs, and cytokine signalling pathways. It can act as a 
negative regulator but also promotes activation and therefore regulation of 
innate immune responses. 
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NK cells are an important component of innate immunity. They directly kill target 
cells by secreting cytolytic granules such as Prf1 and granzyme. Perforin 
creates pores in target cell membranes to allow the entry and/or trafficking of 
enzymes to induce apoptosis or lysis. miR-150 has been shown to control the 
expression of Prf1 in both mouse and human NK cells (Kim et al. 2014). 
Dramatic downregulation of miR-150 occurs in resting mouse or human NK 
cells and negatively correlates with increased Prf1 expression. miR150-/- NK 
cells showed higher Prf1 expression with enhanced cytotoxicity, in a B16F10 
melanoma model in immunocompromised mice (Kim et al. 2014).  
 
Dendritic cells are another important innate immune cell type, involved in 
presenting antigens to T cells and initiating adaptive immune responses. A lack 
of miR-150 has been shown to restrict antigen presentation by skin-residential 
DCs as miR-150-/- DCs pulsed with ovalbumin failed to stimulate proliferation 
and IFN-γ production in antigen-specific CD8+ T cells (Mi et al. 2012b).  
 
miR-150 is also involved in macrophage function by negatively modulating 
inflammatory signalling pathways (Ghorpade et al. 2013; Manoharan et al. 
2014). Gain- and loss-of-function analyses in macrophages suggested Sonic 
Hedgehog (SHH)-dependent upregulation of miR-150 and miR-30 can target 
MyD88, an adaptor protein in TLR2 signalling pathway (Ghorpade et al. 2013). 
Another study showed the expression of miR-150 and miR-124a controlled the 
expression of multiple inflammatory mediators (CCL2, CCL5, CCL7, Cox-2 and 
IL-6) by targeting Klf2. Klf2-/- mice showed elevated levels of inflammatory 
mediators that inversely correlated with downregulation of both miR-150 and 
miR-124 (Manoharan et al. 2014). As most of the above studies were carried 
out using miR-150-/- or miR-150 target gene knockout mice or cell lines, it will 
be interesting to see how overexpression of miR-150 during influenza infection 
plays a role in overall innate immune responses in the wild type B6 model.  
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1.2.2.2 miR-150 in adaptive immunity 
 
As with innate immunity, the role of miR-150 in adaptive immunity is still not 
well understood, but it appears that miR-150 is important for both cellular and 
humoral immunity. There are contradictory findings in terms of miR-150’s role 
on effector CD8+ T cells. An early study using a lentiviral vector overexpressing 
miR-150 suggests that increasing levels of miR-150 are involved in the 
inhibition of cytotoxic T cell (CD8+ T cell) differentiation by targeting the IL-2 
receptor (CD25) to suppress inflammatory signalling (Trifari et al. 2013). This 
suggests that miR-150 may negatively regulate the function of effector CD8+ T 
cells through downregulation of CD25 resulting in less proliferation and 
differentiation (Trifari et al. 2013). In contrast, another study indicated that miR-
150-/- CD8+ T cells have impaired effector function against bacterial and viral 
infections associated with dysregulation of genes governing effector and 
memory surface markers (KLRG1 and IL7r), proliferation (CDK1&2)  and 
effector function (Gzma and Gzmb) (Smith et al. 2015). A recent study of miR-
150-/- naïve CD8+ T cells revealed that miR-150 is required to stimulate 
intracellular Ca2+ by targeting TMEM20, a negative regulator of Ca2+production. 
In the absence of miR-150 expression, naïve CD8+ T cells increased TMEM20 
expression, reducing Ca2+ production and downstream proliferation, cytokine 
production and antitumor activity (Kim et al. 2017). These results suggest that  
overexpression or the absence of miR-150 may result in impaired proliferation 
and differentiation as well as functional loss in CD8+ T cells.   
 
Given the important role of miR-150 in B cell development, it is not surprising 
that this miRNA also controls the function of B cells. miR-150 can block B cell 
receptor signalling pathways and MHC ǁ antigen presentation in adipose tissue 
B cells by targeting Elk1, Etf1 or c-Myb genes (Ying et al. 2016). Interestingly, 
other studies in the influenza virus field found overexpression of miR-150 in 
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serum samples of patients with high influenza-specific antibodies after 
vaccination (de Candia et al. 2013).  
 
1.2.3 miR-150 and inflammation 
 
Detailed studies have identified a role for miR-150 in inflammatory signaling 
pathways. Serum samples from patients following allogeneic haematopoietic 
stem cell transplantation (allo-HSCT) showed decreased miR-150 expression 
four days before developing acute graft-versus-host disease (aGVHD) (Sang 
et al. 2015). It has also been shown that overexpression of miR-150 using a  
lentiviral vector inhibits cytokine production by targeting the ARRB2 gene, an 
important downstream protein associated with the CD28 signalling pathway 
involved in T cell activation (Sang et al. 2016; Wang et al. 2012a) Therefore, 
miR-150 may play a role as a negative regulator of inflammation.   
 
In other diseases, increasing miR-150 expression was associated with 
augmentation of inflammatory responses. miR-150 has been shown to 
downregulate SOCS1 during dengue infection (Chen et al. 2014) and lupus 
nephritis (Zhou et al. 2013) resulting in higher cytokine levels. This is in contrast 
to the aGVHD model above. These contrasting findings show there is much to 
learn about the impact of miR-150 on inflammatory responses. 
 
1.2.4 miR-150 and infection 
 
As one of the more intensively studied miRNAs, there are many studies 
indicating that miR-150 plays a key role in infection. Global screening of the 
miRNA profile during HIV infection reveals that a cluster of miRNAs including 
miR-150 accumulate in resting CD4+ T cells and target the 3’-end of HIV-1 
mRNAs. As the specific target site in the 3’UTRs of HIV-1 is a 1.2kb fragment 
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commonly found in all HIV-1 mRNAs except Nef, expression miRNAs can 
repress the translation of almost all the HIV-1 proteins resulting in HIV-1 latency 
(Houzet et al. 2008; Huang et al. 2007; Munshi et al. 2014). miRNA profiling of 
patients and macrophages infected with Mycobacterium tuberculosis (MTB) 
showed downregulation of miR-150 (Zheng et al. 2015). Of direct relevanace 
to this PhD project is miR-150's involvement in influenza virus infection. Serum 
miRNA profiles from patients with A/H1N1 infection indicate that 
overexpression of miR-150 correlates with elevated secretion of multiple 
cytokines and chemokines involved in pro-inflammatory signaling pathways 
(Moran et al. 2015). Another investigation similarly revealed that after influenza 
vaccination, serum miR-150 was significantly increased and correlated with 
influenza specific antibody titres and the activation of peripheral lymphocytes 
(de Candia et al. 2013). These results indicate that miR-150 is released by 
activated lymphocytes in response to infection or immunisation and that 
expression of miR-150 is correlates with augmented immunity. As antibodies 
and the influenza-specific CD8+ T cell responses are critical for clearance of the 
virus, delivery of miR-150 may result in improved immune responses in the 
present study.  
 
1.3 miR-146a 
 
miR-146a is expressed in mammals and located on chromosome 5 in humans 
and chromosomes 11 in mice. miR-146a is thought to function as a negative 
regulator of a number of different pathways including the TLR/IL-1 signalling 
pathway by targeting interleukin-1 receptor-associated kinase 1 (IRAK1) and 
tumour-necrosis factor (TNF) receptor-associated factor 6 (TRAF6), leading to 
the inhibition of innate immune responses (Hou et al. 2009; Taganov et al. 
2006). miR-146 is also reported to be associated with autoimmune disorders 
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such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 
psoriasis (Nakasa et al. 2008; Pauley et al. 2008; Sonkoly, Ståhle & Pivarcsi 
2008; Stanczyk et al. 2008; Tang et al. 2009).  
 
1.3.1 The role of miR-146a in immune cell development  
 
Significant upregulation of miR-146a and miR-146b has been observed in 
differentiation of human monocytes into immature and mature DCs through 
targeting of TRAF6 and IRAK1 leading to suppression of NF-κB signalling and 
apoptosis (Park et al. 2015). 
 
1.3.2 The role of miR-146a in immune responses 
 
As previously discussed, IRAK1 and TRAF6 are considered targets of miR-
146a. Both are key adaptor proteins downstream of Toll-like and cytokine 
receptors. Additional miR-146a targets (validated) are listed in Table 1.2.  
Table 1.2. Molecular targets of miR-146a (Labbaye & Testa 2012) 
Target Molecules Cell Type Biological Consequences 
TRAF6, IRAK1 LPS-stimulated monocytes Innate immunity  
IRAK2 VSV-infected macrophages Innate immunity  
IL-8, RANTES Lung Epithelial Alveolar Cells Innate immunity  
CCL((MCP2) HIV-infected microglial cells Innate immunity  
FADD Activated T lymphocytes Jurkat 
cells 
Anti-apoptotic effect in adaptive 
immunity 
EGF-R Breast, pancreatic and gastric 
cancer cells 
Cell proliferation, survival 
ROCK1 Prostate cancer cells Cell proliferation, invasion and 
metastasis 
NOTCH1 Glioblastoma cells Cell proliferation, invasion and 
metastasis 
CXCR4 Leukemic cell lines; 
haematopoietic progenitors cells 
Cell proliferation, invasion and 
metastasis 
KLF4 Vascular smooth muscle cells Vascular muscle proliferation 
STAT1 CD4+ Treg cells Cell function 
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1.3.2.1 miR-146a in innate immunity 
 
miR-146a plays an important role in the regulation of inflammatory responses 
involving cells of the innate immune system, including monocytes and 
macrophages. Haematopoietic stem cells (HSC) derived from miR-146a-/- mice 
are dysfunctional under physiological pressure such as ageing or bacterial 
infection. The lack of miR-146a expression in aged mice results in 
overproduction of IL-6 and HSC exhaustion (Zhao et al. 2013).  
 
1.3.2.2 miR-146a in adaptive immunity 
 
Analysis of miRNA expression profiles of T cells indicate that miR-146 is one of 
the few miRNAs differently expressed between CD4+ Th1(high- miR-146) and 
Th2 (low- miR-146) cells in the mouse. The results suggest that miR-146 might 
be involved in the differentiation of these different CD4+ T cells (Monticelli et al. 
2005). Furthermore, there are significant differences in miR-146a expression 
between human naïve T cells and memory T cells, where naïve T cells have 
very low miR-146 expression while high expression promotes TCR activation 
(Rusca et al. 2012). Lu and colleagues also illustrated that miR-146a is a critical 
factor in CD4+ T regulatory (Treg) function. In miR-146a-/- mice, Treg numbers 
are increased but fail to restrict effector T cell responses resulting in 
overproduction of IFN-γ from Th1 effector cells via STAT1 mediated pathway, 
a known target of miR-146a (Lu et al. 2010).  
 
1.3.3 miR-146a and inflammation  
 
A key pathway regulated by miR-146a expression is TNF-α production. This 
pathway is controlled through the expression of IRAK1 and TRAF6 genes. In 
addition, miR-146a is able to negatively regulate the expression of IL-1β-
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induced IL-8 and RANTES (CCL5) (Perry et al. 2008). As IL-8 is an important 
proinflammatory cytokine in the IL-1β signalling pathway, and RANTES is a key 
chemokine for immune cell proliferation and recruitment, this again confirmed 
that miR-146a is part of a negative feedback loop. Thus, miR-146a is able to be 
viewed as a potentially interesting tool for therapeutic intervention in 
pathological conditions where inflammatory processes are key players in 
disease biology. 
 
1.3.4 miR-146a and infection  
 
As a negative regulator in the immune system, miR-146a is also able to be 
hijacked by viruses to escape immune surveillance. In the study of vesicular 
stomatitis virus (VSV) infection, Hou and colleagues reported that VSV infection 
up-regulated miR-146 expression which in turn downregulated type I IFN 
expression through down-regulation of TRAK6, IRAK1 and IRAK2 (Hou et al. 
2009) resulting in increased VSV replication in infected macrophages. Stewart 
and colleagues have also recently reported that Hendra virus utilises miR-146a 
to enhance replication as miR-146a levels were elevated in the blood of infected 
ferrets and horses and following in vitro infection of human epithelial cells (HeLa 
cell line) (Stewart et al. 2013).  
 
Finally a recent study involving global profiling of 337 miRNAs in A549 cells 
infected with H1N1 and H3N2 influenza viruses showed that miR-146a was the 
only miRNA that was up-regulated in response to influenza infection (Terrier et 
al. 2013). A subsequent study confirmed that influenza infection increased miR-
146a expression. When treating with miR-146a inhibitor before infection, viral 
titres were significantly increased in infected cells (Terrier et al. 2013).  
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1.4 let-7  
 
The let-7 family (detailed in Table A.6) was one of the first miRNA families to 
be discovered in C. elegans (Lee, Feinbaum & Ambros 1993) and later also the 
first found to be highly conserved across animal species (Pasquinelli et al. 2003; 
Pasquinelli et al. 2000). So far, 14 different let-7 family members have been 
identified in mice and 13 in humans (Roush & Slack 2008).  
 
1.4.1 The role of let-7 in innate immunity 
 
Activation of IFN-β is important in innate immune responses against virus 
infection. A study in SIV infected pigtailed macaques suggests that multiple 
miRNAs including let-7b regulate the expression of IFN-β by targeting the 
5’UTR of IFN-β (Witwer et al. 2010). Another study comparing miRNA profiles 
of leukocyte subsets (B cells, CD4+ T cells, CD8+ T cells, pDCs, cDCs, 
monocytes, NK cells and polymorphonuclear cells) between neonates and 
adults showed let-7b was highly expressed in adult peripheral leukocytes when 
compared to neonatal cord leukocytes. Neonatal monocytes showed reduced 
IL-6 and TNF-α expression upon LPS stimulation when cultured in the presence 
of a let-7b mimic, while use of a let-7b inhibitor resulted in increased IL-6 and 
TNF-α production in adult monocytes (Yu et al. 2016). 
 
1.4.2 let-7 and infection  
 
The let-7 family is involved in the modulation of immune responses during 
infection. Treatment of the human hepatoma cell line Huh7 with IFN-α and 
interleukin-28B (IL-28B) in the presence of hepatitis C virus (HCV) infection 
significantly increased let-7b expression. Luciferase reporter analysis revealed 
that let-7b inhibits HCV viral protein translation and virus replication by targeting 
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insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) which is 
essential for virus replication. With the inhibition of let-7b expression, IFN-α and 
IL-28B treatments against HCV are significantly attenuated (Cheng et al. 2013). 
let-7b, also directly targets toll-like receptor 4 (TLR4). It is decreased in 
Helicobacter pylori infection resulting in the promotion of NF-κB activity and 
inflammatoion. Overexpression of let-7b inhibits the inflammation induced by 
NF-κB in gastric epithelial cells and is involved in control of persistent 
inflammation reducing the risk of cancer (Teng et al. 2013).  
 
let-7 family members are altered following influenza virus infection (Loveday et 
al. 2012; Ma et al. 2012; Peng et al. 2011). let-7c and let-7g can directly target 
the 3’UTR of the influenza matrix gene to inhibit viral replication (Loveday et al. 
2012; Ma et al. 2012). let-7e and let-7f are upregulated in mice infected with the 
seasonal strains, but not the 1918 pandemic strain.  
 
1.5 Influenza Viruses 
 
Influenza viruses pose a great threat to public health. Influenza viruses are a 
major cause of mortality in the elderly and the very young. Every year five 
million people suffer serious illness due to influenza, resulting in 250,000 to 
500,000 deaths according to an estimate provided by the World Health 
Organization (WHO) (WHO 2016). Importantly, influenza viruses also impose a 
significant economic burden. A study of the 2003 USA influenza season 
estimated that the total cost of influenza virus infection was $US 87.1 billion 
(Molinari et al. 2007). It is therefore critical to improve current vaccine efficacy 
and to develop dose-sparing strategies in preparation for influenza pandemics. 
 
 
 
 35 
 
 
1.5.1 General introduction of Influenza viruses 
 
Influenza viruses are members of the Orthomyxoviridae family, and possess a 
segmented, negative-sense, single-stranded RNA genome that includes eight 
separate gene segments coding at least ten functional proteins (Webster et al. 
1992) and are classified into three groups A, B and C . Influenza A viruses have 
been shown to infect humans, birds and other species and are responsible for 
epidemics in humans and domestic animals. Influenza B viruses only infect 
humans and influenza C viruses cause disease in humans and swine. Influenza 
A viruses are further divided into subtypes through the expression of 
haemagglutinin (HA) and neuraminidase (NA) viral proteins located on the virus 
surface. At this stage, 18 HA types and 11 NA types have been identified 
(Fouchier et al. 2005; Tong et al. 2012; Tong et al. 2013; Webster et al. 1992). 
 
The nomenclature used to name influenza virus strains usually includes the 
type of virus (A or B or C), the species from which the virus was identified 
(omitted in human strains), the place of isolation and the isolation number and 
isolation time. HA and NA subtype are also mentioned in type A influenza 
viruses. As an example, A/Puerto Rico/8/1934 (H1N1) indicates this type A 
human influenza strain was isolated from Puerto Rico in 1934, is the 8th strain 
isolated and the subtype is H1N1. 
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Table 1.3. Influenza A virus genome (modified from (Webster et al. 1992)) 
Gene 
No. 
Gene 
Segment 
Size 
(bp) 
Coding protein Function of protein 
1 PB2 2341 polymerase basic 2 component of RNA polymerase, 
cap recognition 
2 PB1 2341 polymerase basic 1 component of RNA polymerase, 
endonuclease activity, elongation 
PB1-F2 Pro-apoptotic activity 
3 PA 2233 Polymerase acidic Component of RNA polymerase, 
protease 
4 HA 1778 haemagglutinin Surface glycoprotein, receptor 
binding, fusion activity, major 
antigen 
5 NP 1565 nucleoprotein RNA binding, RNA synthesis, 
RNA nuclear import 
6 NA 1413 neuraminidase surface glycoprotein, 
neuraminidase activity 
7 M 1027 Matrix protein 1 Matrix protein, interaction with 
vRNPs and surface glycoprotein, 
nuclear export, budding  
M2 Membrane protein, ion channel 
activity, assembly 
8 NS 890 NS1 Multi-functional protein, viral IFN 
antagonist 
NEP Nuclear export of vRNPs 
 
1.5.2 Influenza virus genome  
 
The influenza virus genome is comprised of eight gene segments encoding at 
least 10 proteins, five of which encode a single protein: polymerase basic 2 
(PB2) (Yamayoshi et al. 2015), polymerase acidic (PA), haemagglutinin (HA), 
nucleoprotein (NP) and neuraminidase (NA). The remaining three gene 
segments encode two proteins each: polymerase basic 1 (PB1) and PB1-F2 
(absent in many animal influenza virus strains); matrix protein 1 (M1), matrix 
protein 2 (M2); non-structural protein 1 (NS1) and nuclear export protein (NEP) 
(also called non-structural protein, NS2). This is detailed in Table 1.3. 
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1.5.3 Influenza virus replication 
 
Figure 1.9 illustrates the life cycle of influenza virus. The first stage of the virus 
infection and replication is attachment. Influenza viruses bind sialic acid on the 
surface of the host cell via HA which is a homotrimer on the viral membrane.  
 
Figure 1.9. Life cycle of influenza A viruses. Infection starts from HA of influenza virus 
binding to sialic acid on the surface of the host cell. The virion is then endocytosed attributable 
to a low pH environment, which triggers the cleavage of HA and fusion of viral and cellular 
membrane to release vRNPs into the cytoplasm. Subsequently, vRNPs enter the nucleus for 
transcription and initiation of replication. Finally, assembly of synthesized proteins and vRNAs 
occurs followed by budding and release of the progeny virion (von Itzstein 2007). 
 
After attachment, receptor-mediated enocytosis allows the virion to enter the 
cell. Surrounded by a low pH environment in the endosome, the precursor viral 
surface protein HA (HA0) is cleaved into HA1 (a heavy chain) and HA2 (a light 
chain) subunits. This cleavage process is essential for virus infectivity as HA2, 
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the fusion peptide, inserts into the endosomal membrane of the host cell to fuse 
the viral membrane. The acidic environment of the endosome also triggers the 
opening of the M2 ion channel, which promotes the separation of M1 from virus 
ribonucleoproteins (vRNPs) (Martin & Helenius 1991), and finally leads to the 
release of the vRNP into the host cell cytoplasm (Schnell & Chou 2008). vRNPs 
then bind to the cellular nuclear import machinery through nuclear localization 
signals (NLSs) and enter the nucleus for transcription and initiation of 
replication (Whittaker et al., 2000).  
 
Influenza virus mRNA synthesis is dependent on cellular RNA polymerase II 
activity and includes two main stages: 1) ‘cap snatching’ from cellular mRNAs 
for initiation of viral transcription and 2) polyadenylation to generate a poly (A) 
tail at the 3’ ends of the viral mRNAs (M.L. 2007; Samji 2009). Replication starts 
by generating a full-length, positive-sense copy of vRNA as complementary 
RNA (cRNA), which then serves as a template to generate negative-sense 
genomic vRNA (Figure 1.9). 
 
Translation of viral proteins is a staged process with the 11 proteins expressed 
based on the role they play at different stages of the virus life cycle as 
documented in Table 1.4. Following replication, progeny vRNPs, that are 
assembled in the nucleus are exported into the cytoplasm for incorporation into 
new virus particles (Figure 1.9). This process is mediated by M1 and NEP 
proteins (Boulo et al. 2007). 
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Table 1.4. The expression of influenza proteins 
Stage Proteins Function References 
Early  NP Replication  (Hatada et al. 1989; Hay et al. 
1977) (Shapiro, Gurney & Krug 
1987; Smith & Hay 1982) 
NS1 blocks host antiviral 
immune responses 
Late  HA Surface protein 
NA Surface protein 
M1 Inhibition of viral 
transcription; export of 
RNPs from nucleus 
(Martin & Helenius 1991; Perez 
& Donis 1998; Watanabe et al. 
1996) 
   
Influenza viral proteins are transported to the plasma membrane of infected 
cells to participate in viral assembly and budding (Figure 1.9) (Chen et al. 2007a; 
Chen, Takeda & Lamb 2005; Leser & Lamb 2005; Takeda et al. 2003).  
 
1.5.4 Splicing 
 
Splicing is an important mechanism in influenza virus replication and can be 
found in all members of the influenza family. Typically, splicing occurs in the 
NS, M and PB1 gene segments and is instigated at a splice initiation site (Bruns 
et al. 2007). This is an imporatnt feature of this project as we are using the NS 
gene segment for insertion of miRNAs 
 
1.5.4.1 Splicing of the NS gene segment 
 
The NS gene segment of influenza A virus encodes two proteins. NS1, is 
translated from an unspliced primary mRNA transcript and plays an important 
role in influenza virus replication by acting as an IFN-α/β antagonist (Kittel et al. 
2004). NS2 is encoded by a spliced NS mRNA transcript and is involved in 
nucleo-cytoplasmic export of viral RNPs (Robb et al. 2009). The cleavage site 
is located at nucleotide 57 near the C terminus of NS1. Both proteins use the 
same start codons, but only share 10 amino acids. The NS gene segment can 
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be modified to express exogenous material due to this splicing feature. The NS 
gene segment has been manipulated in the past through insertion of internal 
ribosomal entry sites (IRES) to produce a bicistronic vRNA (Garcia-Sastre et al. 
1994). Moreover, short 2A cleavage sites have also been inserted into the viral 
RNA to generate multicistronic vectors (Szymczak et al. 2004). Recently, 
Varble and colleagues used reverse genetic technology to create a modified 
influenza virus that expresses miR-124 from the NS gene segment without 
affecting viral replication (Varble et al. 2010). These studies provide the proof-
in-principle support for generating recombinant influenza viruses that express 
miRNAs outlined in this PhD project. 
 
1.5.4.2 Splicing of the M gene segment 
 
Like other viruses that utilise the splicing machinery of host cells for their own 
use (Bohne, Schambach & Zychlinski 2007; Filippova et al. 2007; Kraunus et 
al. 2006; Tormanen et al. 2006), influenza viruses hijack splicing factors to 
splice the M gene segment (Shih & Krug 1996). M1 mRNA encodes the M1 
protein and M2 mRNA encodes the M2 protein. The cleavage site is located 
near the 5′ terminal end after nucleotide 51. Both proteins use the same start 
codons but only share nine amino acids. The ratio of M2  :  M1 mRNA increases 
during infection reflecting the different functions in the viral life cycle (Valcarcel 
et al., 1991).  
 
1.5.5 Influenza virus vaccination 
 
Influenza vaccines have been used extensively for over 70 years since the first 
inactivated influenza vaccine was approved in USA in 1945 (Keitel WA 2013 ). 
To date, inactivated vaccines are the primary prevention strategy used to 
protect people from influenza virus infection. The vaccines stimulate the 
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production of neutralizing antibodies against the viral haemagglutinin (HA) 
protein and neuraminidase (NA) proteins. More recently, live attenuated 
vaccines (LAIV) have also been widely used (WHO 2012).  
 
1.5.5.1 Current influenza vaccines  
 
1.5.5.1.1 Inactivated Influenza vaccines  
 
Inactivated influenza vaccines are the most widely used vaccines in the world. 
The previously commonly used technique to generate vaccine strains involved 
classical reassortment. Six backbone internal gene segments from the A/PR8 
(H1N1) virus strain and the HA and NA from circulating seasonal viruses are 
used to generate a high-yielding hybrid virus that is grown in embryonated eggs 
to allow manufacture of the vaccine. In recent years, this classical reassortment 
has been replaced by influenza reverse genetics techniques (discussed in 
section 1.6). Once the vaccine virus strain is generated, manufacturers grow 
virus in embryonated eggs or in approved cell lines to achieve required 
quantities. Inactivation and splitting of the HA and NA antigens is performed to 
finalise the formulation. Cell-propagated vaccines are now been used to 
decrease the risk of egg allergy and egg adaptation (Palese & Wang 2012). 
The efficacy of inactivated vaccines against laboratory-confirmed influenza in 
healthy adults younger than 65 years is approximately 59% (Osterholm et al. 
2012). Current quadrivalent vaccines recommended by the WHO include the 
influenza A (H3N2), influenza A (H1N1) virus and two influenza B viruses 
lineages and are used in Australia. 
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1.5.5.1.2 Live attenuated influenza vaccines 
 
Live attenuated influenza vaccines (LAIVs) are temperature sensitive 
attenuated vaccines where virus replication is restricted to the upper respiratory 
tract (<33oC)  and are delivered in the form of nasal spray (e.g. Flumist® by 
Medimuune). Like most inactivated vaccines, LAIVs have recently been 
changed to quadrivalent formulations. Some studies have shown that LAIVs 
provide better protection for children and adolescents than traditional 
inactivated vaccines (up to 72% protection against all matched strains) 
(Ambrose, Levin & Belshe 2011; Carter & Curran 2011; Esposito et al. 2012). 
Moreover, unlike inactivated vaccines, LAIVs are more effective against 
seasonal circulating influenza viruses that do not match vaccine strains (Belshe 
et al. 2007; Belshe et al. 2010), as the vaccines not only stimulate a humoral 
response, but also a robust cellular immune response. The T cell response is 
important in virus clearance and has been shown to cross-protect against 
different subtypes of virus in animals (Hillaire, Osterhaus & Rimmelzwaan 2011; 
McMichael et al. 1983). In the USA, this vaccine was recommended for healthy 
people aged 2–49 years who were not pregnant or had a weakened immune 
system, suffered from asthma or had other medical conditions (USA CDC, 
2013). LAIV was not recommended for use during the 2016-2017 flu season, 
due to poor protection observed in 2015-2016 season (3% efficacy compared 
to 63% for inactivated vaccines (CDC 2016). In Europe, it has previously been 
authorised for use in children aged 2–18 years, but not for adults (European 
Medicines Agency 2012). LAIVs are not currently approved for use in Australia 
(Australian Technical Advisory Group on Immunisation (ATAGI) 2017). 
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1.5.5.2 Novel Influenza vaccines 
 
Although inactivated quadrivalent vaccines and LAIVs are widely available and 
effective in preventing seasonal influenza epidemics, these vaccines are 
always closely matched with known circulating strains. Protection from novel or 
high pathogenic pandemic strains is less certain. Many studies are currently 
being carried out to develop a universal influenza virus vaccine. Examples 
include vaccines based on the highly conserved T cell epitopes found in the M2 
protein or antibodies that target that stalk of HA. (Dormitzer, Tsai & Del Giudice 
2012; Kang, Song & Compans 2011; Pica & Palese 2013).  
 
1.5.5.3 Problems with current influenza vaccines 
 
1.5.5.3.1 Vaccination in elderly  
 
People aged 65 and older suffer from influenza virus infection in greater 
numbers than younger people. Data from 1976–2007 suggest that over 65% of 
deaths attributable to influenza virus infection are in the elderly in the USA 
(CDC 2016). Moreover, influenza virus is the major cause of hospitalisations in 
this age group. This is mainly due to the poor efficacy of vaccines in the elderly. 
Some studies suggest 43% protection in adults over 65 compared with 59% in 
adults under 65 (Jefferson et al. 2010). However, according to an estimation for 
the 2012–2013 USA flu season, the effectiveness of the vaccine against 
influenza A (H3N2) among people aged 65 or older was as low as 9%, 
compared with 47% in all other age groups (Jackson et al. 2013).  
 
Immunosenescence is one of the main reasons for the increases in influenza 
virus infection and for failure of the vaccine in the elderly (Gavazzi et al. 2007). 
Immunosenescence refers to the decrease in functional immunity with age, 
which results in a decline of proinflammatory cytokines in the innate immune 
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system as well as reduced T cell diversity and naïve T cell precursors (Aspinall 
et al. 2007).  
 
1.5.5.3.2 Vaccination in youth 
 
Although children younger than 2 years old are vulnerable and have higher risk 
of influenza virus infection, vaccination is still controversial in this age group. 
No vaccines are recommended for infants younger than 6 months old due to 
poor immune responses after vaccination. Although LAIVs in some studies 
(Ashkenazi et al. 2006; Belshe et al. 2007; Bracco Neto et al. 2009; Forrest et 
al. 2008; Rhorer et al. 2009) showed better protection in younger children, an 
increased risk of severe side effects has blocked its application in children aged 
younger than 2 years.  
 
1.5.5.4 Problems with seasonal vaccines 
 
Current vaccines are annually reviewed in order to provide the best possible 
protection. However, protection from the vaccines may be inadequate when 
circulating influenza strains and vaccine strains are not matched. Current 
vaccine strains are predicted well in advance of upcoming influenza virus 
seasons and generally provide good protection. There is however a long period 
required for the generation the seasonal vaccine, which usually takes as long 
as six months (25-50 weeks) (World Health Organization 2007). This may 
increase a risk of a mismatch between the upcoming circulating virus and the 
vaccines strain (Pica & Palese 2013). 
 
1.5.5.5 Problems with current antiviral strategies 
 
There are four licensed prescription influenza antiviral agents approved in the 
USA; amantadine and rimantadine are M2 ion-channel inhibitors and zanamivir 
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and oseltamivir block the function of neuraminidase. The most significant 
limitation of antiviral agents is antiviral resistance during the prevention or 
treatment of influenza (Song et al. 2012a). However, the frequency of 
adamantine resistance in influenza A (H3N2) and circulating 2009 H1N1 and 
the emergence of oseltamivir resistance in influenza A (H1N1) and other strains 
highlight the need for new intervention strategies (De Baets et al. 2013; Tan et 
al. 2012). 
  
1.5.6 The C57.BL/6 mouse model of influenza virus infection 
 
Mice are the most commonly used animal model for influenza virus research 
(Matsuoka, Lamirande & Subbaran 2009). The mouse model is practical in 
terms of size, cost and husbandry requirements. There are also a large number 
of species-specific reagents available. The susceptibility of standard inbred 
mice to influenza viruses following intranasal inoculation can be seen in Table 
1.5. The majority of influenza virus research in mice is performed in either 
BALB/C or C57.BL/6 (B6) mice strains, and the most popular virus strains are 
mouse adapted A/Puerto Rico/8/1934 (H1N1) (PR8), A/WSN/1933 (WSN) and 
a reassortant virus (X31) carrying the HA and NA genes of A/Hong Kong/1/1968 
(H3N2) with the six internal segments from PR8.  
 
A/PR8 and A/WSN viruses are prototype lab strains, and can cause severe 
disease or death with relatively low doses of inoculum. The virulence of the 
reassortant X31 strain sits between the wild-type A/Hong Kong/1/1968 and the 
A/PR8 influenza virus strains. A/PR8 (H1N1) and A/X31 (H3N2) strains are 
serologically distinct as antibodies against the glycoproteins of one virus do not 
neutralise the other. Virus-specific T cells recognise conserved immundominant 
T cell epitopes derived from the NP or PA and so prime boost strategies with 
these viruses (which share common PR8 NP and PA gene segments) can 
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augment T-cell responses. Virus titres in the lung following primary infection 
peak at day 3 post-infection (3dpi) and virus is cleared by day 10. CD8+ T cell 
responses first appear at 5dpi and peak at 10dpi with two immunodominant T 
cell responses observed (NP366-374 and PA224-233). Functionally, these influenza 
specific CD8+ T cell populations are able to kill virus infected targets and 
produce cytokines including IFN- TNF and IL-2 (Doherty et al. 1997).  
Table 1.5. Susceptibility of standard inbred mice to influenza viruses following intranasal 
inoculation (Bouvier & Lowen 2010) 
Viral Strain  50% infectious 
dose (LD50)  
50% lethal dose  
(LD50)  
Mouse 
Strain  
PR8 (H1N1)  102 pfu BALB/C 
WSN (H1N1)  102 – 103.3 pfu BALB/C 
X31 (H3N2) 100.7 EID50 >105.2 EID50, 105.84 
pfu 
BALB/C 
1918 pandemic strain (H1N1) 100.75 pfu 103.25 to 103.5pfu BALB/C 
A/New Caledonia/20/1999 
(H1N1) 
~102.7 pfu  C57BL/6 
A/Texas/36/1991 (H1N1)  >106 pfu BALB/C 
A/Kawasaki/UTK-4/09 (H1N1)  >106.6 pfu BALB/C 
A/Netherlands/607/2009 
(pH1N1) 
 <104.7 pfu C57BL/6 
A/California/04/2009 (pH1N1) 101.5 104.7 to >106 pfu BALB/C 
A/Viet Nam/1203/2004 (H5N1) 101.5pfu,  
102.2 EID50 
101.3 pfu, 101.8 EID50 BALB/C 
A/Hong Kong/483/1997 (H5N1) 102.2 EID50 101.6 to 102.4 EID50 BALB/C 
A/chicken/BC/CN-7/04 (H7N3)  102.4 TCID50 BALB/C 
A/Netherlands/219/03 (H7N7) 100.76 EID50 102.5 EID50,  
100.8 TCID50 
BALB/C 
A/turkey/VA/4529/02 (H7N2) 101.76 EID50 >107 TCID50 BALB/C 
A/Red Knot/NJ/1523470 
/06 (H7N3) 
101.5 pfu >104.8 pfu BALB/C 
A/Ruddy 
Turnstone/DE/650645/02 
(H2N9) 
102.4 PFU >105.4 pfu BALB/C 
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1.6 Reverse genetics  
 
1.6.1 Introduction 
 
Influenza reverse genetics systems allow use of cloned cDNA for the 
generation of influenza viruses. The system provides both viral genome and 
essential viral proteins to the host cell for virion assembly. The first influenza 
reverse genetics system was developed in 1990 (Enami et al. 1990; Luytjes et 
al. 1989) using ‘helper viruses’. Almost ten years later, two individual research 
groups developed a 12 plasmid system to rescue influenza viruses from viral 
cDNAs with each of the eight plasmids encoding viral genomic RNAs and the 
other four ‘helper’ plasmids providing the ribonucleoproteins (Chou et al. 2012; 
Neumann et al. 1999). The current, widely used eight-plasmid reverse genetics 
system (a key part of this PhD project), uses a pHW2000 plasmid backbone 
that contains bidirectional cellular DNA-dependent RNA polymerases I and ǁ. 
Each of the eight pHW2000 plasmids used in transfection contains one 
influenza gene segment, which enables the synthesis of negative-sense viral 
genomic RNA and positive-sense mRNA from one viral cDNA template (Figure 
1.10) (Hillaire et al. 2011a; Hoffmann et al. 2000). The eight plasmids are 
transfected into a co-culture of HEK 293 T cells and MDCK cells to ensure 
transfection and amplification of virus. The addition of trypsin into culture 
facilitates virus replication. Transfection supernatants are then collected and 
amplified in 10-day old embryonated eggs to generate the virus stocks 
(Neumann et al. 1999).  
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Figure 1.10. 8-plasmid reverse genetics system for generation of influenza A Virus. Eight 
pHW2000 plasmids, each encoding one influenza gene segment, are transfected into a co-
culture of MDCK and HEK 293 T cells. The bi-directional DNA-dependent RNA polymerases (I 
and ǁ) on the plasmid allow the generation of negative-sense viral RNA and positive-sense 
mRNA to assemble an infectious virion, which is then released from the cell (Hoffmann et al. 
2000). 
 
1.6.2 Application of reverse genetics technology 
 
Reverse genetics technology is a great tool to understand pathogenesis and 
virulence associated with influenza virus infection (Hatta et al. 2001; Tumpey 
et al. 2005). It has also been used to dissect the importance of T cell immunity 
and has been used to express exogenous antigens (Florido et al. 2013; Sexton 
et al. 2009). The Stambas lab has generated recombinant influenza viruses that 
express HIV, SIV and TB CD4+ and CD8+ T cell epitopes (add refs) from the 
NA gene segment for use as vaccine vectors in mouse and macaque models. 
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1.6.2.1 Generation of seasonal vaccines  
 
As discussed briefly in section 1.5.5.1, reverse genetics technology plays an 
important role in the generation of seasonal influenza vaccines. Most 
manufacturers prefer to use eight- or twelve-plasmid reverse genetics systems 
to generate the seasonal vaccine (Kittel et al. 2004). Briefly, a backbone strain 
(PR8 in inactivated influenza vaccines; or attenuated cold-adapted (ca) 
temperature sensitive strains (A/Ann Arbor) for live attenuated vaccines) 
provides six internal genes, which are recombined with the circulating HA and 
NA genes to generate the seasonal vaccine. Recently, reverse genetics 
technology has been used to prepare the H1N1/2009 pandemic virus vaccine. 
In the present study, we expand this technology to improve immunogenicity of 
the influenza vaccines by engineering recombinant viruses that express 
miRNAs. 
 
1.6.2.2 Pathogenesis research 
 
Reverse genetics systems provide a platform for the dissection of influenza 
virus biology as well as dissection of host-pathogen interactions. Through 
reverse genetics, scientists have rescued the 1918 pandemic influenza virus to 
allow a comprehensive understanding of the characteristics of this devastating 
strain and to understand the contribution of various gene segments to 
pathogenesis (Kash et al. 2006; Kobasa et al. 2007; Tumpey et al. 2005). 
Similar studies have also been performed for avian influenza viruses including 
H5N1 (Imai et al. 2012; Russell et al. 2012) and H7N9 (Luk et al. 2015; Zaraket 
et al. 2015). Two research groups reported that genetically modified H5N1 
viruses with three or four substitutions in the HA gene had the ability to transmit 
between mammals (Imai et al. 2012; Russell et al. 2012). Similar findings were 
also reported for H7N9 (Luk et al. 2015; Zaraket et al. 2015).  
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1.6.2.3 Influenza viruses as vaccine delivery vectors 
 
Viral vectors are usually used to deliver antigens in order to stimulate robust 
immune responses. Influenza viruses have been used as a delivery vector for 
HIV antigens as they are thought to stimulate mucosal immunity (Cukalac et al. 
2009). In addition influenza viruses have been used to deliver Hepatitis B 
antigens (Song, Lee & Seong 2012; Tan et al. 2012) and respiratory syncytial 
virus T cell epiotpes (De Baets et al. 2013). Recently, recombinant influenza 
viruses have also been used to deliver functional miRNAs (Varble et al., 2010), 
which form the basis of the present study. 
 
1.7 Project hypothesis 
 
The project is based on the following hypothesis: 
 
    That infection with recombinant influenza A viruses expressing 
immunomodulatory miRNAs will enhance host immune responses. 
 
1.8 Project aims 
 
 (1): To generate recombinant influenza viruses that express 
immunomodulatory miRNAs using reverse genetics technology; 
  
    (2): To explore the characteristics of recombinant influenza viruses 
expressing miRNAs and validate their expression in vitro. 
     
    (3): To assess the primary innate and adaptive immune responses of mice 
infected with recombinant influenza viruses expressing miRNAs. 
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    (4): To assess the secondary immune responses of mice infected with 
recombinant influenza viruses expressing miRNAs. 
 
    (5): To assess protection provided by recombinant influenza A viruses 
expressing miRNAs against viral challenge. 
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Chapter 2  Materials and Methods 
 
2.1 Buffers, solutions and other reagents 
 
A detailed list of materials is provided in Appendix A. 
 
2.2 Oligonucleotides, cloning plasmids, qPCR probes and peptides 
 
See Appendix A, Table A.1–A.4. 
 
2.3 Culture media 
 
Dulbecco’s modified eagle medium (DMEM) was used for human embryonic kidney 
(HEK) 293T cell growth. The HEK growth medium was prepared with the addition of 
10% fetal calf serum (FCS) and 4.6% enriched supplement, then stored at 4oC. 
 
Ham’s F-12 nutrient mixture (F-12) was supplied by GibcoTM (Life Technologies, 
Australia) and used for culturing human lung adenocarcinoma alveolar basal epithelial 
cells (known as A549 cells). For A549 cell culture, 100 µg/mL penicillin/streptomycin 
(Tissue Culture Group, Australian Animal Health Laboratory (AAHL), CSIRO) and 10% 
heat-inactivated FCS were added. 
 
Hanks’ balanced salt solution (HBSS) was supplied by the Tissue Culture Group at 
AAHL, CSIRO. It contains 400 mg/L potassium chloride (KCl), 60mg/L potassium 
phosphate monobasic ( KH2PO4), 350 mg/L sodium bicarbonate (NaHCO3), 8,000 
mg/L sodium chloride (NaCl), 48 mg/L sodium phosphate dibasic (Na2HPO4), 1,000 
mg/L D-glucose, 10 mg/L phenol red. 
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Opti-MEM® I Reduced-Serum Medium (Opti-MEM medium) was supplied by 
GibcoTM (Life Technologies, Australia) and is an improved minimal essential medium 
(MEM), that allows reduced use of FCS with no effect on cell growth. It was used in 
transfection, reverse genetics experiments and virus infection in vitro. A 5% FCS Opti-
MEM was prepared with the addition of 5% FCS and 100 U/mL penicillin/ streptomycin.  
 
Easy flu medium contained 100 U/mL penicillin/streptomycin in Opti-MEM medium.  
Infection medium was prepared with 1µL/mL TPCK treated trypsin (see A.1.9, 
Worthington Biochemical Corporation, ScimaR, VIC, Australia), 0.1% FCS, 0.3% BSA 
(see A.1.3) and 100 U/mL penicillin/streptomycin in Opti-MEM medium. 
 
Roswell Park Memorial Institute (RPMI) 1640 medium was supplied by GibcoTM 
(Life Technologies, Australia) and used for experiments with Madin–Darby canine 
kidney (MDCK) cells.  
 
The MDCK growth medium (also referred to as RPMI growth medium in Section 2.20 
and 2.23) was prepared with the addition of 4.6% enriched supplement and 10% heat-
inactivated FCS (fetal calf serum).  
 
The plaque assay medium was prepared with 2 mM L-glutamine (Tissue Culture 
Group, AAHL, CSIRO), 1 mM MEM sodium pyruvate (Tissue Culture Group, AAHL, 
CSIRO), 100 U/mL penicillin/streptomycin, 12 mg of gentamycin (Tissue Culture 
Group, AAHL, CSIRO) and 9% heat-inactivated FCS (AAHL, CSIRO) added to RPMI 
medium. RPMI anti-medium was prepared by adding 24 µg/mL gentamycin and 100 
U/mL penicillin/streptomycin to the RPMI medium. 
 
For plaque assays, Leibovitz’s L-15 medium was prepared as 2× stock, and diluted 
1:1 with agarose gel. L-15 powder (GibcoTM, Life Technologies, Australia). The 
ingredients were dissolved into tissue culture water (TC water, Tissue Culture Group, 
AAHL, CSIRO) and the pH adjusted to 6.8 with 1 M hydrochloric acid, followed by the 
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addition of 0.056% NaHCO3 (dissolved to 7% (w/v) in HBSS), 0.8 mM HEPES buffer 
(pH 6.8, Tissue Culture Group, AAHL, CSIRO), 200 U/mL penicillin/ streptomycin and 
48 µg/mL gentamycin. Finally, the medium was filtered and stored at 4oC for later use. 
 
Luria-Bertani (LB) broth was supplied by the Tissue Culture Group at AAHL, CSIRO. 
It contains 10 g/L peptone 140, 5 g/L yeast extract and 5 g/L NaCl. 
 
LB agar was supplied by the Tissue Culture Group at AAHL, CSIRO. Before use, LB 
agar was placed in a microwave for 2-3 min. When the agar reached 42-45oC, 0.2 mL 
100µg/mL ampicillin (Sigma-Aldrich, USA) was added and 15mL agar poured into 
20mL petri-dish plates. After solidification, plates were kept at 4 oC for a maximum 1 
month. 
 
2.4 Antibodies 
 
See Appendix A, Table A.5. 
 
2.5 Bacteria 
 
Escherichia coli (E. coli) strain JM109 (Promega, USA) was used for transformations. 
 
2.6 Cells 
 
The MDCK cell line was a gift from the World Health Organization (WHO) 
Collaborating Centre for Reference and Research on Influenza (VIDRL), Melbourne, 
VIC, Australia. This cell line was used in reverse genetics (Section 3.2.3), plaque 
assays (Section 3.2.4) and in vitro infection studies (Section 3.2.6) using influenza 
virus.  
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The human embryonic kidney 293T cell (HEK-293T cell) line was used in influenza 
virus reverse genetics (Section 3.2.3).  
 
The adenocarcinoma human alveolar basal epithelial (A549) cell line was used in dual-
luciferase assays (Section 3.2.8) and for cytokine detection following in vitro infection 
with influenza viruses (Section 3.2.9). 
 
2.7 Eggs  
 
Embryonated chicken eggs were obtained from a commercial source and incubated 
in the Small Animal Facility (SAF) at AAHL, CSIRO, before amniotic inoculation with 
influenza viruses. 
 
2.8 Mice 
 
Female 6–8-week-old C57.BL/6 (B6) mice were bred and maintained at SAF, AAHL, 
CSIRO. 
 
2.9 Molecular cloning techniques 
 
2.9.1 Agarose electrophoresis 
 
DNA was electrophoresed in 1–1.5% agarose gels (Promega, USA) containing 1× 
GelRedTM fluorescent nucleic acid dye (Biotium Inc, USA) at 100 V. Samples in 6× 
DNA loading buffer were added to individual wells along with a 1 kb Plus DNA Ladder 
(Invitrogen, USA) and electrophoresis performed in 1× TAE buffer. DNA was 
visualised after exposure to ultraviolet light with GelRed TM fluorescent nucleic acid 
dye (Biotium Inc, USA) 
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2.9.2 RNA extraction 
 
RNA was extracted with a RNeasy Mini Kit (Qiagen, Germany) following the 
manufacturer’s instructions.  
 
2.9.3 Reverse transcription 
 
Reverse transcription (RT) was carried out using SuperScript III First-Strand Synthesis 
SuperMix (Invitrogen, USA) following the manufacturer’s instructions. The synthesised 
cDNA was stored at –20oC or used immediately in the next step. 
 
2.9.4 Polymerase chain reaction 
 
Polymerase chain reactions (PCRs) were carried out using Phusion Flash High-
Fidelity PCR Master Mix (Thermo Scientific, USA). The reaction mixture contained: 2 
µL of sense primer (0.5 µM), 2 µL of antisense primer (0.5 µM), 10 µL of 2× Phusion 
Flash PCR Master Mix, 1 pg-10 ng of template DNA and nuclease-free water to make 
a total volume of 20 µL. PCR was performed in a PCR machine (Thermo Fisher, USA) 
with initial denaturation starting at 98oC for 10 seconds, with a further 35 cycles of 
denaturation (98oC for 2 seconds), annealing (58oC for 15 seconds), extension (72oC 
for 30 seconds). A final extension (72oC for 2 minutes) was included. PCR products 
were stored at –20oC or used immediately. 
 
For PCRs performed with GoTaq Flexi DNA polymerase (Promega, USA); 4 µL of 
Green GoTaq Flexi Buffer, 1.2 µL of MgCl2 solution (1.5 mM), 0.4 µL of dNTP (0.2 
mM), 2 µL of sense primer (0.5 µM), 2 µL of antisense primer (0.5 µM), 0.2 µL of 
GoTaq DNA polymerase (1 unit) and 2 µL cDNA products or plasmids (<0.2 µg/20 µL) 
were mixed together with sufficient nuclease-free water to bring the total volume to 20 
µL. The PCR program included an initial denaturation step at 95oC for 3 minutes, and 
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continued with a further 30 cycles of denaturation (95oC for 30 seconds), annealing 
(58oC for 40 seconds), extension (72oC for 2 minutes). A final extension (72oC for 10 
minutes) was included. PCR products were then stored at –20oC, or used immediately. 
 
2.9.5 DNA purification 
 
DNA was purified using a QIAquick Gel Extraction Kit (Qiagen, Germany) or a 
QIAquick PCR Purification Kit (Qiagen, Germany) depending on the size of the PCR 
product. Purification was performed according to the manufacturer’s instructions. 
 
2.9.6 Ligation of DNA inserts into plasmid DNA vectors 
 
Purified DNA products or plasmids were digested with appropriate restriction enzymes. 
For single restriction enzyme digestion or blunt end restriction enzyme digestion, 
samples were treated with an additional 1 µL of thermosensitive alkaline phosphatase 
(TSAP, Promega, USA) at 37oC for 30 minutes to remove phosphate from 5 ends and 
avoid self-ligation. Following inactivation of enzyme activity at 74oC for 15 minutes, 
digestion products were purified as described in 2.9.5. For ligation, the insert to vector 
ratio was 8:1, prior to the addition of 1 µL T4 ligase buffer, 1 µL of T4 ligase (Promega, 
USA) and nuclease-free water to make a final volume of 20 µL. The ligation mixture 
was then kept at 4oC overnight for stick end ligations or at 16oC for 18 hours for blunt 
end ligations in the PCR machine. 
 
2.9.7 Transformation of competent JM109 E.coli 
 
Five µL of ligation mixture was added to 30 µL of competent JM109 E. coli in a 10-mL 
polypropylene tube (Corning, USA), and incubated on ice for 30 minutes. The 
transformation mixture was then heat-shocked at 42oC for 45 seconds, and placed 
back on ice for an additional 3 minutes before adding 900 µL of LB broth. The 
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transformation tube was then put into a shaking incubator at 37oC, 150 rpm for 1.5 
hours. Transformed cells were pelleted at 1,600 rpm for 3 minutes, resuspended in 
100 µL of LB broth, placed evenly on an LB agar plate with 100 µg/mL ampicillin and 
incubated at 37oC overnight. 
 
2.9.8 Screening of recombinant E. coli clones 
 
Identification of recombinant E. coli clones containing plasmids with our inserted DNA 
product of interest was carried out using PCR reaction with insertion-specific primers 
(pHW2000-1, pHW2000-2, detailed in Table A.1). Individual clones were placed into 
3 mL of LB broth containing ampicillin (100 μg/mL) using a sterile tip. The tips were 
then placed into 10 µL of nuclease-free water, from which a 2 µL sample was used as 
a template for a clone-specific PCR. The PCR procedure is described in Section 2.9.4. 
LB broth cultures with the correct insertion were incubated at 37oC, 250 rpm overnight 
in a shaking incubator for miniprep analysis of plasmid DNA.  
 
2.9.9 Miniprep isolation of plasmid DNA 
 
Miniprep isolation of plasmid DNA was performed using a QIAprep Spin Miniprep Kit 
(Qiagen, Germany) using the manufacturer’s instructions. Plasmids were eluted in 
nuclease-free water and stored at -20oC. The presence of an insert was confirmed by 
sequencing. 
 
2.9.10 Maxiprep isolation of plasmid DNA 
 
Endotoxin-free plasmid DNA was purified using an EndoFree Plasmid Maxi Kit 
(Qiagen, Germany). Isolations were performed according to manufacturer’s 
instructions, and the final products stored at -20oC.  
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2.9.11 Sequencing 
 
Sequencing PCRs were performed using a BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, Life Technology, USA). Template DNA (300 ng), 3.5 µL of 5× 
sequencing buffer, 1 µL of 5 µM specific primer, 1 µL of BigDye and nuclease-free 
water were added for a 20 µL reaction. PCRs were performed in a PCR machine 
(Thermo Fisher, USA) with an initial denaturation step at 96oC for 1 minute, followed 
by 25 cycles of denaturation (96oC for 10 seconds), annealing (50oC for 5 seconds) 
and extension (60oC for 4 minutes). PCR products were then submitted to the CSIRO 
AAHL Sequencing Hub for further. The sequences were then analysed using MEGA 
5.0 software. 
  
2.10 Primary microRNAs and scramble microRNA amplification 
 
Murine primary miRNAs were amplified from DNA extracted from murine spleen. 
Scramble miRNA controls were generated through site-direct mutagenesis and 
overlap PCR to replace mature miRNA seed regions with scrambled sequence.  
 
2.11 Reverse genetics 
 
Reverse genetics were performed using an eight-plasmid system initially described by 
a previous study (Hoffmann et al. 2000) with modifications detailed below. In brief, 
HEK-293T and MDCK cells were cultured separately in 5% FCS Opti-MEM in 75 cm2 
flasks. The day prior to reverse genetics, confluent HEK-293T and MDCK cells were 
removed from flasks and resuspended in 5 mL of easy flu medium (Section 2.3). 
MDCK cells and HEK-293T cells (5–6×105 cells/well for each cell line) were mixed with 
16.5 mL of easy flu medium and 3 mL aliquots placed in each well of the 6-well plate 
with a density of 0.2–1×106 total cells per well, overnight. The next day, 90–100% 
confluent co-cultured HEK-293T and MDCK cells were used in reverse genetics 
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transfection experiments; 1 µg of eight pHW2000 plasmids encoding individual gene 
segments of influenza PR8 H1N1 virus or X31 H3N2 virus (PB2, PB1, PA, HA, NP, 
NA, M and NS) were combined with FuGene 6 transfection reagent (Promega, USA) 
at the ratio of 1:2 in Opti-MEM and incubated at room temperature for 45 minutes 
before being added into the HEK-293T and MDCK cells co-culture. Recombinant 
viruses expressing primary miRNAs of interest were incorporated into the NS gene 
segment as previously described (Izzard et al. 2017; Izzard et al. 2014) and detailed 
in Section 3.2.2. The transfection medium was removed after 6 hours and replaced 
with 1 mL of easy flu medium for 18–30 hours, with an additional 1 µg/mL TPCK-
treated trypsin easy flu medium (see Section 2.3) added to each well. The co-cultured 
cells were incubated at 37oC in 5% CO2 for a further 48 hours prior to analysis for the 
presence of virus. 
 
2.12 Haemagglutination assay 
 
Supernatant from reverse genetics co-cultures was collected and the presence of virus 
determined using a semi-quantitative haemagglutination assay (HA) (Palmer et al. 
1975). In brief, supernatant samples were serially diluted (1:2) across a 96-well plate 
with 0.5% chicken RBCs added. Positive wells were identified by agglutination of 
RBCs resulting in RBC suspension in the well. Negative wells did not agglutinate 
RBCs and formed a pellet at the bottom of the V-shaped well.  
If the HA result was negative, 200 µL of supernatant was added to 70–90% confluent 
MDCK cells in a 6-well plate in the presence of 1 µg/mL TPCK-treated trypsin for 48hrs 
to amplify small amounts of virus. Supernatant was collected and a second HA assay 
performed to determine amplification of virus.  
 
Positive HA assay samples underwent RNA extraction as described in Section 2.9.2, 
RT-PCR (see Section 2.9.3–2.9.4) and sequencing with NS specific primers (see 
Section 2.9.11) to confirm miRNA insertion into NS gene segments. Positive 
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transfection supernatants were then injected into 10-day old embryonated eggs to 
amplify virus stock. The titres of recombinant H1N1 or H3N2 viruses was then 
determined using the plaque assay (see Section 2.14) (Huprikar & Rabinowitz 1980). 
 
2.13 Influenza virus infection in eggs 
 
Ten-day-old fertilised chicken eggs were inoculated with 0.1 mL of 10–5 diluted virus 
stock or neat transfection samples into the chorioallantoic cavity. The eggs were 
incubated at 36oC for 48 hours prior to being placed at 4oC overnight to kill the embryo 
and constrict the blood vessels. Allantoic fluid from each egg was harvested and 
stored at –70oC prior to analysis by plaque assay.  
 
2.14 Plaque assay  
 
Traditionally, influenza viral titres have been assessed by determining plaque-forming 
units (PFUs) (Huprikar & Rabinowitz 1980). MDCK cells are initially seeded in 6-well 
plates at a density of 3.8 × 105 cells/mL. The next day, confluent cells are inoculated 
in duplicate with 150 µL of serially diluted allantoic fluid or with a RPMI anti-medium 
alone (negative control). The plates are then incubated at 37oC, 5% CO2 for 45 
minutes and shaken every 15 minutes prior to the addition of a 3mL-agarose overlay 
consisting of L-15 medium and TPCK-treated trypsin (final concentration 2 µg/mL) to 
each well. The plates were placed at room temperature until the agar settled and then 
kept at 37oC, 5% CO2, for 3 days. At this point the agar overlay is removed and cells 
are fixed with ice-cold acetone-methanol solution for 15 minutes before the solution 
was removed and wells air-dried. 1% Crystal violet (see A.1.7, BD, USA) is then added 
to each well for 10 minutes to visualize plaques. Virus titre was calculated using the 
following formula: PFUs/mL = average numbers of plaques/ dilution titre* V, where V 
is the volume of virus placed into each well. 
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2.15 In vitro virus infection  
 
Virus infection was conducted at various multiplicities of infection (MOI, MOI 0.1 for 
miRNA, MOI 2 for cytokine detection, MOI 0.01 for virus growth kinetics). Virus 
dilutions were performed in RPMI containing 1% penicillin/streptomycin and 
gentamycin or easy flu medium, and cell lines (A549 or MDCK) inoculated at 37oC for 
1 hour. The inoculum was subsequently removed and cells were washed with 
phosphate-buffered saline (PBSA) to remove unattached virus. Medium with 1 µg/mL 
TPCK-treated trypsin was then added to cells and cultured for a further 72 hours.  
To determine miRNA or cytokine expression, MDCK or A549 cells were infected with 
recombinant influenza viruses or wild-type controls at a MOI between 0.1 or 2.0 based 
on previous experiments performed in the Stambas laboratory (Izzard et al. 2014; Ye, 
Lowther & Stambas 2015). After 24 hours, cells were washed with PBSA and RNA 
extracted for further analysis. 
 
2.16 Dual-luciferase assay 
 
In order to test the function of the expressed miRNAs of interest, previously identified 
target genes with miRNA seed sites were used in this assay.  A portion of the 3 
untranslated region (3 UTR) of the target gene (c-Myb) containing the binding site for 
miR-150 was amplified from genomic mouse DNA using specific primers (cMyb 3utr F 
and cMyb 3utr R (detailed in Table A.1)). The PCR product was then cloned into 3’ 
UTR of the Renilla luciferase gene in the siCHECKTM dual-luciferase plasmid 
(Promega, USA) according to the manufacturer’s instruction. A549 cells were initially 
transfected with 100 nM of the commercial 3 UTR siCHECKTM vector incorporating 
cMyb and the miRNA seed site and 6 hours later infected with miR-150-expressing 
recombinant influenza virus or PR8 wild type (PR8-WT) at the MOI of 2 and incubated 
for 1 hour. The supernatant was then removed and cells washed with PBSA, before 
further incubation with 1 mL of infection medium (Section 2.3) for 24 hours. The cell 
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lysate was collected and processed using the Dual-Luciferase Reporter Assay System 
(Promega, USA) as per the manufacturer’s instruction and the fluorescence was 
determined using a SynergyTM Multi-Detection Microplate Reader (BioTek, USA). 
 
2.17 Cytokine detection following in vitro infection 
 
A549 cells were infected with miRNA-expressing influenza viruses or wild-type viruses 
at a MOI of 2, and 24 hours after infection and the supernatant was removed. Cells 
were washed once with PBSA and disrupted with lysis buffer (RNA extraction kit, 
Qiagen, Germany). RNA was extracted following the manufacturer’s instructions. 
cDNA was then synthesised as outlined in Section 2.9.3. Cytokine mRNA expression 
levels were determined using a TaqMan real-time PCR assay (Thermo Fisher 
Scientific, USA). The reaction mixture contained 1.25 µL of commercial probe/primer 
mixture (0.5 µM), 12.5 µL of 2× TaqMan® Universal Master Mix II and 11.5 µL of 1/40 
diluted template DNA. Real-time PCR was performed using a StepOnePlus™ Real-
Time PCR System (Applied Biosystems™, USA) with initial denaturation at 95oC for 
10 minutes followed by 40 cycles of denaturation (95oC for 15 seconds) and annealing 
(60oC for 1 minute). The expression of cytokine mRNAs and influenza M gene was 
calculated using the 2-ΔΔCT method described previously where the expression level 
was normalised to uninfected cell controls (Ye, Lowther & Stambas 2015).  
 
2.18 Influenza virus growth kinetics-multicycle growth curves 
 
MDCK cells were infected with influenza viruses at an MOI of 0.01. Supernatant (250 
µL) was collected at 6, 12, 24, 30, 48, 54 and 72 hours post-infection. Supernatants 
were then used in plaque assays as described in Section 2.14.  
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2.19 Infection and immunisation 
 
Female B6 mice used in this study were bred, infected and euthanised in the SAF at 
CSIRO AAHL. For primary infection, B6 mice were infected intranasal with 1×104 pfu 
of A/Hong Kong/1/68 (H3N2) (X31) wild-type or X31 recombinant influenza viruses 
expressing miRNA. For secondary infections, B6 mice were initially primed by 
intraperitoneal injection (1×107 pfu of A/Puerto Rico/8/1934(H1N1) (PR8) or PR8 
recombinant virus expressing miRNA) and 42 days later challenged intranasally with 
a serologically distinct virus (1×104 pfu of X31 H3N2 expressing the same miRNA) to 
characterise immunity. Experimental animals were weighed daily following infection to 
determine weight loss and assess morbidity. For primary experiments, animals were 
euthanised on days 1, 3 or 10, and lung, bronchoalveolar lavage (BAL), spleen (only 
on day 10 experiments) and serum collected for analysis of innate and adaptive 
immune responses. For secondary acute experiments, mice were euthanised on day 
7 after challenge and spleen, BAL and serum collected for analysis of influenza-
specific immune responses. Animal Ethics approval was obtained through the CSIRO 
AAHL AEC (AEC 1468, AEC 1772, AEC 1825) and Deakin University AEC (external 
project, AEC AEX03-2012) and experiments were conducted following the Australian 
Code of Practice for the Care and Use of Animals. 
 
2.20 Murine cell preparation 
 
2.20.1 Spleen 
 
Spleens were placed in a sterile petri-dish with HBSS media (Section 2.3) and 
disrupted using frosted glass slides to generate a single cell suspension. HBSS was 
added to a final volume of 20 mL and the sample filtered through a 70-µm filter. To 
enrich T cells, the single cell suspension was placed on antibody coated (AffiniPure 
goat anti-mouse Immunoglobulin G (IgG) and Immunoglobulin M (IgM) (Jackson 
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ImmunoResearch, USA) panning plates to remove B cells and incubated at 37oC for 
45 minutes. After incubation, 10 mL of HBSS was added the sample centrifuged at 
1,600 rpm for 5 minutes at 4oC. The pellet was resuspended in 5 mL RBC lysis solution 
(ATC buffer) and incubated at 37oC for 3 minutes. HBSS was added to wash the single 
cell suspension prior to centrifugation at 1,600 rpm for 5 minutes at 4oC. Cells were 
finally resuspended in 3 mL of RPAM growth medium (Section 2.3, 10%FCS with 
enriched supplement RPMI medium) for use in functional assays. 
 
2.20.2 Lung 
 
Lung tissue was cut into small pieces with scissors and then digested with 2 mL of 
collagenase (2 mg/mL) at 37oC for 30 minutes. Single cell suspensions were 
generated by pushing the digested mixture through a 70-µm filter using a 3-mL syringe 
plunger. The cell strainer was washed with 5 mL of HBSS and the cells centrifuged at 
1,600 rpm for 5 minutes. The pellet was resuspended in 1 mL of HBSS and treated 
with 5 mL RBC lysis solution at 37oC for 3 minutes. After treatment, HBSS was added 
and the cells centrifuged again prior to resuspension in 1 mL RPMI growth medium. 
 
2.20.3 Bronchoalveolar lavage 
 
Individual BAL samples were placed into 6-well plates and incubated at 37oC for 1 
hour to remove adherent cells (macrophages). For day 10 primary experiments, five 
BAL samples from each group were pooled together to ensure sufficient cells were 
available for analysis. Non-adherent cells (T cells) were centrifuged at 4oC, 1,600 rpm 
for 6 minutes and cells resuspended in RPMI growth medium.  
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2.21 Flow cytometry and phenotypic analysis 
 
For day 1 and day 3 primary experiments, 100 µL of single cell suspension (spleen, 
lung or BAL) was added to 96-well round-bottom plates (BD Falcon, USA) and 
centrifuged at 4oC, 1,600 rpm for 4 minutes. The pellet was resuspended in an 
antibody cocktail (50 µL) of fluorescein isothiocyanate (FITC)-labelled rat anti-mouse 
Ly6G/Ly6C (RB6-8C5; BD Pharmingen™), phycoerythrin (PE)-labelled rat anti-mouse 
CD11b (M1/70; BD Pharmingen™), peridinin chlorophyll (PerCP)-Cy5.5-labelled rat 
anti-mouse MHC II (M5/114; BD Pharmingen™), allophycocyanin (APC)-labelled rat 
anti-mouse CD11c (HL3; BD Pharmingen™), Brilliant Violet™ (BV) 605-labelled rat 
anti-mouse CD45 (30-F11; BioLegend); FITC-labelled rat anti-mouse Ly6G/Ly6C, PE-
labelled rat anti-mouse Ly6G (1A8; BioLegend), PerCP-Cy5.5-labelled rat anti-mouse 
CD69 (H1.2F3; BD Pharmingen™), APC-labelled rat anti-mouse CD3e (145-2C11; 
BD Pharmingen™), BV 605-labelled rat anti-mouse NK1.1 (PK136; BioLegend) 
together with rat anti-mouse CD32/CD16 (BD Pharmingen™) to block Fc receptor 
binding. The plate was placed on ice in darkness for 30 minutes. FACS buffer (100 µL) 
was added to wash cells (X2) by centrifugation and pellets resuspended in 100 µL of 
FACS buffer for analysis on a BD LSRFortessaTM cell analyser (BD, USA). Flow 
cytometry data was analysed using FlowJo software (FlowJo, USA). 
 
For day 10 primary acute experiments, 100 µL of single cell suspension (spleen, lung 
or BAL) was added to 96-well round-bottom plates, centrifuged at 4oC, 1,600 rpm for 
4 minutes and stained with a 50 µL antibody cocktail consisting of FITC-labelled rat 
anti-mouse CD4 (RM4-4; BD Pharmingen™), PE-labelled rat anti-mouse NKG2D 
(CX5; BD Pharmingen™), PerCP-Cy5.5-labelled rat anti-mouse CD69, APC-labelled 
rat anti-mouse CD3e, BV 605-labelled rat anti-mouse NK1.1, BV 785-labelled rat anti-
mouse CD8a (53-6.7; BioLegend); FITC-labelled rat anti-mouse Ly6G/Ly6C, PE-
labelled rat anti-mouse Ly6G, PerCP-Cy5.5-labelled rat anti-mouse B220 (RA3-6B2; 
BD Pharmingen™), APC-labelled rat anti-mouse CD11b (M1/70; BD Pharmingen™), 
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BV 605-labelled rat anti-mouse CD45 (30-F11; BioLegend), BV 785-labelled rat anti-
mouse CD19 (6D5; BioLegend) together with rat anti-mouse CD32/CD16 and 
incubated on ice in darkness for 30 minutes. The cells were washed and analysed as 
above.  
 
For secondary acute day 7 experiments, 100 µL of single cell suspension (spleen, lung 
or BAL) cells was added to a 96-well round-bottom plate, centrifuged at 4oC, 1,600 
rpm for 4 minutes and stained with a 50 µL antibody cocktail consisting of PerCP-
Cy5.5 rat anti-mouse CD8a, FITC-labelled rat anti-mouse CD4, PerCP-Cy5.5-labelled 
rat anti-mouse CD8a, APC-labelled rat anti-mouse CD3e; FITC-labelled rat anti-
mouse CD4, PE-labelled rat anti-mouse CD44 (IM7; BD Pharmingen™), PerCP-
Cy5.5-labelled rat anti-mouse B220, APC-labelled rat anti-mouse CD62L, BV 785-
labelled rat anti-mouse CD19 together with rat anti-mouse CD32/CD16 and incubated 
on ice in darkness for 30 minutes. The cells were washed and analysed as above. 
 
2.22 Tetramer staining  
 
Tetramer (Altman et al. 1996) staining was used to detect two immunodominant 
influenza-specific CD8+ T cell populations: nucleoprotein (H-2DbNP366-374) (DbNP366) 
and acid polymerase (H-2DbPA224-233) (Db PA224) (Webby et al. 2003). T cell enriched 
single cell suspensions (100 µL; spleen, lung or BAL) were added into 96-well round-
bottom plates, centrifuged at 4oC, 1,600 rpm for 4 minutes stained with PE-labelled 
DbNP366 or DbPA224 tetramer (50 µL-Department of Microbiology and Immunology, The 
University of Melbourne, Australia) and incubated in darkness at room temperature for 
1 hour. The cells were then washed twice with FACS buffer by centrifugation and 
stained with a cocktail consisting of rat anti-mouse PerCP-Cy5.5 anti-CD8a, FITC-
labelled rat anti-mouse CD62L, PerCP-Cy5.5-labelled rat anti-mouse CD8a and APC-
labelled rat anti-mouse CD3e (for primary day 10 experiments) or APC-labelled anti-
CD44 (IM7; BD Pharmingen™) for secondary day 7 experiments on ice for 30 minutes 
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in darkness. The cells were then washed twice with FACS buffer by centrifugation 
(1,600 rpm for 3 minutes) and resuspended in 100 µL FACS buffer for analysis on a 
BD LSRFortessaTM cell analyser. 
 
2.23 Intracellular cytokine staining 
 
Enriched lymphocytes from spleen, lung or BAL cells (100 µL) were added to 96-well 
round-bottom plates and incubated for 5 hours at 37oC in the presence of 2 µg/mL 
DbNP366 or DbPA224 peptides in 100 µL of RPMI growth medium containing 50 U/mL 
recombinant human IL-2, and 10 µg/mL GolgiPlug protein transport inhibitor 
(containing Brefeldin A, BD Biosciences) (Belz et al. 2000; Townsend et al. 1986). The 
plates were centrifuged at 1,600 rpm at 4oC for 3 minutes and stained with PerCP-
Cy5.5-labelled rat anti-mouse CD8a in FACS buffer for 30 minutes on ice in the dark. 
Cells were washed twice with FACS buffer by centrifugation (1,600 rpm for 3 minutes), 
then resuspended in 100 µL of golgi solution (10 µg/mL) prior to fixing with 100 µL 0.5% 
paraformaldehyde for 15 minutes at room temperature. The cells were kept at 4oC 
overnight in darkness. The next day, plates were centrifuged at 1,600 rpm at 4oC for 
3 minutes and cells resuspended in 150 µL of 1× Perm Wash solution (BD 
Biosciences). Plates were then incubated at 4oC for 20 minutes in darkness. After 
incubation, cells were centrifuged and stained with an antibody cocktail consisting of 
FITC-labelled rat anti-mouse IFN-γ (XMG-1.2; BD Pharmingen™), PE-labelled rat 
anti-mouse IL-2 (JES6-5H4; BD Pharmingen™), APC-labelled rat anti-mouse TNF-α 
(MP6-XT22; BD Pharmingen™) in 1× Perm Wash for 30 minutes at 4oC in darkness. 
After being washed a further two times by centrifugation with 1× Perm Wash, the cells 
were resuspended in 200 µL of FACS buffer and analysed on a BD LSRFortessaTM 
cell analyser. 
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2.24 Virus neutralisation assay (microneutralisation assay) 
 
Microneutralisation assays were conducted using a method previously described by 
(Harmon et al. 1988). The day before the assay, 100 µL of 3 × 105 cells/mL MDCK 
cells are placed in each well of a 96-well flat-bottom plate and incubated at 37oC, 5% 
CO2 overnight to obtain 90–100% confluency. On the day of the assay, 10 µL of serum 
samples obtained from infected mice is heat-inactivated at 56oC for 30 minutes and 
cooled to room temperature. The inactivated serum is then added to 90 µL of MDCK 
infection medium containing 1 µg/mL TPCK-treated trypsin and serially diluted (2-fold) 
down the plate. Influenza viruses (500 PFUs/well) are then added to wells. The 
inactivated serum/virus samples are incubated together at 37oC, 5% CO2 for 1 hour 
and transferred to a confluent MDCK plate and incubated at 37oC, 5% CO2, for 72 
hours. Microneutralisation results are calculated by performing a HA assay by 
transferring 50 µL of cultured supernatant to corresponding wells on a 96-well V-
bottom plate prior to the addition of 50 µL of 0.5% chicken RBCs as previously 
described in section 2.12. 
 
2.25 Extraction of exosomes from serum 
 
Exosomes were extracted from serum using an ExoQuickTM Exosome Precipitation 
Solution system (System Biosciences, USA). In brief, 50 µL of serum obtained from 
infected mice was mixed with 10 µL of ExoQuick Exosome Precipitation Solution and 
incubated at 4oC overnight. The serum/ExoQuick mixture was then centrifuged at 
1,500 rpm for 30 minutes, and the supernatant removed while the pellet containing 
exosomes was resuspended in 10 µL of nuclease-free water.  
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2.26 Detection of microRNA expression by qPCR  
 
MiRNA expression from infected cells or serum was determined using a previously 
established method (Shi & Chiang 2005). For in vitro study, MDCK cells were infected 
with miRNA expressing recombinant virus at a MOI of 0.01, and infected MDCK cell 
monolayers were processed for miRNA expression at 24 hrs post-infection. For in vivo 
studies, serum exosomes were extracted as described in Section 2.25. RNA was 
extracted from infected MDCK monolayers or serum exosomes using the miRNeasy 
mini kit (Qiagen, Germany) according to the manufacturer’s instruction. Genomic DNA 
was removed from the RNA samples using RQ1 DNase (Promega, USA). The treated 
RNA samples were then polyadenylated using Yeast poly (A) polymerase (PAP) 
(Affymetrix, USA) and cDNA synthesis using the Superscript III first-strand synthesis 
kit (Life technologies, USA) performed. MiRNA expression was determined using a 
SYBR Green PCR master mix containing specifically designed quantitative RT-PCR 
primers and a universal reverse primer (detailed in Table A.2). Real-time PCR was 
performed in a StepOnePlus Real-Time PCR System (Applied Biosystems™, USA) 
with initial denaturation at 95oC for 10 minutes, 40 cycles of denaturation (95oC for 15 
seconds), annealing (60oC for 1 minute), and then the final PCR product was exposed 
to a gradient of temperatures from 60oC to 95oC, with 0.3oC per second, to produce a 
melt curve. MiRNA expression was determined relative to 5S rRNA which was stably 
expressed in the cell line and calculated using 2-ΔΔCT method to normalise against 
uninfected controls. All the experiments were processed in triplicate.   
 
2.27 Statistical analysis 
 
The statistical significance of the data was determined by Student’s t-test. Differences 
with p < 0.05 were considered significant. 
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During our secondary analyses, we observed a variable distribution of raw data 
following tetramer staining. As the Student t- test requires a normal distribution of data, 
the raw data obtained was not suitable for analysis using this statistical test. In this 
circumstance, we converted our raw data into log10 values to obtain a normal 
distribution (Figure 2.1) before using a student T test for analysis of the tetramer results. 
We acknowledge Dr. Steven Bowe at Deakin University assistance with statistical 
analysis of secondary experiments.  
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Figure 2.1: The histogram and distribution curve of the BAL samples in secondary infection.  
The histogram represents different transformations of the numbers of DbNP366-specific (A) or DbPA224-
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specific CD8+ T cells (B) of all the sample in BAL, the blue curve represents the distribution of the data 
sets by transformation. 
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Chapter 3  Generation of influenza viruses expressing 
miRNAs and validation assays in vitro 
 
3.1 Introduction  
 
miRNAs play important roles in post-transcriptional regulation of host gene expression 
and are involved in many physiological and pathological processes. Extensive 
investigations have demonstrated a crucial role for miRNAs in host immunity through 
regulation of development and maturation of haematopoietic cells (Baltimore et al. 
2008; Chen et al. 2004; Monticelli et al. 2005) and through regulation of host-pathogen 
interactions (Bandyopadhyay et al. 2011; Chen et al. 2014; Chen et al. 2007b; Cheng 
et al. 2013; Ottosen et al. 2015). Important roles in virus infection have been 
documented in the literature. For example, a liver-specific expression of miRNA-miR-
122 is essential in the life cycle of hepatitis C virus (Jangra, Yi & Lemon 2010; Jopling, 
Schütz & Sarnow 2008; Jopling et al. 2005). A miR122 antagonism complementary to 
the 5’ end of miR-122 (miravirsen, previously SPC3649) was shown to restrict the 
replication of the virus not only in vitro but also in humans and primates (Lanford et al. 
2010; Li et al. 2011b; Ottosen et al. 2015). It is the first successful miRNA targeting 
agent used in patients (Janssen et al. 2013). In recent years, several studies have 
also focused on the role of miRNAs during influenza A virus infection and indeed 
several miRNAs were shown to be dysregulated in both in vitro or in vivo models 
(Loveday et al. 2012; Ma et al. 2012; Moran et al. 2015; Peng et al. 2011; Terrier et al. 
2013). miR-146a, miR-150 and miR-21 were found to be dysregulatedupon infection 
and associated with alterations in innate or adaptive immunity. As these miRNAs also 
play an important normal immune function, we hypothesised that delivery of these 
miRNAs during infection could modulate host immune responses and improve 
outcomes of disease.  
 75 
 
 
 
As well as miRNAs, the use of artificially designed short hairpin RNAs (shRNAs) is 
another approach to utilised in the field to knockdown gene expression. There are five 
main differences between miRNAs and shRNAs, which have been summarised in 
Table 3.1 suggest fewer off-target effects, lower toxicity and easier synthesis for 
shRNAs when compared to miRNAs, making them popular candidates for gene 
therapy including HIV (Boden et al. 2004; Choi et al. 2015) and cancer (Koornneef et 
al. 2011; Liang et al. 2007). In fact, some groups have embedded shRNAs into the 
backbone of endogenous miRNAs. This miRNA backbone shRNA (also known as 
shRNAmir; Figure 3.1B) mimics and follows the natural biogenesis pathway of miRNA 
processing leading to specific degradation of target RNA with greater efficiency 
(Boden et al. 2004; Fellmann et al. 2013). shRNAmirs are less toxic than nude shRNAs 
as they do not saturate miRNA pathways (Boudreau, Monteys & Davidson 2008; 
Castanotto et al. 2007; Fowler et al. 2016; Grimm et al. 2006). shRNAmirs also 
facilitate precise Dicer cleavage and decrease off-target effects (Gu et al. 2012). 
Furthermore, shRNAmirs can be linked together to achieve greater knockdown or 
multiple gene targeting (Choi et al. 2015; Chung et al. 2006; Liu et al. 2008; Sun et al. 
2006). A number of miRNA backbones have been used to demonstrate efficient 
knockdown of target genes by shRNAs, including miR-30, miR-155, miR-150 and miR-
17-92 (Choi et al. 2015; Chung et al. 2006; Liu et al. 2008; Zeng, Wagner & Cullen 
2002). In this study, a shRNA was designed to target interleukin-1 receptor-associated 
kinase 1 (IRAK1) to directly compare the efficacy of gene regulation by miRNAs and 
shRNA. miR-146a has been shown to target IRAK1 (Hou et al. 2009; Taganov et al. 
2006). The IRAK shRNA was inserted into a miR-30 backbone and introduced into the 
NS gene segment of influenza virus to generate a recombinant virus for proof of 
principle studies in vitro. 
 
Finally, we set out to generate a recombinant virus that inhibits miRNA expression 
using antisense sequences that are complementary to mature miRNAs (Davis et al. 
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2006; Hutvagner et al. 2004; Krutzfeldt et al. 2005). The antisense molecules are 
thought to bind mature miRNAs inhibiting binding to their real targets. Traditional 
chemically modified miRNA inhibitors require high doses and multiple injections 
(Krutzfeldt et al. 2005) making their use impractical and costly. New strategies 
including plasmids or viral vector delivering antagomirs (Scherr et al. 2007), eraser 
(Sayed et al. 2008), sponges (Ebert, Neilson & Sharp 2007) and Tough Decoy (TuD) 
RNAs (Figure 3.1C) (Haraguchi, Ozaki & Iba 2009) have all been developed for this 
purpose. In the present study, we designed miR-146a inhibitor to be expressed from 
the NS gene segment of influenza virus.  
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Figure 3.1. Schematic representations of miRNA, shRNA and miRNA inhibitor constructs used 
in the current study. A). miRNA, either partial complementary to target mRNA resulting in translational 
repression or perfectly complementary to target mRNA leading to mRNA cleavage; B) shRNA 
embedded into the miR-30 backbone (shRNAmir) targeting mRNA (only one strand binds to target 
mRNA) results in the degradation of target mRNA; C) Tough Decoy structure miRNA inhibitor with two 
bulged miRNA binding sites, adapted from Bak et al.(Bak et al. 2013; Haraguchi, Ozaki & Iba 2009). 
 
 
Table 3.1. Comparison of miRNA and shRNA. 
Criterion miRNA shRNA 
Nature of source Endogenous Artificial synthesised 
Complementary to target gene Mostly partial complementarity Perfect complementarity  
Target gene Multiple target genes Only one target gene 
Function 
Direct or indirect degradation 
of mRNA or translation 
repression 
Direct degradation of mRNA 
Specific Off-target effects Higher than shRNA Lower than miRNA 
 
  
Target mRNA 
shRNAmirs 
Target mRNA 
Target mRNA 
miRNA 
Target miRNA 
Target miRNA 
inhibitor 
A B C 
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In the present study, two serologically distinct mouse-adapted influenza viruses PR8 
(H1N1) and X31 (H3N2) were generated to express miRNAs of interest using a 
reverse genetics system. The eight-plasmid system utilises a pHW2000 plasmid 
backbone that encodes each cDNA gene segment of influenza virus. Virus rescue is 
achieved by transfection of all the eight plasmids into a co-culture of HEK 293 T cells 
(high transfection efficiency) and MDCK cells (strong influenza virus replication), 
resulting in the synthesis of the vRNAs and mRNAs which are assembled and 
packaged into viral particles. The viral particles are released into culture to infect 
MDCK cells (Figure 3.2). This method has been used successfully to insert CD8+ T 
cell epitopes (HIV, SIV, TB) into the NA stalk (Florido et al. 2013; Gonzalo et al. 1999; 
Muster et al. 1994; Sexton et al. 2009).  Apart from the HA or NA segments which 
encode influenza virus surface proteins, the non-structural (NS) gene segment can be 
used for insertion foreign sequences of interest. This is because it is the smallest gene 
segment among all eight gene segments allowing easy manipulation but also because 
it uses a splicing mechanism and host cell machinery to express multiple proteins from 
the one gene segment (as does the M gene segment). The NS segment produces the 
NS1 protein that is important for antiviral immunity (Wang et al. 2000) and the nuclear 
export protein (NEP) that is important for virion assembly and replication (O'Neill, 
Talon & Palese 1998; Robb et al. 2009).  NS1 and NEP are not structural proteins 
and so this gene segment is an ideal candidate for expressing 
miRNAs/shRNAmirs/miRNA inhibitors of interest. Previous studies suggest that the 
NS1 gene segment has the capacity to tolerate the insertion of up to several hundred 
base pairs (Ferko et al. 2001; Kittel et al. 2005; Manicassamy et al. 2010; Takasuka 
et al. 2002; Varble et al. 2010). The strategy used in our study is based on previously 
validated work by Varble et al in 2010 in which the NS1 and NEP genes are linearized 
(normally, the C-terminal of the NS1 protein overlaps with the N-terminal of nuclear 
export protein) to create room for an artificial intron for miRNA insertion (Varble et al. 
2010). Linearisation of the gene segment involved separating the NS1 and NEP genes 
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by site-direct mutagenesis of the splice acceptor site in NS1. This reconstruction 
created an artificial intron between the ORF of NS1 and NEP, which allowed the 
insertion of a miRNA of interest. The new miRNA-NS was then cloned into pHW2000 
plasmid used in reverse genetics systems and a recombinant virus rescued. In 
Varble’s study, a brain-specific miRNA, miR-124, was delivered using an engineered 
influenza virus. Differentiation of neuronal precursor cells occured when cells were 
infected with miR-124 expressing recombinant influenza virus which confirmed 
functional miR-124 expression. Moreover, normal viral replication was not disturbed in 
the new recombinant virus. This strategy confirmed the ability of influenza viruses to 
act as a vector for the delivery of functional miRNAs. 
 
Figure 3.2. Schematic representation of influenza virus reverse genetics using an eight-plasmid 
system. Eight plasmids, each encoding one influenza gene segment, were transfected into HEK 293 T 
cells to produce influenza virions. Adapted from from Hoffmann et al (Hoffmann et al. 2000). 
 
In the Stambas laboratory, recombinant influenza viruses expressing 
immunomodulatory miR-155 have been generated and validated through targeting of 
SOCS1 in vitro (Izzard et al. 2014). This work further supported our hypothesis that 
engineered influenza virus expressing miRNAs can be used to manipulate immune 
responses. Taken together, the aim of this chapter is to generate recombinant 
influenza viruses to deliver small non-coding RNAs, including miRNAs, shRNA or 
miRNA inhibitor. There are a number of advantages of expressing small non-coding 
RNA using recombinant influenza viruses. First, the expression of these molecules is 
transient as influenza viruses are normally cleared by the immune system in 7-10 days 
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after infection. This decreases the likelihood of deleterious effects ie oncogenesis 
observed through constant expression of miRNAs using other live virus vector systems 
that can integrate sequences (de Solis et al. 2015; Grimm et al. 2006). Secondly, 
expression can be controlled through the administration of antivirals to shut down 
influenza virus dissemination.  
 
In this chapter, engineered viruses expressing multiple miRNAs of interest were 
generated and virus replication determined using in vitro growth kinetics analyses. 
Mature miRNA expression was confirmed using real-time PCR and validated using a 
luciferase reporter system.  
 
3.2 Results 
 
3.2.1 Cloning of the recombinant NS gene segment  
 
A recombinant NS gene segment was designed to express miRNAs, shRNAmir and 
miRNA inhibitor and cloned into the pHW2000 reverse genetics plasmid, a well-
characterised plasmid in influenza reverse genetics systems (Hoffmann et al. 2000). 
The proposed strategy for generating a linearised recombinant NS construct for 
miRNA expression is based on a previous study (Varble et al. 2010). This modified 
linearised recombinant NS construct was used to rescue two viruses; an A/PR8/8/34 
(H1N1) virus and an A/X31 (H3N2) virus, as both viruses share identical NS gene 
segments. The recombinant NS gene segment was generated through mutagenesis 
and ligation strategies (Figure 3.3). Gel electrophoresis of PCR products was used to 
determine the success of our cloning strategy (Figure 3.4).  The wild type NS gene 
(wtNS, 890bp) encodes two proteins, NS1 and NEP (NS2) by splicing. We began by 
using site direct mutagenesis to mutate the splice acceptor site to stop normal splicing 
of NS1 using a PCR based strategy that included the NS1-510muta F and NS1-
548muta R primers (detailed in Table A.1). The modified NS1 (muNS1, 725bp, Figure 
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3.4B) was amplified from the NS gene segment (muNS, 890bp, Figure 3.4A) using 
Bm-NS-1 and Xho1-NS1-717R specific primers (detailed in Table A.1). The NEP 
(418bp, Figure 3.4B) was then amplified from the wild type NS using primers Xho1-
NS2-508F and Bm-NS890 (detailed in Table A.1). Bm-NS-1 and Bm-NS-890 are 
universal primers used for amplification of the entire NS gene segment in all influenza 
A virus strains and were designed by Hoffmann et al. (Hoffmann et al. 2001). The 
intact NEP gene was subsequently ligated to the NS1 gene through a shared Xhol 
restriction enzyme site. This newly created linear, unspliced recombinant NS gene 
segment (reNS, 1137bp, Figure 3.4C) also included a Xho1 restriction enzyme site to 
allow the insertion of an artificial intron between nucleotide site 725 and 726 for 
expression of primary miRNAs (Figure 3.5). The modified linearised recombinant NS 
segment was then cloned into pHW2000 plasmid for use in reverse genetics (Figure 
3.5).  
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Figure 3.3. Generation of a modified linearised recombinant NS gene segment expressing 
miRNAs. Cloning involves four steps: 1) site-directed mutagenesis of the NS1 splice acceptor site; 2) 
Amplification of a modified NS1 using the mutated NS as the template and generation of an intact NEP 
segment using the wild type NS as the template; 3) ligation of the modified NS1 with NEP to generate 
a modified linearised recombinant NS gene segment that allows for insertion of an artificial intron and 
insertion into the pHW2000 reverse genetics plasmid; 4) amplification of a primary miRNA (eg. miR-
150) from the mouse genome and insertion between the NS1 and NEP (Adapted from Varble et al. 
2010).  
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Figure 3.4. Gel electrophoresis of PCR products using a 1% of agarose gel. Panel A-C shows 
steps 1-3 involved in the generation of a modified linearised NS gene segment for cloning into the 
pHW2000 reverse genetics plasmid. A) site-directed mutagenesis of the NS1 splicing site from the wild 
type NS gene segment to generate a mutated NS (Lane 1); B) Generation of a mutated NS1 gene 
segment (Lane 1) and an intact NEP segment (Lane 2); C) ligation of a mutated NS1 and NEP modified 
linearised NS gene segment (Lane 2) insert into the pHW2000 plasmid for use in reverse genetics; 
Lane 1 is the wild type NS used as a positive control.   
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                          NS1 ORF → 
AGCAAAAGCAGGGTGACAAAAACATA│ATGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGCTTTCTTTGGCATGTCCGCAAACGAGTTGCAGACCAAGAACTAGGC  110                                                  
                            M  D  P  N  T  V  S  S  F  Q  V  D  C  F  L  W  H  V  R  K  R  V  A  D  Q  E  L  G 
 
GATGCCCCATTCCTTGATCGGCTTCGCCGAGATCAGAAATCCCTAAGAGGAAGGGGCAGTACTCTCGGTCTGGACATCAAGACAGCCACACGTGCTGGAAAGCAGATA     218 
 D  A  P  F  L  D  R  L  R  R  D  Q  K  S  L  R  G  R  G  S  T  L  G  L  D  I  K  T  A  T  R  A  G  K  Q  I 
 
GTGGAGCGGATTCTGAAAGAAGAATCCGATGAGGCACTTAAAATGACCATGGCCTCTGTACCTGCGTCGCGTTACCTAACTGACATGACTCTTGAGGAAATGTCAAGG     326 
 V  E  R  I  L  K  E  E  S  D  E  A  L  K  M  T  M  A  S  V  P  A  S  R  Y  L  T  D  M  T  L  E  E  M  S  R 
 
GACTGGTCCATGCTCATACCCAAGCAGAAAGTGGCAGGCCCTCTTTGTATCAGAATGGACCAGGCGATCATGGATAAGAACATCATACTGAAAGCGAACTTCAGTGTG     434    
 D  W  S  M  L  I  P  K  Q  K  V  A  G  P  L  C  I  R  M  D  Q  A  I  M  D  K  N  I  I  L  K  A  N  F  S  V 
  
ATTTTTGACCGGCTGGAGACTCTAATATTGCTAAGGGCTTTCACCGAAGAGGGAGCAATTGTTGGCGAAATTTCACCATTGCCTTCTCTCCCGGGACATACTGCTGAG     542 
 I  F  D  R  L  E  T  L  I  L  L  R  A  F  T  E  E  G  A  I  V  G  E  I  S  P  L  P  S  L  P  G  H  T  A  E 
 
GATGTCAAAAATGCAGTTGGAGTCCTCATCGGAGGACTTGAATGGAATGATAACACAGTTCGAGTCTCTGAAACTCTACAGAGATTCGCTTGGAGAAGCAGTAATGAG     650 
 D  V  K  N  A  V  G  V  L  I  G  G  L  E  W  N  D  N  T  V  R  V  S  E  T  L  Q  R  F  A  W  R  S  S  N  E 
                                                                    ←NS1 ORF 
AATGGGAGACCTCCACTCACTCCAAAACAGAAACGAGAAATGGCGGGAACAATTAGGTCAGAAGTTTGA│CTCGAGCACCATTGCCTTCTCTTCCAGGACATACTGCTG    758 
 N  G  R  P  P  L  T  P  K  Q  K  R  E  M  A  G  T  I  R  S  E  V  -   
       NEP ORF → 
AGG│ATGTCAAAAATGCAGTTGGAGTCCTCATCGGAGGACTTGAATGGAATGATAACACAGTTCGAGTCTCTGAAACTCTACAGAGATTCGCTTGGAGAAGCAGTAATGAGA 869 
     M  S  K  M  Q  L  E  S  S  S  E  D  L  N  G  M  I  T  Q  F  E  S  L  K  L  Y  R  D  S  L  G  E  A  V  M  R   
   
ATGGGAGACCTCCACTCACTCCAAAACAGAAACGAGAAATGGCGGGAACAATTAGGTCAGAAGTTTGAAGAAATAAGATGGTTGATTGAAGAAGTGAGACACAAACTG     977 
 M  G  D  L  H  S  L  Q  N  R  N  E  K  W  R  E  Q  L  G  Q  K  F  E  E  I  R  W  L  I  E  E  V  R  H  K  L   
                             ←NEP ORF 
AAGATAACAGAGAATAGAGACACAAACTGA│AGATAACAGAGAATAGTTTTGAGCAAATAACATTTATGCAAGCCTTACATCTATTGCTTGAAGTGGAGCAAGAGATAA   1085 
 K  I  T  E  N  R  D  T  N  -     
  
GAACTTTCTCGTTTCAGCTTATTTAGTACTAAAAAACACCCTTGTTTCTACT                                                            1137 
Figure 3.5. Sequencing of the modified linearised NS gene segment. Sequencing of the modified linearised recombinant NS gene segment is shown along 
with the NS1 and NEP open reading frames (ORF) within the modified linearised recombinant NS gene segment. The Xho1 restriction enzyme site is highlighted 
in grey.  
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3.2.2 Generation of a modified linearised NS gene segment within the pHW2000 
plasmid encoding primary miRNAs, miR-30 backbone-IRAK1 shRNA and a miR-
146a inhibitor. 
 
3.2.2.1 Primary miRNAs 
 
Genomic DNA was extracted from the spleen of a B6 mouse, and used as a template 
to amplify primary miRNAs of interest, including miR-150 (206bp, Figure 3.6A), miR-
146a 238 (238bp, Figure 3.6C), miR-146a 132 (148bp, Figure 3.6D), let-7b (221bp, 
Figure 3.6E) and miR-21 (183bp, Figure 3.6F). Secondary structures were predicted 
(Figure 3.6) via the mfolder web server (http://unafold.rna.albany.edu/?q =mfold/rna-
folding-form) (Zuker 2003). A miR-150 scramble control (miR-150scbl 206bp, Figure 
3.6B) was generated via overlapping PCR replacing the mature miR-150 seed 
sequence with a scrambled sequence to imitate the structure of primary miR-150. This 
miR-150scbl control is a negative control, that has the exact same secondary structure 
as miR-150 but has no known targets in host cells.  
 
3.2.2.2 miR-30 backbone-IRAK1 shRNA  
 
The generation of miR-30 backbone-IRAK1 shRNA started with the identification of 
the IRAK1 shRNA sequence. Mouse IRAK1 mRNA has 3835 nucleotides. Although 
there are commercially available retroviral or adenovirus vectors expressing IRAK1 
shRNA, the sequence of IRAK1 shRNA is not provided by the manufacturers. In the 
present study, we used IRAK1 siRNA (NM_001569_bp2253_R: GTCAAAGTT-
CTCATGGTCAAA) characterised in a previous study in the treatment of B-cell 
lymphoma to knockdown of IRAK1 expression in vitro (Ngo et al. 2011). IRAK1 gene 
(UCSC genome No.: GRCm38/mm10, uc009tng.2) (mRNA ID: ref/NM_0011 77973.1, 
position 74015386-74015406) is located on chromosome X in B6 mice. Sequence was 
entered into the UCSC Genome Browser (http://genome.ucsc.edu/) (Kent et al. 2002) 
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and a 21nt predicted target at the 3’UTR of murine IRAK1 (GGUCAAAGUUCUCAUG 
CUUGG) was confirmed using the online siRNA prediction tool ‘Designer of Small 
Interfering RNA (DSIR) (Matveeva et al. 2007; Vert et al. 2006). Coincidentally, the 
IRAK1 mRNA region targeted by IRAK1 siRNA overlapped with the target region of 
miR-146a. Following the identification of an IRAK1 shRNA, we inserted the sequence 
into the miR-30 backbone according to protocols published by Fellmann and Chang 
(Chang et al. 2013; Fellmann et al. 2013). In brief, miR-30 was used as the backbone, 
where the 22bp mature miR-30 was replaced by the above IRAK1 shRNA with an 
additional T at the 5’ terminal end. The predicted secondary structure of miR-30 
backbone-IRAK1 shRNA was identical to the wild type primary miR-30 (124bp, Figure 
3.6G). 
 
3.2.2.3 miR146a inhibitor 
 
A key 107bp sequence targeting miR-146a was synthesised from GeneWorks, and 
the miR-146a inhibitor was generated using conventional PCR with XhoI cloning sites 
inserted at both ends of the PCR product to assist with ligation of this structure into 
the modified NS gene segment. The predicted secondary structure of this miR-146a 
inhibitor clearly demonstrates perfect complementarity to the miR-146a hairpin with 
two bulged miRNA binding sites located in the central part of the stem (Figure 3.6H).  
 
3.2.2.4 Ligation of primary miRNAs/ miR-30 backbone-IRAK1 shRNA/ miR-146a 
inhibitor into the modified linearised recombinant NS pHW2000 plasmid 
 
Primary miRNAs, miR-30 backbone-IRAK1 shRNA or the miR-146a inhibitor were 
ligated into the modified linearised recombinant NS gene segment within pHW2000 
plasmid for use in reverse genetics (Figure 3.3 Step 4); constructs included a 
recombinant NS with miR-150 (1342bp), a recombinant NS with a miR-150 scramble 
(1342bp) to act as a negative control, a recombinant NS with let-7b (1362bp), a 
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recombinant NS with miR-21 (1320bp), a recombinant NS with miR-146a 132 
(1285bp), a recombinant NS with miR-146a 283 (1418bp), a recombinant NS with a 
miR-30 backbone-IRAK1shRNA (1265bp) and a recombinant NS with miR-146a 
inhibitor (1261bp). Positive transformants expressing miRNAs were identified using 
PCR and maxi-prep stocks generated for use in reverse genetics. The PCR products 
were visualised by gel electrophoresis shown in Figure 3.7. All of the recombinant NS 
gene segments were sequenced to ensure correct orientation of the inserted products. 
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Figure 3.6. The predicted secondary structures of products inserted into the NS gene segment. 
A. miR-150; B. miR-150 scbl (control); C. miR-146a 238bp; D. miR-146a 132bp; E. let7b; F. miR-21; G. 
miR-30 backbone-IRAK1 shRNA; H. miR-146a inhibitor. Functional sequence in each structure is 
shown in red.   
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Figure 3.7. Gel electrophoresis of pri-miRNAs inserted into the pHW2000 plasmid containing NS 
gene segment. Lane M- 1Kb plus DNA marker; lane 1- wild type NS, lane 2- modified linearised 
recombinant NS, lane 3- modified linearised recombinant NS with miR150, lane 4- modified linearised 
recombinant NS with miR150 scbl (control), lane 5- modified linearised recombinant NS with let-7b, 
lane 6- modified linearised recombinant NS with miR-21, lane 7- modified linearised recombinant NS 
with miR-146a 132bp, lane 8- modified linearised recombinant NS with miR-146a 238bp, lane 9-  
modified linearised recombinant NS with miR-30 backbone-IRAK1 shRNA, lane 10- modified linearised 
recombinant NS with miR-146a inhibitor. 
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3.2.3 Rescue of recombinant influenza viruses expressing miRNAs/miR-30 
backbone-IRAK1 shRNA and a miR-146a inhibitor using reverse genetics 
 
Having established the insertion of products into the modified linearised recombinant 
NS gene segment within the pHW2000 plasmid used for reverse genetics, we rescued 
the following viruses: PR8-reNS-miR150 (H1N1) (PR8-150), X31-reNS-miR150 
(H3N2) (X31-150), PR8-reNS-miR150 scramble (H1N1) (PR8-150scbl), X31-reNS-
miR150 scramble (H3N2) (X31-150scbl), PR8-reNS-let-7b (H1N1) (PR8-let7b), X31-
reNS-let-7b (H3N2) (X31-let7b), PR8-reNS-miR146a inhibitor (H1N1) (PR8-146a 
inhibitor), X31-reNS-146a inhibitor (H3N2) (X31-146a inhibitor), PR8-reNS-IRAK1 
shRNA (H1N1) (PR8-IRAK1 shRNA), X31-reNS-IRAK1 shRNA (H3N2) (X31-IRAK1 
shRNA), PR8-reNS-miR146a (H1N1) (PR8-146a), X31-reNS-miR146a (H3N2) (X31-
146a). X31 influenza virus shares the same six internal gene segments with PR8 
(including the NS gene segment) but expresses HA and NA gene segments from a 
1968 Hong Kong (H3N2) influenza virus. With these two serologically distinct strains 
(X31; H3N2 and PR8; H1N1), primary and secondary in vivo mouse experiments were 
performed to identify the impact of these new viruses on immunity (Chapters 4 & 5). 
Eight plasmids (representing each gene segment including the modified linearised 
recombinant NS) of each influenza strain was transfected into a 3mL co-culture of HEK 
293 T cell and MDCK cell monolayer, and between 72-96 hours post transfection, 
supernatant collected from each well and a haemagglutination (HA) assay performed 
to identify if the rescues were successful. All the recombinant influenza viruses above 
were successfully rescued, except for miR-146a expressing viruses and PR8 viruses 
expressing miR-21 or IRAK1 shRNA.     
  
3.2.4 Propagation of newly generated recombinant influenza viruses 
 
Before proceeding to validation of recombinant virus function in vitro, recombinant 
viruses rescued in 3.2.3 were amplified to generate laboratory stocks in 10-day-old 
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embryonated eggs (Section2.13). Reverse genetics supernatants were used to 
inoculate eggs and after 48 hours post-infection, allantoic fluids containing 
recombinant viruses were harvested and stored in -80oC. Semi-quantitative 
haemagglutination (HA) assays (Section 2.12) were performed to confirm replication 
of the recombinant viruses (Figure 3.8). Viruses were serially diluted across the plate 
before incubation with 0.5% chicken blood cells. Positive wells were identified by 
agglutination of the red blood cells, resulting in RBC suspension in the well. Negative 
wells do not agglutinate red blood cells and formed a clear pellet at the bottom of the 
V-shaped well. The HA titre of each virus was (Figure 3.8): PR8-150; 256, X31-150;  
512, PR8-150scbl; 512, X31-150scbl; 512, PR8-let7b; 256, X31-let7b; 256, X31-21; 
256, PR8-146a inhibitor; 512, X31-146a inhibitor; 256, X31-IRAK1 shRNA; 512, PR8-
WT; 1024, X31-WT; 1024. Virus titres were determined by traditional plaque assays 
described in Section 2.14, and are shown in Table 3.2. All newly generated and 
amplified recombinant viruses have lower virus titre in eggs when compared to the 
wild type virus (pfu/mL) (Table 3.2). PR8-150; 3.82×107, X31-150; 5.6×106, PR8-
150scbl; 2.5×107, X31-150scbl; 1.53×107, PR8-let7b; 1.46×108, X31-let7b; 6.32×107, 
X31-21; 8.54×107, PR8-146a inhibitor; 1.45×108, X31-146a inhibitor; 9.38×107, X31-
IRAK1 shRNA; 8.36×107, PR8-WT; 5.59×108, X31-WT; 1.6×108. 
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Figure 3.8. Haemagglutination assay for rescued recombinant viruses. Egg allantoic fluid was 
tested in a semi-quantitative haemagglutination assay to determine the presence of the virus. The end 
point of agglutination for each virus is highlighted with a black circle.   
 
Table 3.2. Virus titre of recombinant viruses 
Virus name Virus titre (pfu/mL) 
PR8-WT 5.59×108 
X31-WT 1.6×108 
PR8-150 3.82×107 
X31-150 5.6×106 
PR8-150scbl 2.5×107 
X31-150scbl 1.53×107 
PR8-let7b 1.46×108 
X31-let7b 6.32×107 
X31-21 8.54×107 
PR8-146a inhibitor 1.45×108 
X31-146a inhibitor 9.38×107 
X31-IRAK1 shRNA 8.36×107 
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3.2.5 Sequencing of rescued recombinant influenza viruses  
 
RNA from recombinant viruses was extracted from allantoic fluid and PCRs performed 
to amplify the NS gene segment using NS primers described in Hoffmann et. al 
(Hoffmann et al. 2001); Bm-NS-1 and Bm-NS-890R (Detailed in Table A.1). The PCR 
products were run on a 1% agarose gel and DNA excised and purified for sequencing 
PCR (Section 2.9.5). Purified products (300ng) were used to run a sequencing PCR 
(Section 2.9.11) and submitted to CSIRO AAHL Diagnostics Surveillance & Response 
(DSR) Sequencing Lab. Sequencing results confirmed that the presence of inserts 
within the linearised recombinant NS gene segment (Figure 3.9). 
 
3.2.6 Viral growth kinetics of recombinant viruses in MDCK cells 
 
A multicycle growth curve was performed on each rescued recombinant virus to 
assess replication kinetics (Figure 3.10). Viruses were added to a monolayer of MDCK 
cells at an MOI of 0.01 and samples tested at 12, 24, 48 and 72 hours post-infection. 
The replication kinetics of recombinant viruses varied depending on the insert. At 12 
hours post-infection, X31-21 and X31-let7b reached replication yields comparable to 
wild type X31 (X31-WT) but all other X31 recombinant viruses had significantly lower 
yields. Between 24-72 hours post-infection, all recombinant viruses had significantly 
lower yields than X31-WT (Figure 3.10A). PR8-150 replicated at significantly lower 
titres between 12-24 hours post-infection compared with PR8-WT but reached 
comparable titres between 48-72 hours post-infection (Figure 3.10B). 
 
Among those recombinant viruses generated, we chose to at first assess in detail the 
efficacy of recombinant PR8-150 and X31-150 pair of viruses. The reasons for this 
choice are based on critical analysis of the literature and are listed below: 1) serum 
miR-150 levels have been shown to correlate with influenza-specific antibody titres 
following immunisation (de Candia et al. 2013); 2) miR-150 is essential for 
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differentiation of CD8+ T cells following infection (Smith et al. 2015); 3) miR-150 plays 
an important role in cross-presentation in DCs (Mi et al. 2012b). In the following 
sections and chapters, we have specifically focused on recombinant miR-150 virus 
function in vitro and in vivo.
 96 
 
 
 
Figure 3.9. Schematic diagram of inserts within the modified linearised NS gene segment of the recombinant viruses. The mature miRNA (also referred 
to as the seed sequence) or siRNA or miRNA inhibitor are shown in bold, italic and underlined. The two Xho1 restriction enzyme sites are highlighted in grey. 
The numbers indicate the position of the last nucleotide in the recombinant virus NS gene segment. reNS: the modified linearised recombinant NS; Scbl: miR-
150scbl; inhibit: miR-146a inhibitor; shRNA: miR-30 backbone-IRAK1 shRNA.
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Figure 3.10. Growth kinetics of X31 recombinant viruses in MDCK cells. MDCK cells were 
infected in triplicate with an MOI of 0.01 X31 recombinant influenza viruses (A) or PR8-150 
virus (B) respectively. Supernatants were collected at the indicated hours post-infection, and 
virus titres were determined by plaque assay. Data represent the mean ± SEM from three 
individual experiments, and statistical significance (compared with X31-WT) was determined 
by Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001, ***p<0.0001, n=3).  
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3.2.7 Use of real-time PCR to detect mature miR-150 expression 
 
In order to determine if the recombinant viruses expressed mature miR-150, 
SYBR Green qPCR was used as per previous studies (Shi & Chiang 2005) 
detailed in Section 2.26. MDCK cell monolayers were infected with X31-150 
expressing recombinant virus, or X31-150scbl or X31-WT viruses as negative 
controls at MOI of 0.01 (Figure 3.11A). Total RNA was extracted from cells at 
24 hours post-infection and analysed for miR-150 expression by qPCR using 
specific forward primers (miR-150qPCR, miR-107 qPCR) and a universal 
reverse primer (detailed in Table A.2).  Expression of mature miR-150 was 
normalised to 5S rRNA, which is stably expressed in cells. Comparison of 
relative mature miR-150 expression between X31-WT, X31-150scbl and X31-
150, or PR8-WT and PR8-150 was conducted using the 2-ΔΔ CT method and 
amplification of miR-150 was confirmed by melt curves using StepOnePlus 
software (Applied Biosystem) and by analysis of the PCR product by gel 
electrophoresis. We have also included an analysis of miR-107 expression as 
an internal control. miR-107 is an endogenously produced unrelated miRNA 
and is stably expressed in MDCK cells. As shown in Figure 3.8, miR-150 
expression was significantly elevated in cells infected with X31-150 virus 
(6,348.82±49-fold increase) compared with the uninfected control (Figure 
3.11A). miR-107 expression was not significantly altered with either virus. 
Similar results were obtained in MDCK cells infected with the PR8-150 virus, 
where cells infected with PR8-150 showed 1300.65 ± 196.70-fold more 
expression of mature miR-150 compared to PR8-WT or the uninfected control 
(Figure 3.11B). As expected there was no significant difference in miR-107 
expression in PR8-150 and the PR8-WT infected cells (Figure 3.11B).  
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            B 
 
Figure 3.11. Expression of miR-150 in MDCK cells infected with recombinant X31 (A) or 
PR8 viruses (B). Mean fold changes in the expression of mature miR-150 and an unrelated 
control miRNA (miR-107) 24 hours post-infection. Data represent mean ± SEM from three 
individual experiments and statistical significance was determined by One-Way ANOVA 
(compared with X31-WT (A) or X31-150scbl (A)), or Student’s t-test (compared with PR8-WT(B)) 
(***p < 0.00; ****p < 0.0001; NS, not significant; n=3). 
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3.2.8 Validation of miR-150 function through the use of luciferase assays. 
 
In order to determine if recombinant influenza viruses express functional 
miR150, we generated a dual-luciferase reporter assay system psiCHECK, 
containing the target sequence of miR-150, c-Myb. c-Myb is a transcription 
factor that plays a critical role in differentiation of haemopoietic cells, especially 
lymphocytes (Lieu et al. 2004; Thomas et al. 2005). Briefly, a portion of the 
3’UTR of the murine c-Myb gene was amplified by PCR from mouse genomic 
DNA using specific primers (cMyb 3utr F and cMyb 3utr R, detailed in Table 
A.1) and cloned into the 3’UTR of the Renilla luciferase gene within the 
psiCHECK vector, namely psiCHECK-cMyb. psiCHECK-cMyb transfected 
A549 cells were infected with recombinant PR8-150 virus or PR8-WT control. 
As shown in Figure 3.12, c-Myb-conjugated luciferase activity was significantly 
knocked down following PR8-150 infection compared with PR8-WT infection 
(p<0.01), which indicates that PR8-150 virus can express functional miR-150.  
 
3.2.9 Cytokine/chemokine mRNA expression following infection with 
recombinant miR-150 influenza virus  
 
Cytokines play a key role in activating the immune system and clearing 
pathogens. Therefore, cytokine mRNA expression was assessed following in 
vitro infection with a recombinant virus expressing miR-150. In brief, A549 cells 
were infected with PR8-150 or PR8-WT control at an MOI of 2. Twenty-four 
hours post-infection, total RNA was extracted from cells and used to investigate 
cytokine profiles. Four important pro-inflammatory cytokines involved in 
influenza virus host-pathogen responses; IL-6, IFN-β, chemokines CXCL5 (also 
known as regulated on activation, normal T cell expressed and secreted, 
RANTES) and CXCL10 (also known as interferon gamma-induced protein 10, 
 101 
 
 
IP-10) and three molecules involved in the cytokine signalling pathway (NF-κB, 
SOCS1, SOCS3) were analysed using a TaqMan real-time PCR assay. 
Cytokine expression was normalised to uninfected controls. Notably, we 
observed significant fold increases in the expression of IL-6 (233±59-fold) and 
IFN-β (155±58-fold) (Figure 3.13A), as well as important chemokines CXCL10 
(8958±2145-fold) and CCL5 (952±198-fold) (Figure 3.13B) after infection with 
PR8-150. In contrast, PR8-WT infection induced lower fold changes in IL-6 
(40±10-fold), IFN-β (20±4-fold), CXCL-10 (1645±910-fold) and CCL5 (221±25-
fold). We also detected a statistical increase in NF-κB mRNA expression (2±0.2) 
(Figure 3.13C) following PR8-150 infection. No differences in SOCS1 and 
SOCS3 mRNA expression were observed between the viruses (Figure 3.13C). 
Interestingly, influenza M gene fold expression (Figure 3.13D) was significantly 
lower in PR8-150 infected cells when compared to PR8-WT control, suggesting 
that elevated cytokines and chemokines mRNA expression levels could not be 
accounted for by higher viral loads in the PR8-150 infection group.  
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Figure 3.12. Knockdown of c-Myb-luciferase activity following PR8-150 infection of A549 
cells. Data represent the mean ± SEM from three individual experiments and statistical 
significance (compared to PR8-WT) was determined by One-Way ANOVA (MOI=2, **: p<0.01, 
n=3). 
 
  
 103 
 
 
 
     
Figure 3.13. Cytokine and chemokine mRNA expression levels in human epithelial cells 
infected with PR8-150 virus. Cells were infected with PR8-150 or PR8-WT virus for 24 h. 
Uninfected cells served as negative control. The level of mRNA expression and influenza M 
gene expression were standardised to actin. Data represent the mean ± SEM from three 
individual experiments and statistical significance (compared with PR8-WT) was determined by 
Student’s t-test (MOI=2, 24 hours post-infection, **p<0.01; NS, not significant; n=3) 
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3.3 Discussion 
 
In this chapter, recombinant influenza viruses expressing miRNAs/miR-30 
backbone-IRAK1 shRNA and miR-146a inhibitor were generated through 
manipulation of the NS gene segment. Ten recombinant viruses expressing 
non-coding RNAs including miR-150, let-7b, miR-21, miR-30 backbone IRAK1 
shRNA or miR-146a inhibitor were successfully rescued using reverse genetics. 
We did, however, fail to rescue some recombinant viruses and this is discussed 
below. 
 
We were unable to rescue miR-146a recombinant influenza viruses. Reverse 
genetics resulted in the rescue of a mixed population of virions ie viruses that 
encoded miR-146a and wild type virus (PR8 or X31) in the culture supernatant. 
We further confirmed this mixed population by plaque purification and single 
plaque RT-PCR. Wild type virions increased significantly in number following 
egg amplification, with less than 10% of single plaques (1/10) containing the 
miR-146a insert. Two possible explanations may account for the failure to 
rescue a miR-146a expressing virus. The first proposes that miR-146a may 
affect the viral fitness. As such we would expect the virus to delete the insert 
under selective pressure. Evidence for this exists in studies involving rescue of 
a GFP-expressing influenza virus. GFP expression from a recombinant NS 
gene segment resulted in a gradual loss of GFP-expression and replicative 
capacity during infection (Manicassamy et al. 2010). Secondly, the size of the 
miR-146a insert may also have contributed to the failure to obtain a 
homogeneous virus population (Rausalu et al. 2009). The original primary miR-
146a was approximately 300bp long, which is longer than other proposed miR 
inserts. We attempted to shorten the miR-146a to 132bp, however, the rescue 
failed.  
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A constraint of miRNA-based therapies is the potential for off-target effect as 
miRNAs generally target multiple genes. In order to remove this possibility, we 
inserted a shRNA (as opposed to a miRNA) in context of miR-30 backbone 
based on previous studies (Chang et al. 2013; Fellmann et al. 2013), as 
shRNAs show complete complementary to their target. The failure to rescue a 
miR-146a expressing influenza virus led to the generation of a miR-30 
backbone-IRAK1 shRNA virus, as IRAK1 is a confirmed miR-146a target that 
plays an important role in NF-κB signalling. The insertion of miR-30 backbone-
IRKA1 shRNA into the modified linearised recombinant NS was successful and 
further analysis of the function of this shRNA expressing virus is required in the 
future.  
 
Since 2010, a number of studies have outlined methodologies describing the 
expression of exogenous sequences via a manipulated NS gene segment that 
includes GFP (De Baets et al. 2015; Manicassamy et al. 2010) and miRNAs 
(Izzard et al. 2014; Li et al. 2015). Moreover, other viral vector delivery systems 
have also been reported. A manipulated mosquito virus  Aedes aegypti 
densovirus (AaeDV) was shown to deliver miRNA, miRNA inhibitors and 
siRNAs resulting in functional regulation of mosquito genes in vitro and in vivo 
(Liu et al. 2016). Apart from single miRNA insertions, recent studies have also 
attempted to express cassettes of miRNA targets or shRNAs in viral vectors to 
achieve stronger regulatory effects (Chen et al. 2011; Choi et al. 2015; Ebert, 
Neilson & Sharp 2007; Ylosmaki et al. 2013). Up to seven miRNA-based 
shRNAs targeting different HIV genes and CCL5 were integrated into a lentiviral 
construct, that was shown to control HIV-1 replication in vivo and in vitro (Choi 
et al. 2015). Future studies will aim to deliver multiple miRNAs or shRNAs via 
the NS gene segment as described herein or investigate the potential to insert 
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these sequences in other influenza gene segments with splicing characteristics 
such as M gene segment.  
 
Epithelial cells are the major cell type infected by influenza viruses. A549 cells 
are lung epithelial cells which become a popular target in the study of the 
antiviral response to influenza infection in vitro. Upregulation of chemokines 
and cytokines is critical for clearance of influenza infection (Sladkova & 
Kostolansky 2006). IL-6, IFN-β, CCL5 and CXCL10 expression is significantly 
increased in the A549 cells following infection with highly pathogenic influenza 
virus (HPAIV) H5N1 influenza virus infection and 2009 H1N1 pandemic 
(Ramírez-Martínez et al. 2013; Ye, Lowther & Stambas 2015) and were studied 
in detail in this chapter. The expression of two chemokines, CCL5 and CXCL10, 
was higher in the PR8-150 virus infected cells when compared to PR8-WT 
controls. These two chemokines can promote immune cell migration (Oslund & 
Baumgarth 2011). We also observed higher expression of IFN-β and IL-6. IFN-
β is the major cytokine released by influenza virus infected epithelial cells and 
plays a key role as the first line of defence (Jewell et al. 2007; Julkunen et al. 
2000). Moreover, IFN-β is also responsible for NK cell proliferation and 
activation (Biron, Turgiss & Welsh 1983; Nguyen et al. 2002; Salazar-Mather, 
Ishikawa & Biron 1996) along with stimulation, migration and survival of  
influenza-specific T cells (Kolumam et al. 2005; Thompson et al. 2006). IL-6 is 
a pleiotropic pro-inflammatory cytokine that can regulate proliferation, 
differentiation and migration of immune cells (Scheller et al. 2011). In normal 
influenza infection, IL-6 regulates both innate and adaptive immune responses 
(Dienz et al. 2012; Longhi et al. 2008). Recent studies indicate that IL-6 is 
essential for the recruitment of neutrophils into the lung and can prevent 
activated neutrophils from undergoing apoptosis induced by influenza virus 
infection (Dienz et al. 2012). IL-6 deficient mice have been shown to have an 
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impaired T cell response that is associated with a failure to clear influenza virus 
(Lauder et al. 2013). Furthermore, IL-6 can promote the production of 
antibodies through regulation of B cell differentiation (Hunter & Jones 2015).   
 
However, IL-6 is also considered a key contributor to ‘cytokine storms’, a term 
that describes cytokine dysregulation associated infections such as highly 
pathogenic avian influenza (HPAI) H5N1 virus (Baskin et al. 2009; Chan et al. 
2005). It is therefore important to consider the possibility of increased pathology 
with upregulated cytokine expression when infecting with our newly developed 
recombinant viruses. Regulation of expression through the use of antivirals may 
be one way of avoiding deleterious effects. The induction of these cytokines 
during the antiviral response will be investigated in the B6 mouse model in the 
following two chapters. 
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Chapter 4  Evaluation of primary immune responses 
following miR-150 influenza virus infection 
 
4.1 Introduction 
 
Immunity against influenza virus infection requires both the innate and adaptive 
arms of the response. Innate immunity provides the first defence line of the host 
against influenza infection. When influenza viruses enter the host through the 
respiratory tract, they must first navigate through the mucous covering with 
epithelium (Manicassamy et al. 2010). The virus then infects respiratory 
epithelial cells and can spread to other immune or non-immune cells 
(macrophages, dendritic cells) in the lung (Perrone et al. 2008). Viral 
components are recognised via pattern recognition receptors (PRRs) such as 
retinoic acid-inducible gene I (RIG-1) (Koyama et al. 2007; Matikainen et al. 
2006) and Toll-like receptors including Toll-like receptor 3 (TLR3) (Guillot et al. 
2005), resulting in activation of signalling pathways in epithelial cells that lead 
to release of cytokines, chemokines and several type ǀ and III interferons 
(Hogner et al. 2013; Kallfass et al. 2013). The release of cytokines initiates 
activation and recruitment of innate immune cells such as macrophages, 
neutrophils, NK cells, monocytes, and DCs into the lung to assist with clearance 
of infection. Alveolar macrophages and neutrophils phagocytose influenza 
infected cells, a key mechanism of viral clearance (Hashimoto et al. 2007). NK 
cells also contribute to viral clearance through recognition of virus infected cells 
via natural cytotoxicity receptor 1 (NCR-1) and secretion of perforin and 
granzymes to directly kill infected cells (Gazit et al. 2006). Conventional DCs 
(cDCs, also refered to as myeloid DCs) and plasmacytoid DCs (pDCs) are 
involved in the response to influenza virus infection in the lung. cDCs are 
 109 
 
 
responsible for taking up and presenting antigens to initiate adaptive immune 
responses (Grayson et al. 2007). pDCs are the main source of type I IFN during 
influenza infection (Jewell et al. 2007). Monocytes which are recruited into the 
lung upon influenza infection can also differentiate into monocyte-derived DCs 
and produce type I IFNs (Aldridge et al. 2009; Cao et al. 2012; McGill, Van 
Rooijen & Legge 2008). To initiate adaptive immunity, DCs present virus-
derived peptides to T cells to facilitate proliferation and differentiation into CD4+ 
Th1, CD4+ Th2 or CD8+ cytotoxic effector T cells (Ichinohe et al. 2009; Topham, 
Tripp & Doherty 1997). B cells will take up influenza virus antigen and present 
it to CD4+ T cells to generate influenza-specific neutralising antibodies (Gerhard 
et al. 1997; Mozdzanowska et al. 2005; Smith et al. 2000).  
 
Vaccination is the most cost-effective method to control influenza virus infection. 
However, vaccine efficacy in the elderly (only 39%) is still a big challenge 
(Beyer et al. 2013). One way to tackle this problem is through the use of 
adjuvants (Haq & McElhaney 2014). Previous studies have shown that an 
effective adjuvant can increase vaccine immunogenicity, resulting in higher 
antibody titres (Principi & Esposito 2012). miRNAs have been found to 
participate in the regulation of a range of immune responses and thus can serve 
as potential “natural adjuvants”. For example, miR-155 can regulate CD8+ T cell 
proliferation by inhibiting signal transducers and activators of transcription 1 
(STAT1) expression as well as other genes in the type I IFN signalling pathway 
such as IKKε and Bach1 (Gracias et al. 2013). It can also effect the maturation 
of granulocyte numbers by the targeting SH2-domain-containing inositol- 5-
phosphatase 1 (SHIP1) gene (O'Connell et al. 2009). miR-233, on the other 
hand, is involved in the proliferation and activation of neutrophils through 
binding of myeloid ELF1-like factor 2C (Johnnidis et al. 2008). T cell and B cell 
development involves several miRNAs including miR-155, miR-17-92, miR-326 
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and miR-150 (Du et al. 2009; O'Connell et al. 2007; Ventura et al. 2008; Zhou 
et al. 2007).  
 
Our lab has established a murine B6 model of infection using recombinant 
influenza viruses that express miR-155 resulting in enhanced CD8+ T cell 
immunity and higher neutralising antibody titres (Izzard et al. 2017). In this 
chapter, we describe the use of a recombinant influenza virus expressing miR-
150 (X31-150) in vivo to evaluate modulation of immune responses. Information 
in the literature suggests increased cytokine levels in patient serum correlates 
with elevated miR-150 levels (Moran et al. 2015) following infection. Moreover, 
higher influenza-specific antibody production correlates with miR-150 
expression in vaccinated individuals (de Candia et al. 2013). miR-150 has also 
been shown to be essential in maintaining CD8+ T cell functionality as 
adoptively transferred CD8+ T cells from miR-150-/- mice show less proliferation 
and differentiation compared to WT controls following Listeria monocytogenes 
infection (Smith et al. 2015).  In addition, Langerhans cells, show a decreased 
ability to activate proliferation and IFN-γ expression in CD8+ T cells with miR-
150 deficiency (Mi et al. 2012b). Based on the above background, we aim to 
improve immune responses in our murine influenza virus model by 
administering a recombinant X31-150 virus and comparing responses to wild 
type virus (X31-WT).   
 
To evaluate the immunomodulatory role of X31-150 influenza virus, we 
characterised innate and adaptive immune responses. This chapter will focus 
on the characterisation of innate immune responses at 1 and 3 dpi, as well as 
primary adaptive immune responses at 10dpi. Subsequent chapters will focus 
on secondary immune responses as well as challenge experiments. Six- to 
eight-week-old B6 mice were used in the studies and were purchased from the 
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Animal Resources Centre (ARC) and maintained in Small Animal Facility in 
AAHL, CSIRO. All animal experiments were approved by the AAHL CSIRO and 
Deakin Animal Health Ethics Committees and were conducted according to 
approved protocols. 
 
4.2 Results    
 
4.2.1 Characterisation of innate immune responses following infection 
with recombinant X31-150 influenza virus 
 
To characterise murine innate immune responses following X31-150 infection, 
B6 mice were intranasally (i.n.) infected with 1×104pfu X31-150 or X31-WT and 
weight loss, virus titers in the lung and flow cytometric analysis of innate 
immune cell populations were analysed at 1 and 3 dpi. 
 
4.2.1.1 Weight loss and viral titres in the lung of mice infected with X31-150 
virus at 1 and 3 dpi. 
 
The weight of mice was monitored and recorded daily following infection before 
euthanasia. In both X31-150 and X31-WT groups, mice began to lose weight 
after 1dpi. The X31-WT group continued to lose weight for four to five days with 
a maximum 16.6±4.1% weight loss from original starting weight at 6dpi (Figure 
4.1A). Mice gradually gained weight in a typical U shaped curve by 7dpi 
indicating clearance of the virus and recovered completely by 10dpi (Figure 
4.1A). This weight loss curve is consistent with what observed in previous 
studies (Aldridge et al. 2009; Bird et al. 2015). The X31-150 group showed 
significantly less weight loss when compared with X31-WT from 3-8 dpi with a 
maximum 9.6±1.7% at 3dpi with gradual weight gain by 10dpi (Figure 4.1). 
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Given attenuated replication of X31-150 in vitro (Figure 3.10A), it is not 
unexpected that infection with X31-150 results in less weight loss in mice. As 
the X31-150 infected group started to gain weight from 3dpi, we focused on 
early time points to investigate innate immune responses and virus titres in the 
lungs of mice. 
 
Virus titres were evaluated at 1 and 3 dpi in lung tissue (Figure 4.2). X31-150 
lung virus titres were ~1 log10 pfu/lung lower at 1dpi (Figure 4.2A) compared to 
X31-WT controls (3.54±0.70 versus 4.82±0.15 log10 pfu/lung, p<0.01). Again, 
given attenuation of the recombinant X31-150, this result was not unexpected. 
At 3dpi, a timepoint that represents the peak of virus titers, the X31-150 infected 
group showed ~1.5 log10 pfu/lung lower titres than X31-WT controls (4.18±0.43 
versus 5.92±0.26 log10 pfu/lung, p<0.01) (Figure 4.2B). These results again 
correlate with what was observed during in vitro virus kinetics in MDCK cells.  
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Figure 4.1. Weight loss of mice following infection with X31-150 or X31-WT. Naïve B6 
mice were intranasally infected with 1x104 pfu of X31-150 or X31 WT (H3N2) influenza virus. 
The weight changes were monitored daily over a ten-day period following infection. Data 
represent the mean ± SEM for one of five independent experiments. The Student's t-test was 
used for statistical analysis (*p<0.05, **p<0.01, n=5).  
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Figure 4.2. Lung virus titres at 1dpi or 3dpi. Naïve B6 mice were intranasally infected with 
1×104pfu X31-150 or X31-WT virus. Lung virus titres at 1 dpi (A) and 3dpi (B). Data represents 
mean ± SEM of one of three independent experiments. The Student's t-test was used for 
statistical analysis (**p<0.01, n=5).   
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4.2.1.2 Innate immune populations in BAL and lung at 1 and 3 dpi. 
 
To assess the important innate immune cell populations at early time points 
following infection, BAL and lung were collected at 1 and 3 dpi. Flow cytometric 
analysis was performed to identify neutrophils, macrophages, DCs and NKs in 
the lung and BAL using a defined gating strategy (Figure 4.3). We first gated 
on singlets (Figure 4.3A) followed by immune cell populations (Figure 4.3B). 
Lymphocytes were excluded when identifying neutrophils, macrophages 
(alveolar macrophages(AMϕ) in the BAL and interstitial lung macrophages (IMϕ) 
in the lung) and DCs (Figure 4.3C). Neutrophils were readily distinguished 
based on their expression of Gr1 (Ly6G+Ly6C) and Ly6G (Figure 4.3E) (Rose, 
Misharin & Perlman 2012; Tate et al. 2011). Macrophages were identified 
based on negative expression of Gr1 and CD11c, and positive expression of 
CD11b with high side scatter (Figure 4.3F, G)(Kopf, Schneider & Nobs 2015; 
Perrone et al. 2008). DCs were identified using cell surface expression of MHCII 
and CD11c (Figure 4.3H) (GeurtsvanKessel et al. 2008). NK cells were 
identified within the lymphocyte population (Figure 4.3D) and expressed NK1.1 
in the absence of CD3e (Figure 4.3I).  
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Figure 4.3. Gating strategy for immune cell populations. Naïve B6 mice were intranasally 
infected with 1×104pfu X31-150 or X31-WT virus. Lung cell singlets (A) dead cells (B) 
leukocytes other than lymphocytes(C) or lymphocytes(D). From (C), cells were subsequently 
divided into neutrophils or monocytes(E), interstitial lung macrophages (F) & (G), DCs (H) 
depending on cell surface marker expression. From (D), NK cells were further separated 
according to NK1.1 and CD3e (I) expression. Data presents one of three identical experiments 
and was acquired on the BD LSRFortessaTM cell analyser and analysed using Flowjo software.  
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We first characterised the innate immune cell populations in BAL following 
infection. Despite the lower virus titres in the lungs of X31-150 infected mice at 
1dpi, there were higher total cell numbers in the BAL of this group (Figure 4.4A). 
Further analysis showed significantly higher numbers of neutrophils (Figure 
4.4B), DCs (Figure 4.5A) and alveolar macrophages (Figure 4.5B), when 
compared to X31-WT BAL samples. In the lung at the same timepoint, there 
were no significant differences between the two groups with regards to 
neutrophils (Figure 4.6B), DCs (Figure 4.7A) and macrophages (Figure 4.7B). 
As NK cells are normally detected in the BAL and lung from 3dpi (Aldridge et 
al. 2009), it is difficult to detect NK cells at 1dpi. This data suggests accelerated 
kinetics of innate immune cell infiltration into the BAL at 1dpi that may assist in 
early defence. 
 
At 3dpi, significantly fewer neutrophils (Figure 4.4D), NKs (Figure 4.4E), DCs 
(Figure 4.5C) and macrophages (Figure 4.5D) were found in the BAL of X31-
150 infected animals supporting our hypothesis of accelerated kinetics. A 
similar pattern was also observed for neutrophils (Figure 4.6D) and 
macrophages (Figure 4.7D) in the lung. In contrast to our BAL data, lung DCs 
(Figure 4.7C) in the X31-150 infected group were significantly higher than WT 
controls.  
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Figure 4.4. Quantitative analysis of innate immune populations in BAL. Naïve B6 mice 
were intranasally infected with 1×104pfu X31-150 or X31-WT virus. BAL immune cells at 1 dpi 
(A, B) and 3 dpi (C, D, E): total cell numbers (A, C), neutrophils (B, D), NKs (E). Data represents 
mean ± SEM of one of three identical experiments. The Student's t-test was used for statistical 
analysis (* p<0.05; **p<0.01; NS, not significant; n=5).   
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Figure 4.5. Quantitative analysis of innate immune populations (DCs and AMs) in BAL at 
1dpi and 3dpi. Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-WT 
virus. BAL immune cells at 1 dpi (A, B) and 3 dpi (C, D): DCs (A, C) and alveolar 
macrophages(AMϕ) (B, D). Data represents mean ± SEM of one of three identical experiments. 
The Student's t-test was used for statistical analysis (* p<0.05; **p<0.01; NS, not significant; 
n=5). 
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Figure 4.6. Quantitative analysis of innate immune populations in the lung. Naïve B6 mice 
were intranasally infected with 1×104pfu X31-150 or X31-WT virus. Lung innate immune cells 
at 1dpi (A, B) and 3dpi (C, D, E): total lung immune cells (A, C), neutrophils (B, D), NKs (E). 
Data represents mean ± SEM of one of three identical experiments. The Student's t-test was 
used for statistical analysis (* p<0.05; NS, not significant; n=5).   
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Figure 4.7. Quantitative analysis of innate immune populations (DCs and macrophages) 
in the lung. Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-WT virus. 
Lung immune cells at 1 dpi (A, B) and 3 dpi (C, D): DCs (A, C) and interstitial lung macrophages 
(IMϕ) (B, D). Data represents mean ± SEM of one of three identical experiments. The Student's 
t-test was used for statistical analysis (* p<0.05; NS, not significant; n=5). 
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4.2.1.3 miR-150 and exosomes in serum at 3dpi 
 
Previous studies have indicated that cellular miR-150 can be secreted and 
delivered to targets cell via exosomes (de Candia et al. 2013; Zhang et al. 2010). 
Therefore, a supportive preliminary experiment was designed to detect miR-
150 in serum exosomes (Section 2.25 & 2.26). Serum samples from X31-WT 
and X31-150 infected mice were collected before infection (pre-inf) and 3 dpi. 
Each serum sample was mixed with ExoQuick Exosome Precipitation Solution 
for exosome extraction. Total RNA was extracted from the exosome pellet and 
followed by miRNA transcription. The presence of miR-150 was determined 
through SYBR green real-time PCR. Mature miR-150 was detected in both pre-
inf and 3dpi serum samples following gel electrophoresis of PCR samples 
(Figure 4.8A). Here we did not use the 2-ΔΔ Ct method to calculate fold change 
as we discovered the housekeeping gene 5S rRNA used for normalising data 
was not stably expressed in serum exosomes. Indeed, after influenza virus 
infection, 5S rRNA significantly increased in both X31-150 and X31-WT infected 
animals when compared to pre-infection controls (Figure 4.8B). Therefore, 5S 
rRNA is not a reliable reference gene for validation of miRNA expression in 
serum exosomes, and another reference gene such as miR-16, miR-744 (Mi et 
al. 2012a) should be considered for further investigation. Serum miR-150 
expression increased significantly at 3dpi (Ct 33.1±0.5) when compared to the 
pre-infection control (Ct 34.3±0.8) in X31-150 infected animals (Figure 4.8B). 
In contrast, there was no difference in miR-150 expression between the X31-
WT group before (Ct 34.1±0.7) or after (Ct 35.0±1.1) infection (Figure 4.8B) 
where we are detecting baseline levels in a normal mouse. Secondly, miR-150 
expression between X31-150 and X31-WT groups was compared. There was 
no significant difference in miR-150 expression between the X31-150 (Ct 
34.1±0.7) and X31-WT (Ct 34.3±0.8) groups before infection (p=0.65, n=5). 
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However, significant increases in the level of miR-150 was detected in the X31-
150 infected group (Ct 33.1±0.5) when compared to the X31-WT infected group 
(Ct 35.0±1.1) at 3dpi (Figure 4.8B).   
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Figure 4.8. Serum exosome miR-150 expression in serum exosome of X31-WT and X31-
150 infected mice. Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-
WT virus and serum samples collected before infection and at 3dpi. A. Gel electrophoresis of 
mature miR-150 PCR products from serum exosomes pre-infection (lanes 11-20) and 3dpi 
(lanes 1-10) of X31-WT (lanes 1-5, 11-15) and X31-150 (lanes 6-10, 16-20) mice were 
observed using a 1% agarose gel. M, 1kb plus DNA marker. B. RT-qPCR Cts of mature miR-
150 and 5S rRNA in pre-infection (pre-inf) and 3dpi samples from X31-WT and X31-150 groups. 
Data represents mean ± SEM of one of two identical experiments. The Student's t-test was 
used for statistical analysis (* p<0.05, **p<0.01, NS, not significant; n=5).  
B 
M 
M 
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4.2.2 Characterisation of primary T cell responses following infection with 
recombinant X31-150 influenza virus 
 
4.2.2.1 T cell gating strategy for flow cytometric analysis of adaptive immune 
responses 
 
As we observed improved innate immune responses in the X31-150 group at 
early time points after infection, we were determined to investigate the impact 
on adaptive immunity. We started by characterising the primary cellular immune 
response at 10dpi (the peak of T cell responses in the murine model) in BAL, 
lung and spleen tissue. Flow cytometric analysis was used to phenotypically 
characterise T cell populations by cell surface markers. Tetrameric complexes 
were used to assess the number of influenza-specific CD8+ T cells (see Section 
2.22), and intracellular cytokine staining assay was performed to measure 
functionality by assessing IFN-γ, TNF-α and IL-2 production (see Section 2.23).  
 
Following preparation of single cell suspensions of BAL, lung and spleen (see 
Section 2.20), we gated single cells (Figure 4.9A, FSC-H vs. FSC-A), followed 
by lymphocytes (Figure 4.9B, SSC-A vs. FSC-A). CD4+ (CD4+CD8-) and CD8+ 
(CD8+CD4-) T cells were then identified through their expression on CD4 and 
CD8 cell surface markers (Figure 4.9C). To evaluate the ability of the X31-150 
virus to induce influenza-specific CD8+ T cell responses, tetramer staining was 
used to detect two immunodominant influenza-specific CD8+ T cell populations 
targeting the nucleoprotein (H-2Db NP366-374, abbreviated to ‘DbNP366’) or acid 
polymerase (H-2Db PA224-233, abbreviated to ‘DbPA224’’) (Figure 4.10D and 
4.10E). 
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Figure 4.9. Gating strategy for CD4+ T cells, CD8+ T cells and B cells. Naïve B6 mice were 
intranasally infected with 1×104pfu X31-150 or X31-WT virus. Cells were gated for singlets first 
(A), then lymphocytes (B), CD4+ and CD8+ T cells (C) and B cells (CD45r) (D). Data represents 
one of three identical experiments and was acquired an a BD LSRFortessaTM cell analyser and 
analyzed using Flowjo software. 
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Figure 4.10 Gating strategy for CD8+ tetramer staining. Naïve B6 mice were intranasally 
infected with 1×104pfu X31-150 or X31-WT virus. Single cells (A) were gated followed by 
lymphocytes (B), CD8+ T cells (C) and tetramer positive CD8+ T cells (D). DbNP366 or DbPA224 
tetramer positive populations were separated in (E). Data was acquired on a BD LSRFortessaTM 
cell analyser and analyzed using Flowjo software.  
CD8a 
A 
B 
C 
D 
E 
W
it
h
 N
P
3
6
6
 
 
p
e
p
ti
d
e
 
W
it
h
 P
A
2
2
4
 
p
e
p
ti
d
e
 
X31-WT X31-150 
 128 
 
 
4.2.2.2 T cell responses following X31-150 infection 
 
T cell responses in pooled BAL (Figure 4.11A), lung (Figure 4.11B) and spleen 
(Figure 4.11C) were analysed. BAL primary responses were assessed using 
pooled BAL samples given the small number of cells involved. As such no error 
bars are depicted for these results. All results represent at least three 
independent experiments (n=5). Higher numbers of total pooled CD4+ T cells 
were observed in the BAL of the X31-150 group (4.08×105) when compared to 
X31-WT controls (1.1×105) (Figure 4.11A). Higher numbers of total pooled 
CD8+ T cells were also observed in the BAL of the X31-150 group (12.7×105) 
than X31-WT group (6.41×105) (Figure 4.11A). There were no significant 
differences between the X31-150 and X31-WT groups in the spleen (CD4+: 
9.32×106±2.65×106 and 8.12×106 ±2.33×106; CD8+: 6.12×106± 1.49×106 and 
7.00×106 ±2.03×106) (Figure 4.11C). We observed similar results for total CD4+ 
T cells in the lung of X31-150 infected animals (4.87×105±1.33×105) vs X31-
WT controls (4.83×105 ±1.17×105) (Figure 4.11B). It is important to note that 
we observed higher total T cell responses in BAL following infection despite 
lower viral kinetics both in vitro and in vivo (see Figure 3.10A and Figure 4.2).  
 
We then used tetramer staining to detect two immunodominant influenza-
specific CD8+ T cell populations targeting DbNP366 and DbPA224. X31-150 
infection induced greater numbers of influenza-specific DbNP366 (2.32×105) and 
DbPA224 (2.45×105) CD8+ T cell responses when compared to X31-WT controls 
in pooled BAL samples: DbNP366 (5.81×104) and DbPA224 (9.61×104) (Figure 
4.12A). There were no significant differences between the two groups in the 
lung (Figure 4.12B) or spleen (Figure 4.12C).  
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Figure 4.11. Analysis of total CD4+ and CD8+ T cells in pooled BAL, lung and spleen. 
Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-WT virus. Cell numbers 
between X31-150 and X31-WT infected groups was compared in pooled BAL (A), lung (B) and 
the spleen (C). Data presents mean ± SEM (except pooled BAL) of one of three identical 
experiments. The Student's t-test was used for statistical analysis (NS, not significant; n=5).  
 130 
 
 
 
Figure 4.12. Quantitative analysis of the primary day 10 influenza-specific CD8+ T cell 
responses to the DbNP366 and DbPA224 epitopes in BAL, spleen and lung by tetramer 
staining. Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-WT virus. 
Comparison between the X31-150 and X31-WT groups in pooled BAL(A), lung (B) and the 
spleen (C). Data presents mean ± SEM (except for pooled BAL) of one of three identical 
experiments. The Student's t-test was used for statistical analysis (NS, not significant; n=5).  
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4.2.2.3 Enhanced influenza-specific IFN-γ+ CD8+ T immunity following primary 
infection with X31-150 
 
We also assessed the functional capacity of influenza-specific CD8+ T cells 
using the intracellular cytokine staining assay. One of the main functions of 
CD8+ T cell is to generate cytokines. Influenza-specific CD8+ T cells make IFN-
γ (La Gruta, Turner & Doherty 2004). A subset of the IFN-γ+ population makes 
both IFN-γ and TNF-α. A smaller subset of the IFN-γ+ population make IFN-γ, 
TNF-α and IL-2 (La Gruta, Turner & Doherty 2004). These multifunctional cells 
are highly differentiated cells and as a general rule, the total number of IFN-γ+ 
CD8+ T cells correlates with the number of tetramer+ CD8+ T cells.  
 
4.2.2.3.1 Gating strategy for CD8+ T cell flow cytometric analysis of cytokine 
staining 
 
The gating strategy for ICS is demonstrated in Figure 4.13. The cells were first 
gated on single cells (Figure 4.13A), followed by lymphocytes (Figure 4.13B). 
CD8+ T cells were then identified through the expression of the CD8 cell surface 
marker (Figure 4.13C). To evaluate the ability of X31-150 infected mice to 
activate functional influenza-specific CD8+ T cell responses, the ICS assay was 
used to detect the secretion of IFN-γ, TNF-α and IL-2 in two immunodominant 
influenza-specific CD8+ T cell populations (DbNP366 or DbPA224). The data were 
acquired from a BD LSRFortessaTM cell analyser and analysed using Flowjo 
software. In each experiment, the percent of positive cytokine staining cells 
incubated with no peptide was substracted from the percent of positive cytokine 
staining stimulated with peptide to calculate the final value.  
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Figure 4.13. Intracellular cytokine profile of influenza-specific CD8+ T cells in pooled BAL 
at 10dpi in B6 mice. Naïve B6 mice were infected intranasally with X31-150 or X31-WT virus, 
and pooled BAL samples were collected at 10dpi. Enriched CD8+ T cells were first gated on 
single cells (A), then lymphocytes (B), followed by CD8+ T cells (C) and finally as cytokine 
expressing CD8+ T cells stimulated with DbNP366 (D and E) and DbPA244 peptides (F and G). 
No peptide controls are shown in H and I. Data represent one of three identical experiments. 
Data was acquired on a BD LSRFortessaTM cell analyser and analysed using Flowjo software.  
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4.2.2.3.2 Epitope-specific IFN-γ+ CD8+ T cells in pooled BAL, lung and spleen 
of X31-150 infected mice 
 
The IFN-γ+ CD8+ T cell responses targeting DbNP336 or DbPA224 epitopes in 
pooled BAL (Figure 4.14A), lung (Figure 4.14B) and spleen (Figure 4.14C) were 
comparable with trends observed in our tetramer analysis (Figure 4.12). X31-
150 infected mice induced higher numbers of influenza-specific IFN-γ+ CD8+ T 
cells when compared to X31-WT controls in pooled BAL (Figure 4.14A), while 
there were no significant differences observed in the lung and the spleen 
(Figure 4.14B-C).  
 
4.2.2.3.3 Multifunctional TNF-α+ and IL-2+ T cells within total IFN-γ+ CD8+ T cell 
population 
 
Our primary 10dpi experiments were consistent with those observed in the 
Doherty group (La Gruta, Turner & Doherty 2004; Turner et al. 2004) where we 
saw a IFN-γ+ > TNF-α+ > IL-2+ hierarchy for both DbNP366 and DbPA224 specific 
CD8+ T cells. In pooled BAL, almost all the TNF- α+ cells were producing IFN-γ 
(Figure 4.13D, F). Similar findings were also observed in IL-2+ cells (Figure 
4.13E, G). The CD8+ DbPA224 T cell population contained more IFN-γ+ TNF-α+ 
IL-2+ T cells than DbNP336 specific CD8+ T cell population (Figure 4.15).  
 
In the lung, TNF-α+IFN-γ+ DbNP366 specific CD8+ T cells were similar between 
X31-150 (16.49±5.60%) and X31-WT (12.98±0.68%) infected groups and were 
also observed in the DbPA224 specific CD8+ T population (31.68± 6.65% versus 
30.76±4.7%) (Figure 4.15 B). This further extended to IL-2+IFN-γ+ DbNP366 
specific CD8+ T cells where the X31-150 (2.52±0.60%) infected group was 
comparable to the X31-WT (3.03±1.37%) control group and the IL-2+IFN-γ+ 
DbPA224 specific population (5.47±0.78% versus 6.94±3.20%) (Figure 4.15E). 
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In the spleen, X31-150 infected mice had a smaller proportion of DbPA224 TNF-
α+IFN-γ+ CD8+ T cells (54.78±8.40%) when compared to X31-WT 
(75.88±10.59%) controls (Figure 4.15C). This difference also extended to the 
percent of DbNP366 IL-2+IFN-γ+ CD8+ T cells (X31-150; 6.34±1.57% vs X31-WT; 
9.41±0.80%) (Figure 4.15F). The IL-2+IFN-γ+ DbPA224 populations were similar 
between the two groups (Figure 4.15F). The greater number of cytokines 
produced by CD8+ T cells reflects a more differentiated state. 
 
These ICS results further confirm that influenza viruses expressing miR-150 
can induce enhanced functional influenza-specific CD8+ T cell responses in the 
BAL.  
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Figure 4.14. IFNγ+ CD8+ influenza-specific T cell responses for DbNP366 and DbPA224 
epitopes at 10dpi in pooled BAL, lung and spleen. Naïve B6 mice were intranasally infected 
with 1×104pfu X31-150 or X31-WT virus. Pooled BAL, lungs and spleens were collected at 
10dpi for ICS analysis. Data shows the total CD8+ T cells expressing IFN-γ+ from each tissue 
(A-C). Data presents mean ± SEM (except for pooled BAL) of one of three independent 
experiments. A Student's t-test was used to compare samples (NS, not significant; n=5).  
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Figure 4.15. Multi-functional influenza-specific CD8+ T cell responses for DbNP366 and 
DbPA224 epitopes. Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-
WT virus. Pooled BAL, lungs and spleens were collected at 10dpi for ICS analysis. The data 
present the percentage of TNF-α+ within the IFN-γ+ CD8+ subset in pooled BAL (A), lung (B) 
and spleen (C); we also show the percentage of IL-2+ within the IFN-γ+ CD8+ subset in BAL (D), 
lung (E) and spleen (F). Data presents mean ± SEM (except for pooled BAL) of one of three 
experiments. A Student's t-test was performed to compare samples (*, p<0.05; **, p<0.01; ***, 
p<0.001; ****, p<0.0001; NS, not significant, n=5). 
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4.2.3 Characterisation of primary B cell responses following infection with 
recombinant X31-150 virus 
 
Humoral immunity plays a very important role protection against influenza virus 
infection. Therefore, we evaluated primary B cell responses and antibody titres 
at 10dpi to assess if infection with recombinant X31-150 virus would improve 
humoral immunity. We are not assessing antibody responses at the peak of the 
response (normally day 14). Flow cytometry was used to identify the B220+ B 
cell population (Figure 4.9D). Serum samples were collected at 10dpi, and 
neutralising antibody titres were determined using a microneutralisation assay 
(Section 2.24).  
 
We observed no significant changes in B cell numbers in the BAL (Figure 
4.16A), lung (Figure 4.16B) and spleen (Figure 4.16C) when comparing mice 
infected with X31-150 or X31-WT at 10dpi. There was also no difference in 
influenza-specific neutralising antibodies at 10dpi (Figure 4.17). 
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Figure 4.16. Quantitative analysis of B cells in different tissues at 10dpi. Naïve B6 mice 
were intranasally infected with 1×104pfu X31-150 or X31-WT virus. Pooled BAL, lungs and 
spleens were collected at 10dpi for analysis. B cell populations in the pooled BAL (A), lung (B) 
and spleen (C) were compared between X31-150 and X31-WT. Data presents mean ± SEM 
(except for pooled BAL) of one of three experiments. A Student's t-test was performed to 
compare samples (NS, not significant; n=5). 
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Figure 4.17. Serum neutralisation titres in X31-150 or X31-WT infected mice at 10dpi. 
Naïve B6 mice were intranasally infected with 1×104pfu X31-150 or X31-WT virus. Serum 
samples were collected and antibody titres evaluated using a microneutralisation assay. The 
data is representative of one of three identical experiments. A Student's t-test was performed 
to compare samples (NS, not significant; n=5). 
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4.3 Discussion    
 
A successful live attenuated vaccine needs to have two important attributes: 
firstly, it has to be safe and secondly it must stimulate protective immune 
responses against infection. Traditional influenza vaccines only provide 
inconsistent protection to the elderly due to immunosenescence (Haq & 
McElhaney 2014). Furthermore, a large obstacle for pandemic preparedness is 
weak immune responses elicited after vaccination (Jennings et al. 2008). 
Strategies are under investigation to improve the efficacy of influenza 
immunisation in the elderly as well as to develop a dose sparing solutions for 
the pandemic preparedness. The use of adjuvants is a strategy used to improve 
host immune response following vaccination. Alum and emulsions (such as 
MF59 and AS03) adjuvants usually trap antigen at the injection site and 
enhance the activation and recruitment of antigen presenting cells to stimulate 
improved cellular and humoral immune responses. PRR ligand adjuvants (for 
TLR7/8) directly influence proinflammatory cytokine production and enhance 
the adaptive immune response (Didierlaurent et al. 2009; Van Hoeven et al. 
2017). The first adjuvanted influenza vaccine (FLAUDTM) was authorised in 
1997 in Italy (Podda 2001). In 2015, an MF59 adjuvanted influenza vaccine was 
approved by the FDA in US for use in humans over 65yrs of age (Camilloni et 
al. 2015) and was also approved in Australia (Australian Technical Advisory 
Group on Immunisation (ATAGI) 2017) and for a further 36 countries worldwide. 
Studies revealed that the MF59 adjuvanted seasonal influenza vaccine showed 
better protection than the traditional inactivated vaccine by reducing influenza-
like illness and preventing the hospitalisation in the elderly (Domnich et al. 
2017). Adjuvanted pandemic influenza vaccines (such as H5N1 and H7N9) 
were also under investigation (Izurieta et al. 2015; Jackson et al. 2015). Given 
the accelerated innate immune response kinetics and greater influenza-specific 
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CD8+ T cell responses in the BAL induced by our X31-150 virus, we believe our 
miR-150 expressing recombinant virus is a self-adjuvanting influenza vaccine. 
The mechanism underpinning the early shift in immune response kinetics is yet 
to be determined. One possible explanation is that miR-150 expressed from our 
recombinant virus is exported into extracellular vesicles (EVs) for crosstalk with 
other immune cell populations to enhance their migration into the BAL. This 
hypothesis is supported by studies that show miR-150 packed into EVs derived 
from the monocytic cell line THP-1 and delivered to human microvascular 
endothelial cells in order to downregulate c-Myb expression and accelerate the 
migration of the HMEC-1 endothelial cell line (Li et al. 2013; Zhang et al. 2010). 
More importantly, when B6 mice were injected with EVs containing miR-150, 
miR-150 expression was significantly increased as early as 6hrs post injection 
and the angiogenic function of recipient endothelial cells was greatly enhanced 
(Li et al. 2013; Zhang et al. 2010; Zhao et al. 2016). Evidence of miR-150 
enhanced immune cell migration is very limited, and is focused on oncogenesis 
and non-immune cells such as endothelial cells. Additional support for our 
hypothesis comes from two studies where exosomal miR-155 released from 
DCs can be taken up by miR-155-/- DCs (Alexander et al. 2015; Dickey et al. 
2016) where function is restored.   
 
Several studies have revealed dysregulation of serum miR-150 upon influenza 
infection or vaccination (Brogaard et al. 2016; de Candia et al. 2013; Moran et 
al. 2015; Song et al. 2013; Tambyah et al. 2013). Three studies have shown 
upregulation (de Candia et al. 2013; Moran et al. 2015; Tambyah et al. 2013) 
and another two downregulation (Brogaard et al. 2016; Song et al. 2013). In our 
study, serum miR-150 expression in X31-WT infected mice was stable before 
and after infection at 3dpi. Many factors may contribute to this differential 
expression pattern, including: time points of infection, subtypes of influenza 
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viruses, severity of infection, host species, components of blood samples 
(whole blood, peripheral blood, plasma, serum, or circulating leukocytes) and 
methodology. In our present study, mature miR-150 was found in serum 
exosomes from X31-150 infected mice, indicating that miR-150 expressed by 
our recombinant virus may be packaged into exosomes and delivered to target 
cells through the circulatory system to modulate immune responses. Another 
study (de Candia et al. 2013) suggests that elevated levels of miR-150 in 
peripheral blood could come from activated lymphocytes that then export 
endogenous miR-150 into the blood stream. In future, CD8+ T cells and DCs 
could be sorted and cultured in the presence of exosomes containing miR-150 
to investigate alterations in function. This would further expand our knowledge 
in understanding the mechanism of how miR-150 derived from the X31-155 
virus modulated immune responses. 
 
Rapid recruitment of innate immune cells and excessive cytokine and 
chemokine production induced by highly pathogenic influenza viruses causes 
severe pathology in the lung and is considered a key reason for the high 
mortality (Tisoncik et al. 2012) associated with these infections. Our 
experiments show increased numbers of innate immune cells in X31-150 
infected mice and may increase pathology in the lung although this is yet to be 
determined and mice show no additional clinical signs. In future, lung histology 
from X31-150 infected mice will be analysed to assess pathology.  
 
In recent years, miRNA profiles were widely studied in several diseases to 
identify candidates for biomarkers or understand the roles of miRNAs in host-
pathogen interaction. Microarray, deep-sequencing, northern blotting analysis 
and quantitative real-time PCR (qPCR) were all used to try and gain knowledge. 
qPCR methods are considered as the most sensitive and specific methods to 
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identify mature miRNA expression. To obtain reliable data, a reference gene is 
required to normalise miRNA qPCR data. 5S rRNA is abundant in most cell 
types as well as in serum exosomes. 5S rRNA or U6 snRNA are widely used 
as internal controls for miRNA profile studies owing to their stable expression 
(Choong, Yang & McNiece 2007; de Candia et al. 2013; Lin & Lai 2013; 
Takamizawa et al. 2004). In our in vitro study (Section 3.2.7, Figure 3.11), 5S 
rRNA was selected as the reference gene to normalise miR-150 and miR-107 
expression in both MDCK and A549 cells, as its expression in both cells is 
stable. However, when analysing miR-150 expression in serum exosomes, we 
found 5S rRNA was significantly increased upon infection in both X31-WT and 
X31-150 infected animals, excluding 5S rRNA as a normalising RNA for miR-
150 analysis. Other reports have shown that 5S rRNA is not suitable for 
neuronal miRNA profiling or for serum miRNA screening in gastric cancer (Lim 
et al. 2011; Song et al. 2012b). Additional house-keeping miRNAs such as miR-
191 and miR-103 have been assessed in solid tissues (Peltier & Latham 2008). 
miR-93 and miR-127 have been used in bovine serum miRNA screening (Bae 
et al. 2015). Mi and the colleagues found five miRNAs were stably expressed 
in three mice species including B6 (Mi et al. 2012a). Whether these miRNAs 
are stable during influenza infection requires further investigation.  
 
In this chapter, accelerated innate immune response kinetics was achieved 
along with lower viral replication in the lungs of X31-150 infected animals. The 
primary humoral response was comparable between X31-150 infected mice 
and WT controls. The influenza-specific CD8+ T cell response was greater in 
the X31-150 infected group and provides evidence to suggest that these 
recombinant viruses can act as self-adjuvanting vaccines. 
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Chapter 5  Evaluation of secondary immune 
responses and protection following immunisation and 
challenge with recombinant miR-150 influenza viruses  
 
5.1 Introduction  
 
Currently, influenza vaccines are extensively used to reduce the impact 
seasonal influenza epidemics. The efficacy of the influenza vaccine relies 
mainly on the production of neutralisation antibodies that recognise the cell 
surface proteins of virus (HA and NA). Along with the well-known importance of 
antibody mediated protection, T cells can also provide long lasting homologous 
and heterologous protection against secondary infection (Epstein et al. 1998; 
Liang et al. 1994). In recent years there have been significant advances in the 
development of universal influenza vaccines that are antibody based (Krammer 
& Palese 2015) or T cell based (Grant et al. 2016).  
 
With the development of human monoclonal antibody (mAb) technology, 
conserved haemagglutinin stalk-reactive antibodies from mice and humans 
have been identified that make the generation of an antibody-based universal 
influenza virus vaccine possible (Okuno et al. 1993; Sui et al. 2009; Throsby et 
al. 2008). Current inactivated vaccines induce antibodies against the globular 
head of the HA, which is highly variable among strains (Wrammert et al. 2008). 
On the other hand, stalks-reactive antibodies usually bind to epitopes from 
conserved regions of the HA protein that show broad cross reactivity between 
different strains of influenza A virus (Ekiert et al. 2011; Okuno et al. 1993; Sui 
et al. 2009). The proposed mechanism of HA stalk-reactive antibodies includes 
blocking the pre-fusion process (Brandenburg et al. 2013), preventing changes 
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in pH in endosomes to stop the cleavage of HA (Brandenburg et al. 2013; Sui 
et al. 2009), leading to fewer viral progeny budding from the cell surface (Tan 
et al. 2014). Traditional influenza vaccines induce low levels of HA stalk-
reactive antibodies (subdominant antibodies compared to antibodies targeting 
the globular head), and so they provide limited protection against heterologous 
strains under these conditions (Ellebedy et al. 2014). Currently, two types of HA 
universal vaccine have been identified: the headless HA and a chimeric HA 
both of which are in preclinical testing. The headless HA lacks the globular head 
sequence (Graves et al. 1983). The chimeric HA contains H1 (group 1), H3 
(group 2) or influenza B HA stalk domains within the recombinant HA protein 
(Hai et al. 2012). Both generate neutralising antibodies against the stalk domain 
of multiple strains of virus but have short half-lives and may require additional 
boosting vaccines to improve efficacy (Krammer & Palese 2015).  
 
Unlike the antibody-mediated protection provided by traditional influenza 
vaccines, T cells can recognise conserved peptides derived from internal 
proteins (ie NP366-374) across different influenza strains and subtypes. B6 mice 
primed with H1N1 virus and boosted with H3N2 virus establish a large number 
of cross-reactive DbNP366 memory CD8+ T cells that offers protection (transient 
weight loss and survival) when lethally challenged with H5N1 and H7N7 viruses 
(Christensen et al. 2000; O'Neill et al. 2000). Previous studies have shown that 
the peripheral blood mononuclear cells (PBMCs) of individuals who have never 
seen the H5N1 virus contain H5N1-specific CD4+ and CD8+ T cells that bind 
conserved peptides within the H5N1 virus (Lee et al. 2008). Ex vivo screening 
using an IFN-γ enzyme-linked immunosorbent spot assay (ELISpot), has in the 
past highlighted a number of conserved T cell epitopes, most of which were 
derived from the influenza matrix protein (M) 1 and nucleoprotein (NP) (Lee et 
al. 2008; Sridhar et al. 2013; Yewdell et al. 1985). Development and 
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optimisation of T-cell based vaccines will reduce the need for seasonal 
reformulation of vaccines.  
 
Further evidence that pre-existing influenza-specific memory T cells have the 
ability to reduce disease burden is found from studies conducted after the 2009 
(H1N1) pandemic and shows that patients with less severe symptoms had 
higher frequencies of pre-existing influenza-specific CD8+ effector memory T 
cells against conserved epitopes derived from NP, PB1 and M1 proteins 
(Sridhar et al. 2013). Protection was associated with the presence of influenza-
specific IFN-γ+IL-2- CD8+ T cells (Sridhar et al. 2013), that were 
CD45RA+CCR7- (Hillaire et al. 2011b). Seventy percent of the CD45RA+CCR7-  
IFN-γ+IL-2- CD8+ T cells produced CCR5, a lung homing marker that is 
essential for the recruitment of CD8+ T cells to the lung (Kohlmeier et al. 2008; 
Picton et al. 2012). There was no correlation between the occurrence of 
influenza-specific CD45RA+CCR7- IFN-γ+IL-2- CD4+ effector memory T cells 
and disease severity (Sridhar et al. 2013). These results demonstrate the 
critical role of conserved influenza-specific CD8+ T cells plays in heterologous 
protection in humans. Development of universal T cell vaccines will not only 
limit the need for seasonal reformulations but will also restrain the severity 
caused by influenza infection. 
 
Mouse-adapted PR8 and X31 viruses are serologically distinct that differ in the 
constellation of cell surface HA and NA proteins (H1N1 and H3N2 respectively). 
Importantly they share the same PR8 internal genes; NP, NS, M, PA, PB1, and 
PB2. The B6 mouse model for characterisation of CD8+ T cell responses 
following primary and secondary infection has identified a large number of 
H2Db- and H2Kb- restricted viral epitopes (Doherty & Kelso 2008). Primary 
responses are induced by intranasal infection with X31 H3N2 influenza virus as 
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detailed in the previous chapter (Section 4.2.2 and 4.2.3). During the primary 
infection, virus is cleared by 10dpi (Doherty & Christensen 2000), followed by 
the establishment of CD8+ T memory populations. The majority of effector 
DbNP366 and DbPA224 CD8+ T cells undergo apoptosis while a small number 
become memory CD8+ T cells that can be found in the spleen and lung (Belz 
et al. 2000; Hogan et al. 2001). In fact, equivalent numbers of memory DbNP366 
and DbPA224 T cells are established (Flynn et al. 1998; La Gruta, Turner & 
Doherty 2004; Wiley et al. 2001) that can be detected out to at least d500 (Belz 
et al. 2000; Hogan et al. 2001; Marshall et al. 2001). For analysis of secondary 
CD8+ T cell responses, mice are intraperitoneally (i.p.) primed with PR8 virus 
and after six weeks intranasally (i.n.) challenged with the serologically distinct 
X31 virus avoiding neutralisation antibodies. Following primary infection 
influenza-specific CD8+ T cell DbNP366 and DbPA224 responses are co-dominant. 
However, following secondary infection, the DbNP366 is approximately 6-fold 
higher accounting for up to 80% of the total influenza-specific CD8+ T cell 
response (Andreansky et al. 2005; Belz et al. 2000; Flynn et al. 1998). Both 
DbNP366 and DbPA224 memory CD8+ T cell pools are stable at 400d post boost 
(Marshall et al. 2001).  
 
Data generated in Chapter 4 described influenza-specific responses following 
primary infection with recombinant X31-150 influenza virus. In this chapter, the 
secondary response was analysed to determine if introduction of the miRNA 
improves vaccine efficacy. 
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5.2 Results 
 
5.2.1 Characterisation of the secondary immune responses following 
prime-boost vaccination 
 
Six- to eight-week-old female B6 mice were used to study secondary responses. 
Naïve mice were primed intraperitoneally (i.p.) with 1.2×106 pfu PR8-150 (H1N1) 
virus and six weeks later mice challenged intranasally (i.n.) with 1×104 pfu X31-
150 (H3N2) serologically distinct virus. These mice were compared to a control 
group, that received 1.2×106 pfu PR8-WT (H1N1) i.p., and challenged with X31-
WT (H3N2) i.n.. Weight loss data was monitored daily for seven days after 
secondary infection. At day 7 dpi, mice were anesthetised, and bronchoalveolar 
lavage (BAL) and spleen were harvested to characterise adaptive immune 
responses as described in Section 2.19. Lymphocytes from BAL and spleen 
were obtained as previously described (Section 2.20.1 and 2.20.3) for flow 
cytometric analysis.  
 
5.2.1.1. Weight loss following secondary infection 
 
In a secondary study, pooled data from six individual experiments were used to 
study prime-boost vaccination due to variable infections by animal technical 
staff at CSIRO AAHL. Uninfected mice were removed from the analysis and so 
data present in Section 5.2.1 only includes infected mice. X31-WT (n=25) or 
X31-150 (n=22) were used in the analysis of secondary immune responses. 
Statistical support for this analysis was provided by Dr. Steven Bowe, 
Biostatistics Unit, Deakin University. A log10 analysis ensured data was 
normally distributed and suitable for statistical comparisons. X31-WT (n= 25) or 
X31-150 (n= 22), secondarily infected mice showed a typical U shaped weight 
 149 
 
 
loss curve with no significant differences observed between the two groups 
(Figure 5.1). 
 
Mice started to lose weight from 1dpi, and lost 12% of starting weight (88.05% 
± 1.16%) for the PR8-150/X31-150 group and 10% of starting weight (89.98% 
± 0.53%) for the PR8-WT/X31-WT group, with both groups gaining weight after 
4dpi. This was much faster than that observed following primary infection where 
mice only began gaining weight after 7dpi (Figure 4.1). This is due to the 
presence of influenza-specific CD8+ T cell memory (given the virus used are 
serologically distinct). Previous studies have shown that activated influenza-
specific CD8+ T cells are detectable as earlier as 3dpi following secondary 
infection compared to 5dpi following primary infection (Flynn et al. 1998). 
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Figure 5.1. Weight loss following secondary infection. Naïve B6 mice were primed 
intraperitoneally with 1×106 pfu of PR8-150 or PR8-WT, and at least six weeks later, challenged 
intranasally with 1×104 pfu X31-150 or X31-WT influenza virus. Weight loss was monitored daily 
for seven days following challenge. Data represent mean ± SEM percentage of pre-challenge 
weight. A Student t-test was used for statistical analysis.  
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5.2.1.2 Enumeration of influenza-specific CD8+ T cell by tetramer staining 
assay following secondary infection 
 
In order to evaluate secondary CD8+ T cell responses induced by the miR-150 
expressing recombinant viruses, mice were primed and challenged as 
described in Section 2.19. Lymphocytes obtained from BAL and spleen were 
enumerated by tetramer staining for influenza-specific CD8+ T cell populations 
targeting the DbNP366 and DbPA224 peptides. The analysis only contains infected 
mice as mentioned in Section 5.2.1.1. 
 
During analysis of the tetramer responses, large variations in BAL samples was 
observed, resulting in an abnormal distribution of the data set. Expert statistical 
advice provided by Dr. Steven Bowe from Deakin University suggested the use 
of a log10 scale to ensure normal distribution of data (detailed in Section 2.27) 
before further analysis via a Student's t-test between PR8-150/X31-150 and 
PR8-WT/X31-WT infected groups (Figure 5.2A). The data sets in spleen 
followed a normal distribution and so CD8+ T cell numbers were calculated as 
per normal practice (Figure 5.2B). 
 
Following primary X31-WT influenza virus infection, co-dominant DbNP366 and 
DbPA224 specific CD8+ T cell responses are observed in the BAL (Figure 4.12A). 
Following secondary infection using a PR8-WT prime and a X31-WT challenge, 
the DbNP366 is immunodominant (~6 fold higher than DbPA224) (Belz, Xie & 
Doherty 2001; Crowe et al. 2003; La Gruta, Turner & Doherty 2004; Marshall 
et al. 2001). In our WT control secondary challenge, we observed a DbNP366 
response (5.25 log10 ±0.08) response ~0.65 log10 higher than the DbPA224 
response (4.60 log10 ±0.10). A larger immunodominance was observed for the 
PR8-150/X31-150 group where the DbNP366 response (5.77 log10 ± 0.12) was ~ 
1.12 log10 higher than the DbPA224 response (4.65 log10 ± 0.08) (Figure 5.2A). 
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When comparing the PR8-150/X31-150 infected group with the PR8-WT/X31-
WT group, ~0.52 log10 higher DbNP366 CD8+ T cells were detected (P<0.001). 
There was no significant difference in DbPA224 CD8+ T cell responses when 
comparing the same groups in BAL (p=0.7) (Figure 5.2A). 
 
In the spleen, the DbNP366 response was immunodominant for both groups 
(Figure 5.2B). In the PR8-WT/X31-WT control group, the DbNP366 response 
(6.15 log10 ±0.08) was ~0.9 log10 larger than the DbPA224 response (5.26 log10 
±0.16). In PR8-150/X31-150 infected group, the difference was much higher, 
where the DbNP366 response (6.19 log10 ±0.06) was ~1.5 log10 larger than 
DbPA224 response (4.69 log10 ± 0.16). Interestingly when we compared between 
groups ie PR8-150/X31-150 and PR8-WT/X31-WT, the response to DbNP366 
was similar (p=0.96). In contrast, the DbPA224 response in the PR8-150/X31-
150 group was significantly lower than in the PR8-WT/X31-WT controls 
(p<0.05).   
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Figure 5.2. Enumeration of influenza-specific CD8+ T cell responses using tetramer 
staining 7dpi. Naïve B6 mice were intraperitoneally primed with 1×106 pfu of PR8-150 or PR8-
WT, and then intranasally challenged with X31-150 or X31-WT six weeks later. Lymphocytes 
from BAL (A) and spleen (B) were analysed using tetrameric complexes to assess influenza-
specific CD8+ DbNP366 and DbPA224 T cell. Data is presented as mean ± SEM, n=22 for PR8-
150/X31-150, and n=25 for PR8-WT/X31-WT. A student's t-test was used for statistical analysis 
(*,p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; NS, not significant). 
  
 PR8-WT/X31-WT   PR8-150/X31-150  
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5.2.1.3 Influenza specific neutralising antibody titres at the day 42 primary 
memory timepoint. 
 
Serum samples from PR8-150 or PR8-WT primed mice were collected prior to 
intranasal secondary challenge. A microneutralisation assay (detailed in 
Section 2.24) was conducted to assess the level of influenza-specific 
neutralising antibody titres.  
 
We observed no significant difference in neutralising antibody titres between 
the PR8-150 (2840±255) or PR8-WT (2766±230) primed mice (Figure 5.3) at 
the day 42 timepoint. Analysis of day 10 acute neutralising titres when using a 
recombinant X31-155 virus in an earlier study by our group stimulated greater 
antibody responses when compared to X31-WT controls (Izzard et al. 2017) 
suggesting there may be miRNA specific differences in antibody responses.  
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Figure 5.3. Influenza-specific neutralising antibody titres in PR8-150 primed animals. 
Serum were collected from B6 mice at day 42 following intraperitoneally priming with 1×106 pfu 
of PR8-150 or PR8-WT. Microneutralisation assays were conducted to evaluate the level of 
influenza specific neutralizing antibody titres. Data presented shows mean ± SEM of one of six 
individual experiments (n=5). A student's t-test was used for the statistical analysis. NS, not 
significant different. 
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5.2.2 Efficacy of protection following use of recombinant influenza 
viruses expressing miRNAs. 
 
In order to evaluate the protective efficacy of using miR-150 expressing 
recombinant influenza viruses, six- to eight-week B6 mice were intranasally 
vaccinated with 1×104 pfu X31-150 or X31-WT for six weeks and then 
challenged intranasally with 1×104 pfu X31-WT virus. This would mimic a real 
world scenario where a self-adjuvating vaccine expressing miRNAs would be 
used to generate a strong memory response just as current commercially 
available seasonal vaccines do. The animals would then be challenged with a 
homologous strain as would be the case in human infection given that we are 
normally aware of circulating strains. Serum samples were collected prior to 
challenge, and spleen and lung samples were collected at day 3 post-challenge 
to assess efficacy. 
 
5.2.2.1. Weight loss in immunised group post challenge 
 
Weight loss in X31-150 immunised indicated there were no significant 
difference when compared to X31-WT control (Figure 5.4A). Given the use of 
homologous virus in challenge experiments and the presence of neutralising 
antibodies no weight loss was detected post challenge.  
 
5.2.2.2. Lung viral clearance in lung samples from challenged mice at 3dpi 
 
RNA was extracted from lung samples to detect the presence of virus 3dpi after 
challenge. A plaque assay was also performed to assess viral titres but failed 
to detect plaques in all samples (Figure 5.4B) as expected given the presence 
of neutralising antibodies (Figure 5.5A). Similarly, no trace of influenza M gene 
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was detected by real-time PCR, indicating the complete clearance of influenza 
virus at 3dpi in both groups. 
 
5.2.2.3 Characterisation of adaptive immune responses following vaccine 
challenge 
 
Influenza specific antibody titres in the serum were analysed at day 42 after 
X31-150 and X31-WT vaccination and before challenge using a 
microneutralisation assay (see Section 2.24). No significant difference was 
observed between the X31-150 (906±174) and X31-WT (960 ± 156) immunised 
mice (Figure 5.5A). This was consistent with what we observed at the primary 
10dpi timepoint (Figure 4.17) and the primary 42dpi memory timepoint following 
PR8 intraperitoneal injection (Figure 5.3). Influenza specific neutralising 
antibody titres vary depending on time post infection and antigen dose.  
 
At day 42, mice immunised with X31-150 or X31-WT were challenged i.n. with 
1.0x104 pfu of X31-WT, and spleen samples collected at 3dpi as described in 
Section 2.20.1. Flow cytometric characterisation of adaptive immune 
populations in the spleen revealed there were significantly higher B220+ B cells 
in the spleen of X31-150 immunised group (Figure 5.5C) post challenge when 
compared to controls. Although there was no statistical significance in CD4+ 
and CD8+ T cell numbers between X31-150 and X31-WT vaccinated and 
challenged mice, consistently higher numbers of CD4+ and CD8+ T cell 
population were observed in X31-150 group (Figure 5.5D) suggesting that the 
initially priming with X31-150 is generating a larger number of memory 
lymphocytes.  
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Figure 5.4. Efficacy of the recombinant X31-150 vaccine (weight loss and lung plaque 
assay results). Naïve B6 mice were intranasally vaccinated with 1×104 pfu of X31-150 or X31-
WT control and 6 weeks later intranasally challenged with 1×104 pfu homologous X31-WT. Mice 
were monitored for weight loss (A). Results are shown as mean ± SEM percentage of pre-
challenge weight. A Student’s t-test was used for the statistical analysis (n=5). Spleen and lung 
samples were collected on day 3 post-challenge. Lung homogenates were assesed by plaque 
assay (B) and for viral M gene by RT-qPCR (data not shown). (-): negative control, (+): positive 
control. The results represent two individual experiments.  
 159 
 
 
   
 
Figure 5.5. Efficacy of the recombinant X31-150 vaccine (serum antibodies and spleen 
lymphocytes). Naïve B6 mice were intranasally vaccinated with 1×104 pfu of X31-150 or X31-
WT control and 6 weeks later serum samples were collected for analysis of influenza-specific 
neutralization antibody titres (A). Mice were then intranasally challenged with the homologous 
X31-WT virus using 1×104 pfu. Spleen and lung samples were collected 3dpi. Single cell 
suspensions were prepared from spleen and stained with cell surface antibodies for flow 
cytometric analysis of total lymphocyte number (B), B cell number (C) and total CD4+ and CD8+ 
T cell number (D). Results are shown as mean ± SEM (n=5 representing two individual 
experiments). A Student’s t-test was used for the statistical analysis (*, p<0.05; NS: not 
significant). 
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5.3 Discussion 
 
Improvement of influenza vaccine efficiency has attracted a lot of attention in 
recent years. With the development of novel technologies, new strategies have 
been tested in this field. We have established a system using reverse genetics 
technology that delivers miRNAs to the respiratory tract to modulate immunity 
(Izzard et al. 2017; Izzard et al. 2014). We have shown that following primary 
infection recombinant X31-150 influenza viruses have the ability enhance the T 
cell responses in the BAL. In this chapter, we show that a prime-boost strategy 
(PR8-150/X31-150) can further enhance influenza specific DbNP366 CD8+ T cell 
immunodominance.  
 
A number of studies have demonstrated that an immunodominant DbNP366 
CD8+ T cell response is established following PR8-X31 secondary infection 
(Belz, Xie & Doherty 2001; Flynn et al. 1998; La Gruta, Turner & Doherty 2004; 
Marshall et al. 2001). Understanding the biology of T cell responses induced by 
miR-150 in our model is important. A possible mechanism behind enhanced 
secondary immune responses may be that expression of miR-150 by 
recombinant influenza viruses leads to the generation of greater numbers of 
memory cells when compared to WT controls. Previous studies have 
highlighted factors that impact immunodominance and recall responses. By 
using reverse genetics, the NP366-374 (ASNENMETM) and PA224-233 
(SSLENFRAYV) epitopes were mutated by replacing the fifth asparagine with 
glutamine (N5Q) and the wildtype epitopes inserted in the NA stalk to equalise 
expression and assess immunodominance (La Gruta et al. 2006). Infection 
experiments suggested that the size of the memory pool was the major factor 
determining the magnitude of the secondary response. Our experiments 
following primary infection indicate that higher numbers of DbNP366 CD8+ T cells 
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are found in the BAL of X31-150 infected mice that is normally associated with 
a larger pool of memory cells. In future, a day 30 analysis of DbNP366 and 
DbPA224 memory CD8+ T cell populations is required after primary infection to 
determine if higher numbers of the DbNP366-specific memory CD8+ T cells are 
found in the X31-150 group. Moreover, adoptive transfer experiments using 
equal numbers of sorted DbNP366 cells derived from secondarily infected PR8-
150/X31-150 vs PR8-WT/X31-WT will provide further insight into the 
functionality of these cells. This could be paired with a transcriptional analysis 
to further understand how miR-150 impacts overall cell function. 
 
A change of microenvironment associated with miR-150 expression may also 
contribute to higher numbers of DbNP366 CD8+ T cells. Smith and colleagues 
have found a number of genes including those involved homing (CCR5) are 
downregulated in miR-150-/- CD8+ effector T cells following infection with L. 
monocytogenes (Smith et al. 2015). In future, sorting CD8+ T memory cells from 
X31-150 (primary) and PR8-150/X31-150 (secondary) infected animals and 
analysing gene expression may assist in determining what other factors are 
involved in development of immune responses. 
 
We observed no significant differences in influenza-specific neutralising 
antibody titres (Figure 5.3 and 5.5A) which suggests overexpression of miR-
150 by our recombinant viruses has minimal impact on antibody responses 
following infection. This is in contrast to a previous study carried out in our lab 
where higher influenza-specific neutralising antibody titres were observed in 
X31-155 primed mice when compared to X31-WT controls (Izzard et al. 2017). 
In future, we may be able to manipulate our vaccination strategy to express 
both miR-150 and miR-155 from our recombinant viruses to augment both 
humoral and cellular immune responses. Other studies suggest this may be 
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possible as multiple miRNAs have been expressed from a single delivery vector 
(Chen et al. 2011; Chen et al. 2010; Choi et al. 2015). In our model, this could 
be achieved by expressing miR-155 and miR-150 as a tandem between the 
NS1 and NEP of the modified linearised recombinant NS gene segment or by 
modifying other gene segments to express additional miRNAs. The M gene 
segment of influenza virus undergoes splicing to express M1 and M2 proteins 
(detailed in Section 1.5.4.2). A recent study has split the overlapping M1 and 
M2 mRNA using a similar strategy as defined for the NS gene segment to create 
a linearised recombinant M gene (Nogales et al. 2016). A temperature sensitive 
live influenza virus was rescued using this modified linearised modified M gene 
that was attenuated in vitro and in vivo but provided very good protection 
against virus challenge in mice (Nogales et al. 2016). Furthermore, the authors 
also rescued a recombinant virus expressing modified NS and M gene 
segments, suggesting a dual miRNA-expressing system is feasible in the future. 
 
Herein, we describe the impact of a recombinant virus expressing only a single 
miRNA (miR-150). Other miRNAs should be validated in the future using this 
approach. A combination of miRNAs may further improve the adjuvant effects 
observed to date. This is important as traditional adjuvants in the vaccine 
production have been shown to cause side effects (Sivakumar et al. 2011).  
For example, during 2010 flu season, several children under the age of five 
suffered side effects including fever, febrile convulsions after receiving the 
bioCSL vaccine Fluvax. Symptoms were associated with abnormal cytokines 
and chemokines induced by this vaccine (Blyth et al. 2011). In addition, an 
increasing number of narcolepsy cases have been observed after vaccination 
with AS03 adjuvanted inactivated influenza vaccine (influenza A (H1N1) 
pandemic 2009) (Dauvilliers et al. 2013; Nohynek et al. 2012; Oberle et al. 
2015). As a novel self-adjuvanting approach, the use of miRNA-carrying virus 
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is promising. The miRNA-carrying vaccine may eliminate some of these issues 
given we have not observed any adverse events in our mouse experiments.  
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Chapter 6  General Discussion 
 
6.1 Overall discussion 
 
Influenza viruses cause significant morbidity and mortality with 2-5 million 
serious infections and approximately 300,000-500,000 deaths annually (Girard 
et al. 2005). It is well-established that this increased vulnerability is associated 
with a decline in the immune system in old age (Reber et al. 2012; Webster 
2000). Despite this, vaccination remains the best way to protect individuals from 
influenza virus infection. However, our current influenza vaccine will only 
protect 39% of 65+ individuals from influenza-like disease (Beyer et al. 2013).  
This thesis explored a reverse genetics strategy to improve immunity using a 
self-adjuvanting approach. Our strategy combined direct mutagenesis and 
recombinant DNA technology to generate recombinant influenza viruses that 
express immunomodulatory miRNAs to enhance influenza-specific immune 
responses.  
 
The addition of adjuvants is an effective method for boosting immune 
responses in the elderly. To date, two oil-in-water emulsion adjuvants have 
been approved for use in inactivated influenza vaccines; MF59 and AS03 (Reed, 
Orr & Fox 2013). The main component of both adjuvants is squalene oil which 
is a natural ingredient found in animal sterols (Garcon, Vaughn & Didierlaurent 
2012; Ott, Barchfeld & Van Nest 1995). MF59 has been found to stimulate in 
vitro cultured human macrophages to express chemokines MCP-1, IL-8, CCL3 
and CCL4 (Seubert et al. 2008). These chemokines are able to recruit 
monocytes, macrophage and granulocytes to injection sites. In addition, MF59 
can drive monocytes to differentiate into DCs, that in turn enhances antigen 
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uptake and presentation. Increased numbers of DCs migrating into draining 
lymph nodes augments adaptive immunity (Seubert et al. 2008). Similar to 
MF59, AS03 can increase expression of chemokines including CCL2, CCL3 
and CCL5 (Morel et al. 2011). Moreover, AS03 has been found to increase 
antigen uptake by granulocytes and monocytes (Morel et al. 2011). Recent 
studies have shown that the efficacy of MF59 adjuvanted inactivated influenza 
vaccine increases by up to 25% in the elderly (Mannino et al. 2012; Van 
Buynder et al. 2013). Furthermore, a Phase 3 randomised trial demonstrated 
that when the elderly were vaccinated with an inactivated influenza vaccine 
adjuvanted with AS03 there was an average four-fold higher haemagglutination 
-inhibition (HI) antibody titres against the H3N2 strain of virus (H3N2 is the main 
cause of mortality and mobility in individuals ≥ 65) when compared to those 
immunised with non-adjuvanted vaccine (McElhaney, Coler & Baldwin 2013; 
Ruiz-Palacios et al. 2016). Previous studies with MF59 adjuvanted vaccines 
show that they are able to also provide heterologous protection. In the present 
study, our X31-150 recombinant influenza virus stimulated what appears to be 
accelerated innate immune cell kinetics accompanied by higher influenza-
specific CD8+ T cell responses after infection. Therefore, recombinant viruses 
expressing miRNAs may serve as excellent ‘self-adjuvanting’ next generation 
vaccine candidates in the future. 
 
Apart from seasonal influenza vaccines, we have significant issues associated 
with pandemic preparedness. Two major limitations restrict our preparations of 
pandemic vaccines: 1) egg-based manufacturing processes where unplanned 
increases in production put pressure on vaccine companies and governments  
(Racaniello 2010); and 2) lower immunogenicity of current pandemic vaccine 
candidates (lower protective HI titres) when compared to seasonal vaccines 
(Couch et al. 2012; Cox et al. 2009; Krammer & Palese 2015). The addition of 
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current adjuvants such as MF59 to H5N1 vaccines still requires a prime-boost 
strategy to establish protective immunity (Del Giudice & Rappuoli 2015). This 
suggests a large number of doses or repeat immunisation will be required 
during a pandemic outbreak which is expensive, time consuming and 
impractical. Our self-adjuvanting strategy involving miR-150 expression may 
assist in pandemic preparedness by reducing the possibility of prime-boost 
vaccination although this remains to be proven.  
 
Commercially available influenza vaccines are produced in fertilised chicken 
eggs (Australian Technical Advisory Group on Immunisation (ATAGI) 2017). 
Egg-based production requires a large number of eggs (on average two eggs 
are used to produce one dose influenza vaccine in humans) (Hegde 2015). As 
there is increasing demand for seasonal influenza vaccine and pandemic 
preparedness by health authorities, vaccine candidates that are highly 
immunogenic are required. Previous work in our laboratory has demonstrated 
that a recombinant influenza virus expressing miR-155, induced higher 
influenza-specific neutralising antibody titres in mice at 10dpi (Izzard et al. 
2017). miR-155 regulates a wide range immune cell functions in NK cells, DCs, 
T cells and B cells (Faraoni et al. 2009). This miRNA is tightly linked to 
regulation of the CD8+ T cell response after infection (Dickey et al. 2016; 
Gracias et al. 2013). Future experiments will look at co-expressing both miR-
150 and miR-155 from our self-adjuvanting recombinant influenza viruses to 
augment both arms of the immune response. In addition to expression of 
miRNAs, siRNAs may also be included in the expression cassettes as they are 
designed to be fully complementary to target sequences reducing the likelihood 
of off-target effects (Lam et al. 2015). In Chapter 3, we designed and rescued 
recombinant viruses expressing an siRNA that targets IRAK1, a major target of 
miR-146a. Further in vito and in vivo analyses are required to ascertaing the 
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effectiveness of these recombinant viruses. Other siRNAs can also be 
considered. SOCS1 is a negative regulator of cytokine signalling pathway and 
a target for miR-150 (Chen et al. 2014; Zhou et al. 2013) and miR-155 (Izzard 
et al. 2014; Lu et al. 2009). Expression of a SOCS1 siRNA may also assist 
influenza specific immune responses.  
 
The work described in this thesis explored a reverse genetics strategy for the 
generation of recombinant influenza viruses that delivered immunomodulatory 
miRNAs. The advances provided by this influenza virus reverse genetics 
technology not only influences research relating to influenza viruses but also 
serves to optimise an underutilised viral vector to deliver other antigens (Li, 
Arevalo & Zeng 2013). The influenza-based viral vector platform technology is 
safe and provides transient delivery of exogenous sequences (detailed in 
Section 1.1.6.4). A series of antigens/epitopes have already been expressed 
from this system including those derived from HIV, SIV, Brucella abortus and 
Mycobacterium tuberculosis (Florido et al. 2013; Garulli, Kawaoka & Castrucci 
2004; Sexton et al. 2009; Stukova et al. 2006; Tabynov 2016). Safety concerns 
for immunocompromised individuals has been raised, however given that LAIV 
has been safely delivered to these susceptible patient groups the risk is greatly 
diminished (Choi & Chang 2013). Insertion of miR-150 into the influenza virus 
vector saw an attenuation in viral replication (see Figure 3.10 and Figure 4.2) 
in the presence of improved immune responses (see Figure 4.12, Figure 4.14 
and Figure 5.2) showing that immunity can be improved in these circumstances. 
 
Expression of miRNAs from viral vectors to enhance host immune response 
may also be applicable to other respiratory infections. Respiratory syncytial 
virus (RSV) is negative stranded, enveloped RNA virus belonging to the 
Paramyxoviridae family (e.g mumps, measles) (Collins & Melero 2011; Meng 
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et al. 2014), responsible for widespread infection of infants and young children 
worldwide (Blount, Morris & Savage 1956; Nair et al. 2010). In fact, 
approximately one-third of deaths in the first year of life caused by lower 
respiratory tract infections are due to RSV infection (Lozano et al. 2012; Nair et 
al. 2010). The elderly is also vulnerable to RSV infection. In the USA alone, 
there are 14,000 deaths annually (Matias et al. 2014). There is no licenced 
vaccine available for RSV (Higgins, Trujillo & Keech 2016). The inactivated 
paediatric RSV vaccine generated in 1960 showed poor protection with 
enhanced disease severity (Wright, v Mills & Chanock 1971). A reverse 
genetics system is available for RSV (Collins et al. 1995), to date, all live 
attenuated vaccine candidates (12 of which is in clinical trials now) have been 
generated using this system (Karron, Buchholz & Collins 2013) (Higgins, Trujillo 
& Keech 2016). The biggest challenge for the development of a new RSV 
vaccine is to find the balance between safety and immunogenicity (Higgins, 
Trujillo & Keech 2016). Recent studies have demonstrated that RSV can 
regulate host immune responses through dysregulation of host miRNAs 
(Inchley et al. 2015; Othumpangat, Walton & Piedimonte 2012; Thornburg, 
Hayward & Crowe 2012). miR-150 is significantly decreased in RSV-infected 
human bronchial epithelial cells (NHBE) (Othumpangat, Walton & Piedimonte 
2012). Nasal mucosa microarray screening has showed distinct miRNA profiles 
in RSV-infected children compared to healthy controls (Inchley et al. 2015). A 
significant increase of miR-155, let-7d and downregulation of miR-125, miR-
29c were observed in nasal airways of RSV-infected patients (Inchley et al. 
2015). Furthermore, miR-125, a negative regulator of CCL5 (a chemokine 
responsible for immune cells recruitment) (Zhao et al. 2010), was significantly 
downregulated in mild RSV infection but not in severe RSV when compared to 
healthy controls (Inchley et al. 2015). These findings demonstrate that miRNAs 
play an important role in modulation of immune responses following RSV 
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infection. Expression of immunomodulatory miRNAs in the context of a live RSV 
vaccine may induce rapid, protective immune responses against RSV infection 
without the deleterious side-effects observed in the past.  
 
Another potential application for this technology given influenza virus replication 
is restricted to the respiratory tract, is the delivery of therapeutic miRNAs to the 
lung to improve cancer outcomes. Aberrant expression of miRNAs has been 
associated with cancer whilst modulation of miRNA expression has been found 
to inhibit tumorigenesis (Chen, Gao & Huang 2015). Reintroduction of miRNAs 
such as let-7 in vivo can cause regression of tumours in a lung cancer murine 
model (Trang et al. 2010). miR-150 used in our study is a suppressor for small-
cell lung cancer through targeting c-Myb (Bi et al. 2014). Furthermore, delivery 
of miR-34a by nanoparticles significantly limited tumour growth and inhibited 
tumour metastasis in a B6 mouse model (Chen et al. 2010). Precise delivery of 
miRNAs to target organs such as the lung is critical to limit toxicity and 
dysregulation to surrounding tissue/organs.  
 
The mechanism by which our expressed miRNAs facilitate immune responses 
is unclear. Further investigation is required to identify key molecules and 
systems involved. Extracellular vehicles (EVs), including exosomes, have been 
implicated in cellular cross communication (Barth, Meister & Grasser 2011). 
Almost all cell types can release EVs that contain proteins, mRNA, non-coding 
RNA including miRNAs. Once released, EVs can bind to the extracellular matrix 
or neighbouring cells or traffic through the blood stream (Zhang et al. 2015b). 
As epithelial cells are the major cell type infected by influenza viruses in the 
lung (Fukuyama et al. 2015; Manicassamy et al. 2010), it is possible EVs 
derived from these cells could be released to influence immune cell trafficking 
and function. Moreover, lines of evidence from other studies suggest that EVs 
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released from cells have the ability to transfer miRNAs to other targets (de 
Candia et al. 2013; Li et al. 2013; Trifari et al. 2013; Zhang et al. 2010). One 
such study has shown that activated CD4+, CD8+ and B cells selectively export 
exosomes containing a high concentration of endogenous miR-150 to culture 
media, that correlates augmented immunity (de Candia et al. 2013). 
Macrophage-derived miR-223 has been shown to be transferred through EVs 
to target monocyte in order to increase monocyte differentiation (Ismail et al., 
2013, Johnnidis et al., 2008). Therefore, studies that monitor EVs derived from 
lung tissue, serum and BAL fluid in mice infected with our recombinant X31-
150 and X31-WT viruses may contribute to our understanding of the underlying 
mechanisms behind enhanced T responses observed in this PhD project. 
Experiments exploring the addition of EVs that contain miRNAs to DC or CD8+ 
T cell cultures may shed light on function. 
 
6.2 Research outcomes 
 
This PhD project has successfully generated a recombinant influenza virus that 
expresses miR150 using reverse genetics technology and evaluated the 
murine innate and adaptive immune responses following primary and 
secondary infection. The key research outcomes are: 
 
1. Generation of recombinant PR8 and X31 influenza viruses expressing 
miRNAs using reverse genetics technology. 
 
2. Confirmation of mature miR-150 expression and function in vitro. 
 
3. In vivo demonstration that the miR-150 expressed by recombinant influenza 
viruses can stimulate a higher number of influenza-specific DbNP366 and 
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DbPA224 CD8+ T cells in the bronchoalveolar lavage (BAL) at the site of 
influenza replication. 
  
4. Improved influenza-specific DbNP366 CD8+ T cell responses following 
secondary infection (PR8-150/X31-150). 
 
6.3 Future directions 
 
Due to time limitations, only primary and secondary acute immune responses 
were characterised in great detail. Given the dramatically improved CD8+ T cell 
responses observed following primary and secondary infection we need to 
better characterise memory CD8+ T cells such as CD103+ CD127+ CD8+ TRM in 
the lung, that have been shown to be important for mucosal immune responses 
against influenza virus infection (McMaster et al. 2015; Wu et al. 2014). 
Importantly we would also like to optimise our real-time PCR protocols with 
appropriate internal controls in order to detect miR-150 expression in mouse 
tissue and exosomes from bodily fluids to give us insights into the mechanism 
of miR-150 action in the disease model.  
  
Another key question we want to ask is do the recombinant viruses improve 
immune responses in ageing mouse models. Aged mouse shows similar 
impaired immune responses as humans, and serve as an ideal model for 
related studies (Ackert-Bicknell et al. 2015). In the B6 mouse model, when aged 
mice are infected with PR8 virus a significant reduction of DbNP366 CD8+ T cell 
responses is observed at 10dpi. The peak CD8+ T cell response is delayed until 
14dpi and IFN-γ production is impaired (Po et al. 2002). In addition, memory 
DbNP366-specific CD8+ T cell numbers are diminished in aged mice (Decman et 
al. 2010; Yager et al. 2008). As we observed earlier infiltration of innate immune 
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cell populations and enhanced CD8+ T cell response in X31-150 infected mice, 
it would be interesting to see if miR-150 expression could compensate for 
delayed responses currently observed in aged mice. Another option for the 
evaluation of miR-150 induced CD8+ T cell responses is to adoptively transfer 
equal amounts of DbNP366 and DbPA224 specific CD8+ T cells (derived from X31-
150 or X31 WT mice) into naïve mice and challenge them with a lethal dose of 
virus to see if the miR-150 induced CD8+ T cells function better than WT 
controls. 
 
Finally, insertion of tandem or multiple miRNAs into one influenza construct 
should be investigated as outlined by Naglos and colleagues (Nogales et al. 
2016) as previous studies expressing multiple miRNAs in one vector have 
demonstrated greater knockdown of the target genes (Chen et al. 2011; Choi 
et al. 2015; Chung et al. 2006).  
 
In conclusion, studies optimising influenza vaccines for the elderly and 
immunocompromised are of the utmost importance especially. Development of 
vaccines that directly enhance host immune responses and limit adverse 
effects would be commercially attractive with the benefit of decreasing the 
overall disease burden of influenza virus. 
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Appendix 
 
A.1 Buffers, solutions and other reagents 
 
A.1.1 Acetone-Methanol solution.  This solution contained acetone (Mefck 
KGaA, Germany) and methanol (Chem-Supply, Australia) at the volume ratio 
of 3:2, and stored in -20oC. 
 
A.1.2 Ammonium Tris Chloride buffer (ATC). This buffer was used in 
lymphocyte isolation and selectively lyses red blood cells. It contained 0.14M 
Ammonium chloride (NH4Cl) (BDH, AnalaR), 0.017 M Tris (Merck KGaA, 
Germany), dissolved in Tissue Culture water (Australian Animal Health 
Laboratory (AAHL), CSIRO, Australia), and the pH was adjusted to 7.2 with 1M 
HCl (Ajax Finechem, Australia), and then filtered through 0.45 µm filter and 
stored at room temperature. 
 
A.1.3 Bovine Serum Albumin (BSA). BSA was supplied as 10% in PBSA by 
the Tissue Culture Group in AAHL. 
 
A.1.4 Enriched Supplement. This supplement was used to make up growth 
media for MDCK and HEK 293T cell culture. It was prepared with the addition 
of 2 mM L-glutamine (GibcoTM, Life Technologies, Australia), 1 mM MEM 
sodium pyruvate (MP Biomedicals, USA), 100 µM MEM nonessential amino 
acids (MP Biomedicals, USA), 5 mM HEPES buffer solution (MP Biomedicals, 
USA), 55 µM 2-mercaptoethanol (Sigma-Aldrich, USA), Penicillin/Streptomycin 
(100 U/mL penicillin/100 µg/mL streptomycin) (GibcoTM, Life Technologies, 
Australia) to TC water. 
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A.1.5 FACS Buffer. FACS buffer was made up to its final concentration of 1% 
BSA (Tissue Culture Group, AAHL, CSIRO, Australia), 0.02% Sodium azide 
(Sigma-Aldrich, USA) with PBSA, and stored at 4oC. 
 
A.1.6 Foetal Calf Serum (FCS). FCS was Australian origin, supplied by Serana 
Europe GmbH, Germany, and was aliquoted and heat inactivated by the Tissue 
Culture Group in AAHL, CSIRO, Australia.  
 
A.1.7 Gram Crystal Violet. This reagent was supplied by BD, USA, and was 
used to stain plaque assay plates.  
 
A.1.8 Phosphate Buffered Saline (PBSA). This buffer was supplied by Tissue 
Culture Group, AAHL, CSIRO, which contains 8g/L NaCl, 0.2 g/L KCl, 1.42 g/L 
Na2PO4, 0.24 g/L KH2PO4.   
 
A.1.9 L-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK) Treated 
Trypsin Worthington. This reagent was made up with Trypsin Worthington 
powder (Worthington Biochemical Corporation, ScimaR, VIC, Australia) in 
PBSA with the stock concentration of 1 mg/mL, filtered through 0.45 µm 
Minisart filter, and stored at -80oC. 
 
A.1.10 Tris-Acetate-EDTA buffer (TAE). This buffer was prepared as a 40× 
stock solution, and contained 1.6M Tris (hydroxymethyl) aminomethane (Merck 
KGaA, Germany), 40 mM Ethylenediaminetetraacetic acid disodium salt 
dehydrate (EDTA) (SIGMA Ltd, USA), and the pH was adjusted between 8.2 to 
8.4 with acetic acid (Merck KGaA). 
  
A.1.11 UltraPure™ DNase/RNase-Free Distilled Water. Dnase/RNase-free 
distilled water was supplied by Life Technologies, Australia and was used for 
all molecular experiments.
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Table A.1. Oligonucleotides for RT-PCR 
Name Sequence (5’-3’) Description 
uni 12 primer AGCRAAAGCAGG Reverse transcription primer 
specific for influenza virus RNA  
pHW2000seq1 GTTAACCGGAGTACTGGTCG Forward primer for pHW2000 
plasmid sequencing 
pHW2000seq2 ATCTTTCGCTCCGAGTCGGC Reverse primer for pHW2000 
plasmid sequencing 
NS1-510muta F CCATTGCCTTCTCTCCCGGGACATACTGC
TGAGGATGTC 
Sense primer for site directed 
mutagenesis 
NS1-548muta R GACATCCTCAGCAGTATGTCCCGGGAGAG
AAGGCAATGG 
Antisense primer for site 
directed mutagenesis 
Bm-NS-1 TATTCGTCTCAGGGAGCAAAAGCAGGGTG Sense primer with BsmBI site 
Bm-NS890R ATATCGTCTCGTATTAGTAGAAACAAGGGT
GTTTT 
Antisense primer with BsmBI 
site 
Xho1-NS2-508F ACGCCTCGACCACCATTGCCTTCTCTTCC
AGG 
Sense primer with XhoI site 
Xho1-NS1-717R CGTCTCGACTCAAACTTCTGACCTAATTGT
TCCC 
Antisense primer with Xho1 site 
miR-150 F –Xho1 CGCTCGAGCCTCAGCAGCCTGGTTAAATG Sense primer with  XhoI site 
miR-150R-Xho 1   CGCTCGAGGGGAGAAGCTGGAGTTGTTG
C 
Antisense primer with XhoI site 
miR150scbl-R1 GTTCACAACTCGTATCGGATTTGCTGAGG
CACAGACATCCGATAACGCATTGTGAACA
GGGCATTGAGAAGAGTCC 
Antisense primer for site 
directed mutagenesis 
miR150scbl-F2 TCACAATGCGTTATCGGATGTCTGTGCCT
CAGCAAATCCGATACGAGTTGTGAACAGG
GACTTGGGAACC 
Sense primer for site directed 
mutagenesis 
cMyb 3utr F CCGCTCGAGGTGTCAGGGGGCAATAGAG
C 
Sense primer with  XhoI site 
cMyb 3utr R CCGCTCGAGTCAGAAAAACGCCCAAACGG Antisense primer with XhoI site 
Xho1-miR146a-1 CGCCTCGAGGTGCTTTTGGATTTATCAGA
GATTTC 
Sense primer with SalI site 
Xho-miR146a-
275R 
GTCCTCGAGCCCCACTCTCTCCACTCTTC
AAGTTC 
Antisense primer with XhoI site 
miR146a-132bp-
Xho1-F 
CGCTCGAGCCAGTGTTCTTCAGGTCCGTG Sense primer with  XhoI site 
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Name Sequence (5’-3’) Description 
miR146a-132bp-
Xho1-R 
CGCTCGAGGCCTCATCTGGAGAGTCTGT Antisense primer with XhoI site 
 
IRAK1 3utr F GCACGCTCGAGGACAAATCCCTCAGACTC
AGAGGTCAAAG 
Sense primer with XhoI site 
IRAK1 3utr R CGCTCGAGGTCTTCAGACACTCCAGAAGA
GGGCGTC 
Antisense primer with XhoI site 
miR146a-inhib-
Xho-F 
CGCTCGAGCCGACGGCGCTAGGATCATC
AAC 
Sense primer with XhoI site 
miR146a-inhib-
Xho-R 
CGCTCGAGTTTCCAAAAAGACGGCGCTAG
GATCATCTTG 
Antisense primer with XhoI site 
miRE-IRAK1-
shRNA 
TGCTGTTGACAGTGAGCGGGTCAAAGTTC
TCATGCTTGGATAGTGAAGCCACAGATGT
ATCCAAGCATGAGAACTTTGACCTGCCTA
CTGCCTCGGA 
Oligonucleotides sequencing 
mire-Xho-F TGAACTCGAGAAGGTATATTGCTGTTGAC
AGTGAGCG 
Sense primer with XhoI site 
mire-EcoOligo-R TCTCCTCGAGTAGCCCCTTGAAGTCCGAG
GCAGTAGGC 
Antisense primer with XhoI site 
miR-21-F CGCTCGAGTGCAAACCATGATGCTGGGTA Sense primer with XhoI site 
miR-21-R CGCTCGAGGACATCGCATGGCTGTACCA Antisense primer with XhoI site 
miR-181a F-Xho1 CCGCTCGAGTGCTCCAGACTCCCACAGAT
AC 
Sense primer with XhoI site 
miR-181a R-
Xho1 
GCTCGAGGGTCCTGCTTTGCGGTTCT Antisense primer with XhoI site 
Mmu-let-7b 
Forward(Xho1) 
CTATACCTCGAGTCTAGTGGCCTGTGGCC
AGG 
Sense primer with XhoI site 
Mmu-let-7b 
Reverse (Xho-I) 
AGCTCTGACGCTCGAGAATCTGTGGCTCC
ATTTAGC 
Antisense primer with XhoI site 
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Table A.2. Primers for SYBR Green qPCR 
Name Sequence (5’-3’) Description 
Universal 
reverse primer 
GCGAGCACAGAATTAATACGAC Universal antisense 
primer  
Poly(T) 
adapter 
GCGAGCACAGAATTAATACGACTCACTAT
AGG(T)12VN 
Universal poly(T) adapter 
miR-150 
qPCR 
CCCAACCCTTGTACCAGTGA Sense primer for mature 
miR-150 detection 
miR-107 
qPCR 
GCAGCAGCATTGTACAGGGCT Sense primer for mature 
miR-107 detection 
 
Table A.3. Cloning plasmids 
Name of 
plasmid 
Description Source 
pHW2000 Amp resistant vector, used to insert cDNA 
of each influenza gene segment in reverse 
genetics experiments 
Gift from Dr Webby, St Jude 
Children’s Research 
Hospital, TN, USA 
pGEM-T easy Amp resistant vector Promega 
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Table A.4. Peptides 
Name Amino acid sequence Description 
Db NP336-374 ASNENMETM An immunodominant influenza peptide 
that is recognised by influenza specific 
CD8+ T cells 
DbPA224-233 SSLENFRAYV An immunodominant influenza peptide 
that is recognised by influenza specific 
CD8+ T cells 
 
  
 179 
 
 
Table A.5. Fluorochrome conjugated anti-mouse monoclonal antibodies 
Anit-mouse monoclonal 
antibodies 
Fluorochrome Clone Supplier 
Hamster Anti-mouse CD3e APC 145-2C11 BD Pharmingen™ 
Rat Anti-mouse CD4 FITC RM4-4 BD Pharmingen™ 
Rat Anti-mouse CD8α FITC 53-6.7 BD Pharmingen™ 
Rat Anti-mouse CD8α PE 53-6.7 BD Pharmingen™ 
Rat Anti-mouse CD8α PerCP-Cy5.5 53-6.7 BD Pharmingen™ 
Rat Anti-mouse CD8α APC 53-6.7 BD Pharmingen™ 
Rat Anti-mouse CD8α BV605 53-6.7 BioLegend 
Rat Anti-mouse CD8α BV785 53-6.7 BioLegend 
Rat Anti-mouse CD11b PE M1/70 BD Pharmingen™ 
Rat Anti-mouse CD11b APC M1/70 BD Pharmingen™ 
Hamster Anti-mouse CD11c APC HL3 BD Pharmingen™ 
Rat Anti-mouse CD19 BV785 6D5 BioLegend 
Rat Anti-mouse CD197 (CCR7) PerCP-Cy5.5 4B12 BioLegend 
Rat Anti-mouse CD44 PE IM7 BD Pharmingen™ 
Rat Anti-mouse CD45 BV605 30-F11 BioLegend 
Rat Anti-mouse CD45R (B220) PerCP-Cy5.5 RA3-6B2 BD Pharmingen™ 
Rat Anti-mouse CD62L FITC MEL-14 BD Pharmingen™ 
Rat Anti-mouse CD62L APC MEL-14 BD Pharmingen™ 
Hamster Anti-mouse CD69 PerCP-Cy5.5 H1.2F3 BD Pharmingen™ 
Rat Anti-mouse F4/80 PerCP-Cy5.5 BM8 BioLegend 
Rat Anti-mouse Ly-6G & Ly-6C 
 (Gr1) 
FITC RB6-8C5 BD Pharmingen™ 
Rat Anti-mouse IFN-γ FITC XMG1.2 BD Pharmingen™ 
Rat Anti-mouse IL-2 PE JES6-5H4 BD Pharmingen™ 
Hamster Anti-mouse KLRG1 
(CD127) 
APC 2F1/KLRG1 BioLegend 
Rat Anti-mouse Ly6G PE 1A8 BioLegend 
Rat Anti-mouse MHC II (I-A/I-E) PerCP-Cy5.5 M5/114.15.2 
(M5/114) 
BD Pharmingen™ 
Rat Anti-mouse NKG2D 
(CD314) 
PE CX5 BD Pharmingen™ 
Anti-mouse NK 1.1 BV605 PK136 BioLegend 
Rat Anti-mouse TNF-α APC MP6-XT22 BD PharmingenTM 
  
 180 
 
 
Table A.6. miRNA Clusters and miRNA family 
Name of 
Cluster of 
family * 
H. sapiens 
(Human) 
M. musculus 
(mouse) 
miR-17~92 
cluster 
miR-17, miR-18a, miR-18b, miR-
20a, miR-20b, miR-93, miR-106a 
and miR-106b 
miR-17, miR-18a, miR-18b, miR-20a, 
miR-20b, miR-93, miR-106a and miR-
106b 
let-7  let-7a-1, let-7a-2, let-7a-3, let-7b, 
let-7c, let-7d, let-7e, let-7f-1, let-7f-
2, let-7g, let-7i, miR-98, miR-202 
let-7a-1, let-7a-2, let-7b, let-7c-1, let-
7c-2, let-7d, let-7e, let-7f-1, let-7f-2, 
let-7g, let-7i, miR-98, miR-202a, miR-
202b 
miR-29  miR-29a, miR-29b-1, miR-29b-2, 
miR-29c 
miR-29a, miR-29b-1, miR-29b-2, miR-
29c 
*: The members from each family are published in miRbase 
(http://www.mirbase.org/index.shtml)
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